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Abstract
It is generally accepted that metabolism is able to shape the immune response. Only recently we are 
gaining awareness that the metabolic crosstalk between different tumor compartments strongly 
contributes to the harsh tumor microenvironment (TME) and ultimately impairs immune cell fitness 
and effector functions. The major aims of this review are: i) to provide an overview on the immune 
system in cancer; ii) to position oxygen shortage and metabolic competition as the ground of a 
restrictive TME and as important players in the anti-tumor immune response; iii) to define how 
immunotherapies affect hypoxia/oxygen-delivery and the metabolic landscape of the tumor and iv)
vice versa, how oxygen and metabolites within the TME impinge on the success of immunotherapies. 
By analyzing preclinical and clinical endeavors, we will discuss how a metabolic characterization of 
the TME can identify novel targets and signatures that could be exploited in combination with 
standard immunotherapies and can help to predict the benefit of new and traditional 
immunotherapeutic drugs.
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Graphical abstract
Call-out box for clinicians
Metabolism strongly shapes the interplay between cancer cells and immune cells, modulating the anti-
tumor immune response. Most cancer cells adopt glycolytic metabolism with subsequent production 
of lactate and acidification of the tumor microenvironment (TME), which is associated with several 
parameters of aggressiveness, including immune evasion. The similarities in the metabolic pathways 
between cancer cells and several anti-tumor immune cells promote the establishment of a harsh 
metabolic competition in the TME and also pose some challenges to the use of metabolic targets in 
the clinic. Moreover, cancer cell metabolic changes can alter the expression of immune checkpoint 
proteins, which can either be stimulatory (e.g. CD40L) or inhibitory (e.g. PD-L1) and could 
contribute to cancer cell evasion from the immune system. Immune checkpoint inhibitors (ICIs) have
been highly investigated in recent years, with the use of antibodies that block T cell co-inhibitory 
receptors or ligands. Among them, CTLA4, PD-1, and PD-L1 are the most explored across different 
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cancer types, including advanced melanoma, non–small cell lung carcinoma, renal cell carcinoma, 
bladder cancer and lymphoma.
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I. Intertwined relationship between inflammation, hypoxia and metabolism in the tumor
Tumors are not only composed of cancer cells but also of the tumor microenvironment (TME), which 
comprises tumor-associated stromal cells (namely tumor-infiltrating immune cells, cancer-associated 
fibroblasts (CAFs) and endothelial cells), the extracellular matrix and a wide range of metabolites and 
cytokines. The TME represents most of the tumor mass and actively participates in tumorigenesis 
(441). Immune cells engage the TME since the early beginning of tumorigenesis. Tumors evolve 
through different phases that profoundly impact the recruitment and phenotype of tumor-infiltrating 
immune cells (section II). In turn, the dynamic tumor immune landscape deeply influences tumor 
progression, dissemination and response to therapy (sections III and VIII-X). Besides immune cells, 
CAFs are a key component of the TME and, in most cases but not all, they have pro-tumorigenic and 
immunosuppressive properties. A detailed analysis of this population is out of the scope of this review 
and, therefore, we refer the interested readers to other extensive recent reviews (74, 123, 337).
Blood vessels provide oxygen and nutrients, remove byproducts of cellular metabolism and are one of 
the main transport routes for immune cells and disseminating cancer cells. As tumors grow, pre-
existing blood vessels fail to sufficiently perfuse the tumor. Consequently, oxygen levels drop 
(ranging from nearly anoxia to 8% O2 in the most oxygenated areas) and an hypoxic and nutrient-
poor environment is established where metabolic byproducts and immunosuppressive modulators 
accumulate (98). Hypoxia is rapidly sensed by the O2/prolyl hydroxylases (PHD)/Von Hippel Lindau 
(VHL) axis, w -
HIF-
hypoxia (section V) (532). Hypoxia triggers angiogenesis, namely the formation of new blood vessels, 
rewires cell metabolism and modulates the expression of several immunomodulatory molecules, 
thereby shaping immune cell infiltration and phenotype (161, 532, 563). Importantly, since HIFs can 
be stabilized by O2-independent stimuli and immune cells are also sensitive to other hypoxia-driven 
signals (i.e. low pH, cytokines and nutrient fluctuations), the intrinsic effect of HIF- does not 
always meet the global effect of hypoxia. Thus, the integration of HIF-mediated responses together 
with other hypoxia-driven signals and intercellular crosstalks are key to understand the biology of 
immune cells in hypoxia (section V). 
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In the past decade it has become evident that immune cell phenotypes are linked to distinct metabolic 
profiles and that interfering with metabolism can profoundly impact immune cell function. Moreover, 
the nutrient scarcity in some areas of the TME imposes a harsh metabolic competition that, together 
with tumor acidosis and the build-up of metabolic byproducts, further impact the metabolic and 
functional reprogramming of cancer cells and tumor-associated stromal cells (sections VI-IX) (116).
Thus, hypoxic areas can be regarded as metabolic niches within the tumor that strongly fine-tune the 
tumor-associated immune response. 
Numerous studies have been carried out aiming to reveal correlations between immune cell 
infiltration and patient prognosis. However, it is becoming clear that i) the overall number of tumor-
infiltrating immune cells does not always offer a precise indication of disease outcome, ii) the 
phenotype of immune cells can overrule their abundance, iii) positioning of immune cell subsets in 
specific niches can actually provide a better tool to predict progression and therapy response (17, 54, 
99, 159, 241-243, 402, 702, 761, 786, 794). The segregation of distinct immune cell subsets between 
different tumor niches also suggests that their localization and phenotype is dictated by a match 
between their metabolic demands, oxygen levels, nutrient availability and cytokine composition 
(section V) (17, 54, 242, 243, 379, 402, 786, 794). In sum, it is not the cell type but rather the specific 
immune skewing and its localization what is important to define disease outcome and progression. 
With this regard, although we are well aware that other components (i.e., antigenicity of the tumor or 
organ-specific cues (616)) can participate to this fate, we believe that the metabolic imprinting of the 
niche where the immune cells are located will emphasize their anti-tumor or pro-tumor functions, 
leading to the need of better defining the “metabolic immune niches” of the tumor. 
Overall, cancer cell escape from innate and adaptive immunity as well as the success of anti-cancer 
therapies are widely influenced by hypoxia and cell metabolism and, therefore, to unravel how these 
processes control immune cell activation and differentiation in the TME deserve much more attention. 
Starting from a general overview on the role of the immune system in cancer (section II), its impact 
on the success of conventional therapies (section III) and how to exploit the reactivation of immune 
responses for therapeutic purposes (section IV, VIII-X), in this review we will surf on the wave of 
how hypoxic and metabolic changes within the TME impact on the overall immune landscape and 
Downloaded from www.physiology.org/journal/physrev at Hauptbibliothek Univ Zurich (130.060.047.189) on September 17, 2019.
Riera-Domingo et al. (revised version) 9 
fitness (sections V-VII), how they affect the success of immunotherapeutic treatments and how 
targeting hypoxia and metabolism may sensitize refractory tumors to immunotherapy (sections VIII 
and IX). 
II. The immune system in cancer
Whether the immune system is capable of controlling the development of malignant tumors has been
one of the most controversial questions in Immunology. Macfarlane Burnet and Lewis Thomas first 
proposed the concept of cancer immunosurveillance, that is, that lymphocytes could recognize and 
eliminate nascent cancer cells and, therefore, that the immune system actively prevents tumor 
formation (76, 691). However, this concept remained a longstanding debate for several decades due to 
the lack of substantial experimental evidence supporting their hypothesis. Importantly, the 
immunosurveillance theory failed to explain why some tumors undergo immune escape and become 
resistant to elimination by the immune system. Later on, Robert Schreiber and colleagues embedded 
immunosurveillance in a broader concept termed the cancer immunoediting theory, which 
encompasses the dual host-protecting and tumor-sculpting effects of the immune system on tumor 
development (192). The cancer immunoediting theory postulates that, in cases which 
immunosurveillance is not successful, the immune system favors the prevalence of non-antigenic 
cancer cells with an enhanced ability to survive and to evade the immune system recognition. Besides 
this, inflammation may promote cell transformation as, in fact, 25% of cancer cases are associated 
with chronic inflammation of diverse origins (146, 201).
The immune system requires several steps to initiate and amplify anti-tumor immunity and all these 
steps together are known as the anti-tumor immune cycle (121). This cycle starts with the release of 
neo-antigens from dead or dying cancer cells, which are captured and processed by antigen-presenting 
cells (APCs) for presentation or cross-presentation on MHC-II or MHC-I molecules, respectively. 
After loaded with antigens, APCs migrate to the draining lymph nodes to prime and activate T cells. 
Antigen-educated T cells then exit the lymph node and infiltrate into the tumor. Tumor antigen-
specific CD8+ T cells (or CTLs) can recognize cancer cells through TCR-MHC-I signal. In addition, 
tumor antigen-specific CD4+ T cells also exert immune responses by communicating with APCs 
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residing in the tumors. Upon recognition of cancer cells, CTLs kill cancer cells and release effector 
molecules to restrain tumor growth. These processes can release more tumor-associated antigens to 
enhance the anti-tumor immune responses and amplify the anti-tumor immune cycle. 
Nowadays it is conceived that different subsets of immune cells can exert pro- or anti-tumor roles and 
that the skewing towards these opposing phenotypes is susceptible to environmental stimuli within the 
niche they occupy (Figure 1). Thus, identifying the functions and effects of different tumor-
infiltrating immune cells during tumorigenesis and understanding the mechanisms underlying their 
abundance, distribution and phenotypes are key to elucidate how the immune system contributes to 
the clinical therapeutic outcomes and to envisage strategies to favor an anti-tumor immune response. 
II.I The innate immune system in cancer
The innate immune system comprises macrophages, dendritic cells, neutrophils, MDSCs and,
although wrapped in some controversy, innate lymphoid cells (ILCs). In the context of cancer, the 
innate immune system is quickly recruited to the nascent tumor, where it recognizes damage-
associated molecular patterns (DAMPs) through pattern recognition receptors (PPRs) and, in turn,
initiates and shapes the actions of the adaptive immune system. Therefore, the activation of innate 
immune system and the coordination between innate and adaptive immune cells are critical to launch 
efficient and effective immune responses against cancer, tissue damage and infections. Nevertheless,
the innate immune system can also promote tumor initiation due to its ability to induce inflammatory 
responses. Here we will summarize the major types of innate immune cells and their contribution in 
tumor progression and anti-tumor immunity.
II.I.I Macrophages in cancer
Macrophages are very plastic cells display a wide range of phenotypes in response to the 
environmental stimuli they receive (497). The two extremes are represented by M1 or classically 
activated macrophages and M2 or alternatively activated macrophages, arising from stimulation with 
LPS and IFN- IL-4, respectively (497) (Figure 1). While long-lived tissue-resident 
macrophages arise from embryonic precursors, the majority of tumor-associated macrophages 
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(TAMs) differentiate from circulating monocytes (490). STAT1 and STAT6 are necessary for the 
polarization into M1 and M2 macrophages, respectively (497).
GM-CSF, IFN- , TNF- TGF- and TLR agonists typically induce macrophage differentiation or 
polarization into M1-like macrophages. M1-like macrophages can produce inflammatory cytokines 
(i.e. IL-1, IL-6, IL-12 and TNF- ) and effector molecules (i.e. iNOS/NOS2) and efficiently present 
antigens to T cells (Figure 1) (497). Thus, M1-like macrophages can promote anti-tumor TH1 and 
TH17 immune responses. Moreover, IFN- tumoricidal activity and further induces 
secretion of CXCL9 and CXCL10 by TAMs, which support the recruitment of cytotoxic CD8+ T cells 
and halt tumor progression. On the other hand, IL-4, IL-13, IL-10 and M-CSF typically induce 
macrophage differentiation or polarization into M2-like macrophages. M2-like macrophages express 
higher levels of anti-inflammatory cytokines (i.e. IL-10, IL-6, TGF- ), scavenging receptors (CD206, 
CD204), pro-angiogenic molecules (VEGF-A) and proteases (MMP9), which allow them to promote 
TH2 immune responses (Figure 1). Whereas in the context of inflammation M2 macrophages serve to 
maintain homeostasis and promote tissue repair, in the tumor context they favor immune escape, 
tumor growth and metastasis.
In tumors, cancer cells produce various cytokines and chemokines, such as colony-stimulating factor 
1 (CSF1), VEGF-A, CCL2, and CXCL12, to recruit macrophages (687). Recruited macrophages in 
the TME tend to polarize into M2-like or mixed M1/M2 phenotypes, supporting angiogenesis, tumor 
progression and metastasis. The pro-angiogenic functions of TAMs and a subset of perivascular 
TIE2+ monocytes and macrophages are carried out, in part, by the release of VEGF-A (162, 402, 675)
and several proteases, including matrix metalloproteinases and cathepsin, which degrade the 
extracellular matrix and increase VEGF-A bioavailability (107, 189, 258, 334). TAMs can suppress 
CD8+ T cell infiltration and cytotoxicity through the expression of inhibitory ligands (i.e. PD-L1 and 
PD-L2 (371, 374)), ARG1 or NOS2 activity (186, 588-591, 684) and the CCL22-mediated 
recruitment of Tregs (153). Importantly, hypoxia fine-tunes the M2 phenotype of macrophages (384)
and accumulation of macrophages in hypoxia promotes their pro-angiogenic and T cell suppressing 
capacity (99).
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High density of TAMs in tumors is generally considered to associate with poor clinical survival in 
human cancer patients (794, 797). However, in some cases such as in colorectal cancer high TAM 
density correlates with good prognosis ((70) and references therein). This apparent discrepancy 
illustrates that, as introduced above, the sublocalization of macrophages within different tumor niches 
may account for a pro- or an anti-tumor function (99, 104, 489, 786). In this line, re-educating TAMs 
to acquire M1-like phenotype has been suggested to be an attractive strategy to alleviate the 
immunosuppressive features of the TME and lead to tumor regression in pre-clinical models. 
II.I.II Dendritic cells in cancer
Tumor-infiltrating dendritic cells (TIDCs) capture and process tumor-associated antigens from dying 
cancer cells. Matured TIDCs then migrate to draining lymph nodes, where they prime and activate T 
cells (121).
There are two major subsets of DCs in the TME, plasmacytoid DCs (pDCs) and conventional DCs 
(cDCs), which derive from the common DC progenitor (CDP) but differ in morphology and functions 
(Figure 1) (459). pDCs were originally described to respond to viral infections by the production of 
type I interferon. In the tumor context pDCs support Tregs function via Sema4A and IDO production, 
among others, and thus are considered to be immunosuppressive and promote tumor progression and 
metastasis ((168, 391, 647), reviewed in (474)), although they have been less studied than cDCs. 
FLT3L and GM-CSF participate in the differentiation of both cDC1 and cDC2. cDCs can be further 
divided into cDC1 and cDC2 based on their functions and surface marker expression pattern (136, 
459). cDC1 express XCR1 and CD8 in the lymphoid organs or CD103 within peripheral tissues and 
require the transcription factors IRF8, BATF3, and ID2 for their development (136, 459, 496). On the 
Notch2 for their development (136, 459, 496) (Figure 1). cDC1 are necessary to elicit an MHC-I-
mediated anti-tumor CD8+ T cell response and secrete IL- 12 to support T cell effector functions,
while cDC2 seem to participate in the MHC-II-mediated activation of CD4+ T cells, although their 
role in tumor development is still less studied (302, 332). In addition, cDC1 attract CD8+ T cells 
through production of CXCL9 and CXCL10 (671). It has been recently shown that CCL4 production 
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by cancer cells is required for the infiltration of anti-tumor cDC1s and CD8+ T cells (670). Moreover, 
prostaglandin E2 production can impair the recruitment of cDC1s into tumors by impairing natural 
killer (NK) cell-mediated CCL5 production (65). These findings reveal the critical role of cDC1s on 
tumor growth control. 
In the context of immunotherapy, cDC1s are required to promote anti-tumor effects upon PD-1
blockade and efficient adoptive T cell transfer therapy (72, 615, 618, 671). Moreover, the efficiency 
of cDC1 or cDC2 vaccination in murine tumor models depends on their immune contexture. While 
cDC1 vaccination enhances CD8+ T cell anti-tumor performance, vaccination with cDC2 enhanced 
TH17 differentiation and the skewing of TAMs into an anti-tumor M1-like phenotype (383). Notably, 
the gene signatures of cDC1 positively correlate with survival of human cancer patients in different 
tumor types, including, breast cancer, head and neck squamous cell carcinoma, and lung 
adenocarcinoma (65). More studies are required to describe the actual role of cDC2 in tumor 
development.
II.I.III Neutrophils and myeloid derived suppressive cells (MDSCs) in cancer
Neutrophils are a subset of myeloid cells often referred to as polymorphonuclear granulocytes due to 
their lobulated nuclei and cytoplasmic granules. STAT3 is the main transcription factor governing 
neutrophil formation (539) (Figure 1). Tumor-derived factors stimulate granulopoyesis as well as 
neutrophil release from the bone marrow. Despite neutrophil maturation is normally completed inside 
the bone marrow, tumors can exert such pressure that undifferentiated immature progenitors are 
prematurely released (101, 132, 610, 735). MDSCs comprises a heterogeneous group of Gr1+
immature myeloid cells that exhibit immunosuppressive functions and are only found in pathological 
conditions such as chronic infection, autoimmunity and cancer (239, 376, 685) (Figure 1). MDSCs 
have been subdivided into two different subtypes based on their morphology: mononuclear MDSC 
(M-MDSC), which resemble monocytes and may give rise to TAMs (489), and polymorphonuclear 
MDSC (PMN-MDSC), which are similar to neutrophils (488). Importantly, the term “myeloid-
derived suppressive cell” remains very controversial because it suggests that these cells can only be 
immunosuppressive, colliding with the dynamic nature of myeloid cells, and also due to the technical 
difficulties to unequivocally distinguish MDSC subsets from neutrophils, monocytes and TAMs 
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(685). For instance, the anti-Gr1 antibody used to define MDSCs recognizes both Ly-6G and Ly-6C 
antigens, which are also found on mature neutrophils (Ly-6Ghigh Ly-6Cmed) and monocytes (Ly-6G-
Ly-6Cmed/high); and some MDSCs express F4/80, like TAMs, or CSF1R, like monocytes (134, 685).
Moreover, MDSCs share other surface molecules, intracellular proteins and strategies to promote 
immunosuppression with neutrophils, monocytes and TAMs (239, 556). In this review we will use the 
same nomenclature as in the original work cited.
Far from being static and short-lived cells after maturation, neutrophils are now regarded as 
environment-responding cells that can carry out both pro- and anti-tumor functions. Generally, it is 
believed that neutrophils oppose tumor growth in early stages but, as tumors progress and under 
certain therapies, tend to support tumor growth and metastasis ((257, 472) and reviewed in (134)). 
Similar to other myeloid cells, intratumoral neutrophils can be divided between anti-tumor “N1-like” 
and pro-tumor “N2-like” neutrophils (Figure 1). IFN- and HGF support the anti-tumor roles of N1 
neutrophils (14, 220, 323, 772), while TGF- and G-CSF are the main cytokines supporting the pro-
tumor roles of N2 neutrophils (233, 735). In this line, circulating neutrophils in cancer can be divided 
into high density anti-tumor neutrophils and low density pro-tumor neutrophils and MDSCs (610).
More evidence is required to better define these polarization states and to clarify if they really 
represent two phenotypes of mature neutrophils or if they refer to rather immature cells. 
Neutrophils play a key tumor-promoting role in models of inflammation-induced carcinogenesis (201, 
327, 646). MDSCs and neutrophils continuously produce reactive oxygen species (O2-, H2O2, ONOO-
) and nitric oxide (NO) that hinder T cell infiltration and activation and lead to T cell apoptosis (132, 
478) high levels of ARG1, which promotes T cell cycle arrest by depleting L-arginine in the TME 
(588-591). Moreover, MDSCs express immunosuppressive cytokines (i.e. IL-10 and TGF- -
L1 to inhibit effector T cells function, induce Tregs activation and promote NK cell anergy (403, 511, 
537) and facilitate Tregs tumor infiltration in a CCR5-dependent manner (633). MDSCs and 
neutrophils promote cancer cell proliferation and angiogenesis via the secretion of pro-angiogenic 
molecules, such as VEGF-A, FGF and Bv8 (103, 654, 655) and matrix remodeling enzymes (i.e. 
elastase and MMP9) (305, 518). Finally, neutrophils can form neutrophil extracellular traps (NETs), a 
mixture of DNA, histones and anti-microbial peptides that trap and kill microorganisms and that have 
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been associated with several pro-tumor mechanisms (reviewed in (139)). In contrast, anti-tumor and 
anti-metastatic neutrophils can induce cancer cell killing in a H2O2 and NO-mediated mechanism 
(220, 263) and secrete TNF- (14).
The presence of circulating or tumor-associated neutrophils (TANs) is associated to poor prognosis 
(649, 688) and poor therapy outcome (257) in bronchoalveolar carcinoma (46), glioma (230),
metastatic melanoma (634), metastatic renal cell carcinoma (26), and pancreatic cancer (579). In 
contrast, elevated numbers of TANs in patients with advanced gastric carcinoma correlated with a low 
mortality rate (96). Targeting the recruitment of pro-tumor neutrophils or MDSCs or promoting 
neutrophil anti-tumor functions could be an attractive strategy for alleviating anti-tumor immunity.
II.I.IV Innate lymphoid cells in cancer
Innate lymphoid cells (ILCs) are a recently discovered group of immune cells with some analogy to T 
cell subsets at the functional level. Unlike T cells, ILCs are activated by cytokines and as a result of a 
balance of activating and inhibitory signals in an antigen-independent manner since they do not 
express antigen receptors (TCR-/CD3-). Based on the expression of a particular set of surface markers 
and transcription factors as well as functional features, ILCs can be divided into three subtypes: 
conventional NK/ILC1s, ILC2s and ILC3s (194, 669) (Figure 1). The ILC subtypes fulfill non-
redundant functions and play a pivotal role in the pathogenesis of inflammatory diseases. However, 
recent findings indicate an ambiguous role for different ILCs in the context of cancer.
II.I.IV.I Group 1 ILCs in cancer
Group1 ILCs include conventional natural killer (NK) cells and non-NK ILC1s. Group 1 ILCs are 
characterized by constitutive expression of the transcription factor T-bet and the release of TH1
cytokines such as IFN- and TNF- in response to IL-12, IL-15 and IL-18 (52, 235). ILC1s can be 
further subdivided based on the expression of the IL-7 receptor (CD127), T-bet, and Eomes (665)
(Figure 1). 
NK cells can be identified by the expression of the surface marker CD56 in humans, NK1.1+ in some 
murine strains (such as C57BL/6 but not in BALB/c), or NKp46+ in both species (86). NK cells 
possess unique cytotoxic functions and the ability to fight cancer cells without prior sensitization (19).
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Whether an NK cell stays put or eliminates a target cell depends on the balance of signals coming 
from activating and inhibitory signals. NK cells can kill cells that downregulate inhibitory MHC class 
I molecules, including both cancer cells and non-transformed cells (731). Alternatively, NK cells 
attack cancer cells that still express MHC-I but express enough stress ligands for activating NK cell 
activating receptors (108, 179, 574). The most thoroughly studied activating receptors in the context 
NK cell responses against malignant cells are NKG2D, the natural cytotoxicity receptors (NCRs), 
DNAM1 and CD16 (483). Mature NK cells are morphologically characterized as lymphocytes with 
large cytoplasmic granules that contain perforin (that causes membrane-disruption) as well as 
granzymes (a family of proteolytic enzymes) (734). Upon NK cell activation these granules are 
exocytosed and target cells are lysed (372). An alternative way of NK cell-mediated killing is 
executed by so-called death ligands on the NK cell surface, namely FAS ligand and TNF-related 
apoptosis-inducing ligand (TRAIL) (736), which leads to caspase-dependent apoptosis in target cells 
(662). In addition, activated NK cells can secrete cytokines and chemokines which then orchestrate 
the recruitment and the response of other cells of the innate and adaptive immune system (731).
Several studies revealed a key role for NK cells in tumor immunosurveillance and limitation of 
metastasis in mice and humans (483). However, some tumors undertake several routes to escape from 
NK cell-mediated immunosurveillance. Noteworthy, if the tumor is not completely eradicated, NK 
cell-mediated killing will contribute to tumor editing and immune escape. Indeed, Balsamo et al. have 
demonstrated that after initial NK cell-mediated killing, the residual melanoma cells develop 
resistance to IL-2-activated NK cells. The resistance mechanism depends on NK cell-derived IFN-
and involves upregulation of inhibitory HLA class I molecules as well as decreased expression of 
activating NKGD2 ligands on melanoma cells (34).
In contrast to the well accepted anti-tumor role of conventional NK cells, a role for the involvement of 
non-NK cell ILC1s in tumor immunity is just emerging. Non-NK ILC1s have been reported to be 
anti-tumor based on their ability to secrete the effector cytokines IFN- TNF- in response to the 
anti-tumor cytokine IL-12 (91, 357, 705). Both cytokines induce strong anti-tumor immune responses 
via enhanced recruitment and stimulation of other immune cells (84, 580, 754). Moreover, IFN-
TNF- can lead to vessel growth inhibition (or disruption) and apoptosis of cancer cells, independent 
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of host immune cells (41, 71, 173, 180). On the other hand, IFN- TNF- can promote 
inflammation in murine models and these pro-inflammatory functions may foster tumor growth and 
the expression of growth factors and angiogenic molecules (31, 665, 745, 792). Recent studies 
revealed that tumor-derived TGF- conversion of anti-tumor NK cells into ILC1s in 
a SMAD4-dependent manner, which, strikingly, resulted in pro-tumor and pro-metastatic effects (143, 
244). Thus, although ILC1s seem to primarily inhibit tumor formation and progression, this effect 
might be context and tumor-dependent.
II.I.IV.II Group 2 ILCs in cancer
ILC2s protect against infections with helminths and viruses in tissues with a barrier function like the 
gut, lung and skin (594). In addition, ILC2s are characterized by constitutive expression of the 
transcription factor GATA3 and secretion of the type 2 cytokines IL-5 and IL-13 in response to IL-33, 
IL-25, and thymic stromal lymphopoietin (TSLP) (19, 194). Owing to the fact that type 2 cytokines 
create a TME that inhibits anti-tumor immunity, ILC2 are considered to be pro-tumorigenic (Figure 
1). IL-13 drives polarization of tumor-associated macrophages towards an immunosuppressive M2 
phenotype that fosters tumor progression, is also involved in generation of MDSCs and may support 
apoptosis resistance, proliferation and migration of carcinoma cells (278, 494). Noteworthy, ILC2-
derived IL-13 is also a major driver of organ fibrosis, namely in the liver and lung, which predisposes 
for subsequent malignant transformation (283, 454). Further support for the tumor-promoting role of 
ILC2s comes from studies that identify ILC2s as a major source for the Th2 cytokine IL-4 (516, 551).
Thus, ILC2-derived IL-4 secretion is likely to further promote tumor progression. In contrast, IL-5
secreted by ILC2 may prevent tumorigenesis indirectly via enhanced eosinophil recruitment (317). In 
general, intratumoral accumulation of eosinophils is correlated with an improved prognosis (425).
Consequently, ILC2-derived IL-5 prevents pulmonary metastasis in the B16F10 melanoma model 
(317).
In summary, the existing experimental evidence indicates that ILC2-derived cytokines promote 
tumorigenesis, particularly in epithelial tissues with a barrier function, where ILC2s are abundantly 
present. 
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II.I.IV.III Group 3 ILCs in cancer
ILC3s depend on the transcription factor ROR t and secrete IL-17 and IL-22 in response to IL-23.
ILC3s subsets are heterogeneous and are most abundantly found in mucosal layers and mucosa-
associated lymphoid tissues, where they are crucial for mounting adequate immune responses against 
bacteria and fungi, as well as in orchestrating homeostasis and repair of epithelial barriers (75).
However, ILC3s in the gut lung and skin have been shown to drive IL-23-mediated chronic 
inflammation. Murine ILC3s are further subcategorized by the surface expression of chemokine 
receptor CCR6 and the NCR NKp46 (669). The role of ILC3s in tumor immunity and tumorigenesis 
is debated controversially (Figure 1). Whereas some studies suggest anti-tumor activity, studies on 
tumors that are driven by inflammation indicate a pro-tumorigenic effect of ILC3s, which might 
reflect the heterogeneity of ILC3s subsets. NCR+ ILC3s are able to secrete a set of chemokines and 
pro-inflammatory cytokines that are likely to be involved in the formation of tertiary lymphoid 
structures and improved tumor immune surveillance in patients with non-small cell lung cancer (95).
Moreover, in a model of IL-12-overexpressing melanoma, ILC3s showed anti-tumor functions in a 
mechanism independent of their signature cytokines (199). Instead, ILC3s fostered the expression of 
adhesion molecules in the tumor vasculature and the recruitment of other immune cells (199). On the 
other hand, based on the numerous reports that describe a tumor-promoting role for IL-23, ILC3s as 
downstream effectors are believed to be pro-tumorigenic in a IL-17 or IL-22-dependent manner (113, 
310, 352).
In summary, the role of ILC3s in tumor initiation and progression remains ambiguous and 
incompletely understood. Moreover, it seems that the pro- or anti-tumor effects might be exerted by 
distinct ILC3 subsets in a cytokine-dependent or independent manner.
II.II The adaptive immune system in cancer
The adaptive immune system, including T cells and B cells, provides antigen-specific immune 
responses against tumors by recognizing tumor antigens presented on cancer cells or antigen-
presenting cells (APCs) (77, 704). T cells are divided into subsets based on their T cell receptor 
(TCR) chain, co-receptor and cytokine expression profile. During development in the thymus, T cell 
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precursors commit into two T cell lineages, T cells or T cells, expressing different TCR chains.
T cells (T cells from now on) are further subdivided into CD4+ T cells and CD8+ cytotoxic T cells 
(CTLs) according to their co-receptor expression. Activation of CD4+ and CD8+ T cells occurs upon
TCR ligation to tumor antigens presented on major histocompatibility complex class II (MHC-II) and 
class I (MHC-I) molecules, respectively. MHC-II complexes are expressed by professional APCs, 
whereas MHC-I complexes are expressed by all nucleated cells. Influenced by the cytokine milieu, 
CD4+ T cells differentiate into TH1, TH2, TH17 or Tregs subsets, which are controlled by distinct 
molecular programs and differ in their functions and cytokine expression profile (Figure 1). Although
other helper T cell subsets (i.e. TH3, TH9, TH22) have recently been discovered, their role in tumor 
biology is still unclear and thus will not be included in this review. After the primary immune 
response, most T cells undergo apoptosis to allow the resolution of the immune response.
Nevertheless, a fraction of T cells remains and gives rise to memory T cells (553). Memory T cells 
respond faster to a second antigen exposure and can undergo proliferation and deploy their effector 
functions more effectively (326). In the last years, a new subtype of CD8+ memory T cell has been 
discovered, resident memory T cells (TRM), which holds a promising anti-tumor capacity (10, 248, 
449). TRM are long-lived non-recirculating cells that reside in the tissue where they were originated. 
TRM are characterized by CD69 and CD103 expression, respond faster to antigen re-exposure and 
have a superior cytotoxic capacity than other types of memory T cells (10, 326). In the clinical arena, 
using memory CTLs instead of naïve or effector CTLs holds promise for an improved and long-
lasting anti-tumor effect that locally protects from recurrence (10, 57).
A detailed analysis of the current knowledge on B cells and T cells is out of the scope of this 
review. Thus, we refer the interested readers to other extensive recent reviews on B cells (622, 748) or 
T cells  (658). In this section, we will focus on the tumor-promoting or tumoricidal effects of the 
distinct T cell subsets and we will describe different dysfunctional states that compromise T cell 
function.
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II.II.I Type 1 T helper cells (TH1) in cancer
Type 1 T helper cells (TH1) promote host protective immunity against intracellular pathogens as well 
as malignant cells. TH1 cells express transcription factor T-bet and produce high amounts of IFN- ,
IL-2 and TNF- in response to IL-12 (Figure 1). T-bet supports differentiation program and immune 
responses of TH1 cells, including macrophage activation, cell-mediated immunity and phagocyte-
dependent protective responses. IFN- TNF- secreted by TH1 cells are also involved in anti-
tumor and anti-angiogenic activities (144, 493, 568). In addition, IFN- and TNF- are required for 
cytokine-mediated activation and regulation of tumor-specific CTLs (210) and are reported to induce 
cancer cell senescence (39). Intriguingly, IFN- also provides positive feedback mechanism to support 
TH1 cell differentiation and lineage stability by activating STAT1. STAT1-deficient mice decreased 
IFN- -deficient mice 
increased TH2 polarization of CD4+ T cells (209, 339). Moreover, IFN- the 
production of immunosuppressive cytokines, including TGF- and IL-10, an action that has been 
considered to support anti-tumor immune responses (187, 198). In addition to their effect on immune 
and cancer cells, TH1 cells have recently been reported to support vascular normalization in tumor 
through secretion of IFN- (696). Thus, tumor-specific TH1 cells can restrain tumor progression 
(275).
II.II.II Type 2 T helper cells (TH2) in cancer
TH2 cells support humoral immune responses and host immunity against extracellular pathogens and 
play a significant role in induction and persistence of allergic responses and asthma. TH2 cells express 
the transcription factor GATA3 and produce IL-4, IL-5 and IL-13 in response to IL-4 (Figure 1). In 
contrast to TH1 cells, cytokines produced by TH2 cells exhibit tumor-promoting activities. TH2 can 
induce T cell anergy, inhibit T cell mediated cytotoxicity and promote the immunosuppressive 
functions of other immune cells. In many tumor types, elevated IL-4 and IL-13 in the TME can 
polarize TAMs into M2 pro-tumor phenotype, which hampers anti-tumor immune responses,
promoting stromal cell formation, angiogenesis and the secretion of immunosuppressive cytokines 
TGF- -10 (170, 656). Human clinical data indicated that higher intratumoral TH2 cell 
infiltration reduced patient survival rate in pancreatic cancer patients and other tumor types (159).
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II.II.III Type 17 T helper cells (TH17) in cancer
Type 17 T helper cells (TH17) owe their name to their ability to produce IL-17 (289, 541) and play 
critical roles in autoimmunity and in host protection against bacterial and fungal infections (365).
TH17 differentiation is induced by IL-6, IL-22, IL-23 and TGF- and regulated by the transcription 
factors STAT3 and orphan receptor ROR t. In addition to IL-17, TH17 also exert their immune 
responses by producing other cytokines, including IL-21, IL-22 and GM-CSF. Despite the 
contributions of TH17 in gut homeostasis and autoimmunity are well established, the role of TH17 
cells in cancer remains controversial since they are reported to have both pro-tumor and anti-tumor 
effects (20) (Figure 1). IL-17A has been reported to promote tumor angiogenesis (780), but other 
TH17 cytokines, such as IL-21 and IL-22, were shown to display anti-angiogenic effects (756). In 
addition to cytokines secreted by conventional TH17 cells, tumor-infiltrating TH17 cells could have 
distinct cytokine profiles that could be influenced by the stage of tumorigenesis and tumor types 
(252). Indeed, tumor-infiltrating TH17 cells have been reported to express IL-17 and IFN- (“TH1-
like” TH17 cells) or IL-17 and IL-10 (“Tregs-like” TH17) cells, which exhibit distinct effector and 
regulatory functions and have different impacts on tumorigenesis (20). Intriguingly, TH17 cells can
differentiate into TH1 or Tregs and vice versa in a process that is, at least in part, governed by hypoxia 
and metabolism (sections V.II.I and VII.II.I). The balance and plasticity between TH17 cells and Tregs
have been reported to have the correlation of patient clinical cancer stage and associated with tumor 
progression (448). In lung cancer, TH17 cells cooperate with Tregs to promote lung cancer progression 
and metastasis (190, 447). In contrast, in ovarian cancer patients, TH17 exhibit a polyfunctional 
effector T cell phenotype to stimulate recruitment of effector T cells into the TME by promoting 
CXCL9 and CXCL10 production in tumors, and induce expression of chemokines for type I immune 
responses in recruiting effector T cells (370). Yet, TNF- induced the secretion of IL-17 by TH17 
cells and elicited the recruitment of neutrophils that supported tumor progression (119). Again, this 
highlights the potential pro- and anti-tumor effects of TH17 cells. 
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II.II.IV Regulatory T cells (Tregs) in cancer
Regulatory T cells (Tregs) play a crucial role in maintaining immune homeostasis and self-tolerance 
and preventing autoimmune disease. TGF- can induce Tregs polarization. Tregs are characterized by 
the expression of the transcription factor Foxp3, which is key for Tregs development and function and 
is considered as a lineage-specific marker for Tregs. Unlike other CD4+ helper T cells, Tregs exhibit 
immunosuppressive activities through different mechanisms. Foxp3 suppresses IL-2 production in 
Tregs, but Tregs constitutively express the high-affinity IL- (Figure 1). Thus, 
Tregs sustain their survival by competing for IL-2 with other T lymphocytes and this competition could 
further hamper proliferation and survival of effector T cell subsets. Migration of Tregs into tumors is 
mediated by their chemokine receptors CCR4, CCR5, and CXCR1 (183). Once in the tumor, Tregs
also upregulate the expression of co-inhibitory receptors, including CTLA4, programmed cell death 
protein 1 (PD-1), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte 
activation gene-3 (LAG-3), inducible T cell co-stimulator (ICOS), and glucocorticoid-induced TNFR 
family related gene (GITR). The expression of these co-inhibitory receptors on Tregs dampens the anti-
tumor functions of effector T cells, as well as potentially promote Tregs generation (509). For instance, 
CTLA4 competes for binding to CD80 and CD86 on antigen-presenting cells (APCs) with the co-
stimulatory receptor CD28. Since CTLA4 has a higher affinity for CD80/CD86 than CD28, it impairs
T cell activation by reducing CD28-mediated co-stimulatory signal in other T cells (137). Moreover,
Tregs dampen immune responses in both T cells and APCs by producing immunosuppressive 
cytokines, such as IL-10 and TGF- (744). The stability and function of intratumoral Tregs is 
maintained by pDC-derived Semaphorin 4A (Sema4A) signaling through neuropilin 1 (Nrp1) on Tregs
(168).
In humans, various tumor types such as breast (422), ovarian (153), lung (555) and gastric (554)
cancer, show high levels of Tregs either in circulation or intratumoral, or a low CD8+/Tregs ratio, which
correlate with a poor clinical prognosis. In contrast, a few studies provided evidence that Tregs may 
also be associated with improved clinical outcome in head and neck (29) and colorectal carcinoma 
(614). In general, tumor-infiltrating Tregs promote tumor immune evasion and development of the 
immunosuppressive TME through their abilities to dampen anti-tumor immune responses. 
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II.II.V CD8+ cytotoxic T cells (CTLs) in cancer
CD8+ cytotoxic T cells (CTLs) CTLs play 
an important role in immunity against intracellular pathogens and tumor immunosurveillance. After 
being primed by APC in the lymphatic organs, CTLs become activated and gain the ability to 
eliminate infected or malignant cells upon recognition of peptides presented by MHC-I. Upon 
recognition of the peptide-MHC-I complex, effector CTLs secrete cytokines, including TNF-
and IFN- activate macrophages and cell-mediated immunity. Moreover, effector CTLs can 
directly lyse target cells by producing and releasing cytotoxic granules containing perforin 
and granzymes. Perforin is a glycoprotein, which can form pores on target cell membrane (527).
These pores allow granzymes, a serine proteases, to enter the target cells, cleave proteins inside these
cells and induce their programmed cell death (126). In addition, effector CTLs express Fas ligand 
(FasL) on the cell surface, which binds Fas expressed on the surface of target cells. Fas-FasL 
interaction stimulates caspase cascade activation and engagement of apoptosis in Fas-expressing 
target cells (Figure 1). Clinical observations and retrospective studies suggest that high densities of 
infiltrating CTLs in the TME, or a high CD8+/Tregs ratio, associates with better clinical outcomes, 
including prolonged survival and higher response rates to cancer immunotherapy, in many different
tumor types, such as melanoma (697), breast (437), ovarian (624), renal (499), colorectal (243, 358),
pancreatic (237), and lung cancer (342).
II.II.VI Dysfunctional T cell states: ignorance, tolerance, anergy, exhaustion and 
senescence
As a result of the intensity and duration of antigen exposure, the cytokine and metabolic milieu as 
well as the intercellular crosstalk within the TME, T cells may exhibit a series of dysfunctional states, 
namely ignorance, tolerance, anergy, exhaustion and senescence, that compromise their anti-tumor 
function (reviewed in (149, 631, 692, 762)). The term ignorance refers to a state in which naïve T 
cells fail to recognize their cognate antigen that can be either i) physically sequestered, ii) have low 
expression or iii) be scarcely cross-presented. As a result, the T cell remains in its naïve status with 
the possibility to be still activated in the right circumstances and conditions. Tolerant T cells, on the 
other hand, are (self-) antigen antigen-experienced cells that have been inefficiently primed and is 
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associated to a dysregulated expression of effector molecules, master transcription factors, chemokine 
receptors, exhaustion-associated markers and cell cycle-associated genes (631). Therefore, tolerant T 
cells are unable to undergo clonal expansion even if antigen re-stimulation takes place under optimal 
conditions, but yet may retain a degree of effector function (631). The development of peripheral 
tolerance is a physiological mechanism to prevent autoimmunity, but it can also arise in pathological 
conditions such as cancer. CD8+ T cell tolerance can occur when tumor antigens derive from tissue-
specific genes (i.e. prostate-specific antigen PSA and melanocyte glycoprotein PMEL) or from 
overexpressed wild type genes (i.e. c-MET proto-oncogene). Anergy is an hyporresponsive state that 
arises as a result of in vitro stimulation in the absence of co-stimulatory or cytokine signals or of in 
vivo sub-optimal stimulation. Anergy is characterized not only by an impaired proliferation, as in 
tolerant T cells, but also by defective IL-2 production (638). Exhaustion is a state of 
hyporresponsiveness due to the combination of a persistent antigen stimulation with the absence of 
CD4+ T helper stimulation and an immunosuppressive environment. It is the most common situation 
encountered by tumor-infiltrating T cells. Exhausted T cells have a decreased proliferation, impaired 
effector function and increased expression of inhibitory receptors (PD-1, LAG3, Tim3, CTLA4, 
among others) (762). While anergy occurs within a few days after TCR stimulation, exhaustion may 
take up to several weeks. Finally, senescent T cells display a shortening of telomere length as a result 
of ageing after several rounds of division, a reduction of CD28 expression and undergo an irreversible 
cell cycle arrest (149). Importantly, tolerance, anergy and exhaustion are reversible states that could 
potentially be targeted by immunotherapies while senescence is irreversible. With this respect, it is 
relevant not only to define whether tumors are “cold” or “hot”, but also to characterize the fitness of 
tumor-infiltrating T cells in order to find tailored strategies to reverse T cell dysfunction. In other 
words, hot tumors with senescent or anergic T cells would require a different approach than hot 
tumors characterized by exhausted T cells. 
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III. Positive and negative involvement of the immune system in the success of therapeutic 
approaches such as chemotherapy and radiotherapy
Conventional therapies, such as chemotherapy and radiotherapy, are widely used in clinical cancer 
treatment. Chemotherapy drugs eliminate cancer cells through inhibition of DNA replication and 
synthesis, induction of DNA damage or prevention of cell mitosis. Radiation causes DNA damage, 
including single-strand and double-strand breaks. In addition to a direct effect on cancer cells, 
localized radiation or systemic chemotherapy can initiate cell death-induced immune responses, 
namely immunogenic cell death (ICD), and induce production of inflammatory cytokines and 
chemokines, leading immune cells infiltration and reprogramming the TME to exert a potent anti-
tumor immunity (169, 217, 397) (reviewed in (240, 758)). Mechanistically, dying cancer cells release 
immunogenic tumor antigens and emit danger-associated molecular patterns (DAMP). The liberation 
of DAMPs, such as calreticulin, ATP, and high-mobility group protein B1 (HMGB1), stimulate 
phagocytosis and enhance APCs activation. Dying cancer cells also release DNA and RNA in the 
cytosol. DNA triggers cGAS-STING pathway, whereas RNA induces toll-like receptors (TLRs), RIG-
I-like receptors (RLRs) signals. The activation of those pathways induces type-I IFN expression, 
which is essential for DC activation and function. Hence, radiotherapy- or chemotherapy-induced ICD 
leads to DCs maturation and migration to the draining lymph node, where they prime tumor antigen-
specific T cells and initiate systemic immune responses. Additionally, type-I IFN in tumors can 
further stimulate recruitment effector CD8+ T cells and anti-tumor responses of those recruited 
effector T cells (171, 405, 758, 771). Very few standard chemotherapeutics elicit ICD (i.e. 
anthracyclines, oxaliplatin, mitoxantrone, among others) (191, 240). Thus, drug combinations with 
the potential to enhance ICD and to revive the anti-tumor function of the immune system, for instance 
metabolism-targeting agents with tolerogenic chemotherapies, would hold promising effects.
In addition to the activation of TIDC-CTL-mediated anti-tumor immune responses, conventional 
therapies also trigger chemokine production on cancer cells to recruit T cells. Radiotherapy induces 
the expression of T cell attracting chemokines, including CXCL9, CXCL10, CXCL1, and CXCL16 
(450, 456) and chemotherapy promotes T cell infiltration in the TME by stimulating expression of 
CXCL9, CXCL10, and CCL5 in cancer cells (303). Moreover, cytotoxic chemotherapy can alleviate 
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the immunosuppressive features of the TME through the elimination of immunosuppressive cells. For 
instance, low dose cyclophosphamide and gemcitabine selectively ablate Tregs or MDSCs and dampen 
production of the immune suppressive cytokines, such as IL-4, IL-10 and IL-13 (390, 430, 650).
These findings pave the foundations for several pre-clinical and clinical studies in which treating 
cancer-bearing mice or patients with cyclophosphamide in combination with cancer vaccine achieve 
higher response rates (388, 725, 740). Even though conventional therapies can augment T cell 
responses, there are several downsides for conventional therapy. Intensive chemotherapy and 
radiotherapy can cause neutropenia and lymphopenia and significantly decline total numbers of 
immune cells. Furthermore, in some cases radiotherapy can even induce the recruitment of MDSCs 
into tumors (721).
It is becoming increasingly recognized that NK cells significantly contribute to the so-called ICD and 
the overall therapeutic outcome. In the context of chemotherapy-elicited NK cell responses, changes 
in the expression of death receptors as well as of NK cell-activating and inhibitory ligands following 
therapy play a major role. Classical cytotoxic drugs that are currently in clinical practice can 
upregulate the expression of the stimulatory ligands NKG2D and DNAM-1 through the DNA damage 
response pathway as well as the expression of the NKp30 ligand B7-H6 via an unknown mechanism 
(803). Alternatively, they decrease the expression of NK cell inhibitory ligands such as Clr-b (219, 
255, 261, 651). Finally, chemotherapeutic drugs regulate NK cell activating ligands at the post-
translational level. For instance, metalloproteinases (MMP) and ADAM enzymes on the surface of 
cancer cells can trigger the release of soluble NKG2D ligands in response to chemotherapy (802, 
803). In contrast, treatment with gemcitabine was shown to inhibit shedding of the NKG2D ligand 
ULBP2 through ADAM10 in pancreatic cancer (414). In murine models, cisplatin induced the release 
of the chemokine chemerin, which enhanced NK recruitment and showed enhanced efficacy when it 
was combined with anti-angiogenic therapy targeting VEGF (354). Regarding NK cell responses to 
radiotherapy, it has been shown that irradiation of various cancer cell lines induced the upregulation 
of the NKG2D ligands MICA, MICB and ULBP1 (45, 661, 776), whereas the irradiation of human 
endothelial cells did not change the expression of NKG2D ligands (583). Thus, irradiation upregulates 
NKG2D ligands and, hence, potentially triggers anti-tumor NK cell responses. With respect to MHC-I
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molecules it seems more likely that radiation therapy has a negative impact on NK cell-dependent 
cancer cell clearance. Yet, irradiation-induced upregulation of MHC-I molecules likely renders cancer 
cells more susceptible to clearance by cytotoxic T cells (599). Hence, a better understanding of 
dosage of conventional therapies in combination with immune therapies is direly needed to achieve 
long-term clinical benefit by reigniting anti-tumor immunity.
IV. Immunotherapy: a promising therapeutic option for cancer patients but with room for 
improvements
Despite improved treatment options, cancer remains the leading cause of morbidity and mortality 
worldwide and the number of newly diagnosed cases is expected to rise by 70% over the next two 
decades (World Cancer Report 2014), further emphasizing an urgent need for new therapeutic 
strategies. Traditional chemotherapy and targeted therapies have achieved limiting success, as 
resistance mechanisms and toxicity still represent major challenges for effective cancer treatment. In 
this scenario, cancer immunotherapy has emerged as a revolutionary and promising treatment 
approach. The relevance of the progress in this field was recently recognized by the Nobel 
Committee, leading to the assignment of the 2018 Nobel Prize in Physiology or Medicine to Dr. 
Allison and Dr. Honjo "for their discovery of cancer therapy by inhibition of negative immune 
regulation". Human antibodies directed against immune checkpoint proteins such as cytotoxic T
lymphocytes antigen-4 (CTLA4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-
L1) have been employed to break the immune tolerance and stimulate T cell response (68, 268, 700).
Adoptive T cell transfer (ACT), STING agonists and cancer vaccines harness the ability of the 
immune system to recognize and reject the tumor (663). In addition, multiple strategies have been 
envisaged to stimulate the function of anti-tumor effector cells or to dampen the pro-tumor functions 
of immunosuppressive cells (663).
Recent studies highlight the lack of correlation between T cell infiltration in solid tumors, response to 
immunotherapy (i.e., anti-PD-1) and density of immunogenic antigens (672), leading to the key 
questions of which antigen-independent factors limit anti-tumor responses. Growing evidence shows 
that, even in the presence of an immunotherapeutic intervention aiming to promote T cell expansion 
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and anti-tumor activity, the TME can compromise functions and fate of tumor-infiltrating immune 
cells to favor immunological tolerance and reduce anti-tumor effector functions. For instance, low pH, 
hypoxia, metabolic competition for limiting nutrients (e.g. glucose and glutamine), some metabolites 
(e.g. adenosine), macrophage-driven arginine depletion, nitric oxide (NO) production as well as
tryptophan catabolism by indoleamine-pyrrole 2,3-dioxygenase (IDO) within the TME greatly impair 
T cell functions (47, 99, 116, 132, 249, 335, 557). The next challenge is therefore to anticipate the 
reasons why in certain patients and tumors immune intervention does not offer a durable response, or 
in the worst case, the tumor is completely refractory to this treatment. In this section, we offer an 
overview of the current state-of-the-art immunotherapies and the challenges that still need to be 
tackled in order to improve its efficacy.
IV.I Immune checkpoint blockade (ICB)
Immune checkpoints provide negative signals that restrict T cell immune responses and are critical for 
self-tolerance. However, cancer cells take the advantage of these co-inhibitory signals to limit T cells 
activity and further establish an immunosuppressive TME. In order to rejuvenate T cell anti-tumor 
responses, immune checkpoint blocking antibodies or recombinant forms of ligands have been 
developed. Currently, two classes of immune checkpoint blockade (ICB) have been approved by the 
FDA, the antagonistic antibodies of cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) (i.e. 
ipilimumab, tremelimumab) and programmed death receptor 1 (PD-1) (i.e. nivolumab, 
pembrolizumab, pidilizumab) or its ligand (PD-L1) (i.e. atezolizumab, avelumab, durvalumab) (39).
Clinical data have demonstrated that monoclonal antibodies that block CTLA4 and PD-1 signals can 
prevent the inhibition machinery on T cells and enhance T cell functions and lead to impressive 
therapeutic benefits in patients with different cancer types.
CTLA4 is a transmembrane glycoprotein constitutively expressed on Tregs and also expressed on other 
T cells following activation. CTLA4 can bind to its ligands CD80 (B7-1) and CD86 (B7-2) expressed 
on APCs. Since CTLA4 has a greater affinity to B7 proteins than the co-activating receptor CD28, 
CTLA4 is able to compete with CD28 for ligand binding and deliver an inhibitory signal to restrain T 
cell immune responses (39). Indeed, CTLA4 expression in T cells tunes down the amplitude of T cell 
receptor activation, resulting in reduced T cell proliferation and IL-2 production (369, 741). Similar to 
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CTLA4, PD-1 is also expressed on the surface of activated T cells and interacts with its own ligands, 
PD-L1 (B7-H1) and PD-L2 (B7-DC), which are expressed on the surface of APCs, myeloid cells, and 
cancer cells. The interaction between PD-1 and its ligands provides a negative signal to inhibit 
cytokine production and T cell proliferation (216, 585). interferes with the formation of 
immunological synapses and inhibits TCR-mediated effector functions. CTLA4-mediated inhibitory 
signaling usually takes place within the lymph nodes, where APCs interact with T cells, while PD-1-
mediated inhibitory signaling is triggered mostly in the periphery, including the tumor. 
Mechanistically, both CTLA4 and PD-1 signals impede Akt activation, but they target different 
signaling molecules. CTLA4 signaling dampens T cell activation pathways by activating the 
serine/threonine phosphatase PP2A and SHP2, which directly dephosphorylates CD3 (396, 446). In 
contrast, PD-1 signaling phosphorylates ITSM/ ITIM motifs located in PD-1 cytoplasmic domain, 
which recruits tyrosine phosphatases SHP-1 and SHP-2. As a result of recruitment, SHP-1 and SHP-2
further inhibit TCR-induced activation of PI3K/Akt pathway (585, 788).
Immune checkpoint inhibitors have shown high response rates of prolonged duration in a subset of 
melanoma (312, 627, 713), renal cancer (21, 485) and lung cancer patients (63, 297, 577), raising the 
enthusiasm of setting-up new clinical trials for many other cancer types. It is clear that for several 
tumors such as colorectal cancer (CRC) (68, 389, 700), and pancreatic ductal adenocarcinoma 
(PDAC) (603), immunotherapy fails to show any clinical benefit. T cell infiltration and intratumoral 
localization, PD-L1 expression, tumor antigenicity and the fitness of tumor-infiltrating T cells are 
important factors that determine the success of ICB. Novel strategies aiming to modulate these 
features are attractive candidates to predict response to ICB as well as to restore sensitivity in those 
refractory cases. A list of the currently ongoing clinical trials with anti-PD-1, PD-L1 and CTLA4 
antibodies can be found in (Table 1). More recently, co-inhibitory receptors have been described
(namely Lag-3, Tim-3 and TIGIT) that are expressed by T cells, NK cells and some APCs and have 
more specialized and organ-specific functions. Targeting these receptors represents an alternative 
strategy with potentially more specificity and lower toxicity (12, 39, 663). More research is required 
to unravel which tumors are susceptible to these therapies and to design successful combinational 
therapies.
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IV.II Adoptive T cell transfer (ACT)
Adoptive cell transfer (ACT) consists in collecting patients’ own T cells, improve their performance 
ex vivo and re-transfer them back. There are three types of ACT: tumor infiltrating lymphocytes 
(TILs), chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells. In TILs therapy, 
the TILs isolated form patients are expanded in vitro supplementing with IL-2 and anti-CD3. Prior to 
TILs re-transfer, patients have to be treated with lymphodepletion drugs to support the expansion and 
survival of infused TILs. In addition, treatments with high-dose of IL-2 are used to increase the 
survival of TILs (307, 597, 798). The therapeutic potential of TIL therapy is mainly hampered by the 
low frequency of TILs in tumor and the challenge to acquire sufficient cell numbers of tumor-reactive 
T lymphocytes during in vitro expansion phase. In contrast to TILs, CAR and TCR T cells use gene 
modification strategies to overcome the bottlenecks of TIL therapy and immune tolerance. Since most 
of tumor-associated antigens are derived from self-antigens, T cells recognizing tumor antigens are 
not naturally abundant. Thus, TCR therapy consists in overexpressing tumor-specific TCR on the 
surface of autologous T cells. In contrast, CAR T cell therapy consists in overexpressing chimeric 
antigen receptors, which are artificial fused membrane proteins, on autologous T cells (598). In this 
design, CARs directly recognize tumor antigens in an MHC-I-independent manner and could deliver 
TCR and co-stimulatory receptor signals into T cells upon recognition of tumor antigens. Importantly, 
CAR T cell therapy can be used in tumors downregulating antigen presentation and MHC-I
expression. 
Among all three treatments, CAR T cells therapy is the most advanced. In 2017, two CAR T cell 
therapies approved by FDA, Axicabtagene for refectory large B cells lymphoma and Tisagenlecleucel 
for B-cell precursor acute lymphoblastic leukemia (B-ALL) (502, 565). Although CAR T cell therapy 
has been a breakthrough success in hematopoietic malignancies, new clinical regimens are needed to 
make them effective against solid tumors. Moreover, T lymphocytes expressing CAR or TCR against 
tumor antigens retain their expression of endogenous TCR, which may recognize a variety of 
antigens. This may increase the risk of autoimmunity or other severe immune responses in patients 
receiving this therapy. Thus, enhancing therapeutic efficacy while keeping an adequate T cell 
response is a major challenge of ACT.
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IV.III Cancer vaccines
The idea behind cancer vaccines is different from the vaccines that work against viruses. Instead of 
preventing diseases, cancer vaccines are designed to trigger and amplify anti-tumor immunity. Cancer 
vaccines aim to boost the quantity and activity of tumor antigen-specific CTLs as well as to create 
memory immune responses against tumors (79). Cancer vaccines can be made from tumor lysates, 
cancer cells with engineered cytokine production, tumor antigens or APC pulsed with tumor lysates. 
Many therapeutic cancer vaccines are under development. Among them, Sipuleucel-T is approved by 
FDA on treating metastatic prostate cancer, which is made by ex vivo activated endogenous APCs 
pulsed with recombinant prostate antigen-prostatic acid phosphatase fused with GM-CSF (338). In 
this design, the growth factor signal promotes antigen presentation ability of the endogenous APCs to 
enhance CTL activation. The combination of conventional therapy or immunotherapy with cancer 
vaccine is the current strategy in many clinical trials. Moreover, the concept to develop personalized 
cancer vaccine is emerging, which contains predicted specific patient’s neo-antigens, which is 
believed to provide more specific immune responses and better harness the existing anti-tumor 
immune responses in individual patient. In early phase of small cohort trial, melanoma patients treated 
with personalized cancer vaccine in combination with anti-PD-1 therapy showed striking clinical 
outcome (528, 611). Thus, cancer vaccine may provide safe, immunogenic and broad therapeutic 
options as a combinatory intervention to enhance tumor-specific immune responses.
IV.IV Stimulator of interferon gene (STING) pathway
STING, a transmembrane protein located on endoplasmic-reticulum (ER) membrane, acts as a sensor 
for cytosolic DNA to stimulate expression of interferon genes. Numerous cell types express the 
STING complex, such as endothelial, epithelial and hematopoietic cells (320). Mechanistically, 
cytosolic double strand DNA derived from pathogens or dying cells binds and activates cyclic GMP-
AMP synthase (cGAS). Activated cGAS catalyzes the conversion of ATP and GTP into cyclic 
guanosine monophosphate-adenosine monophosphate (cGAMP), the ligand of STING. The 
accumulation of cGAMP stimulates STING-dependent phosphorylation of tank-binding kinase 1 
(TBK1), which further phosphorylates the interferon regulatory factor 3 (IRF3). In addition, activated 
STING is reported to activate NF- -
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transcription of type I interferons (IFN) and pro-inflammatory cytokine (80, 320). In anti-tumor 
immunity, STING-mediated production of type I IFN in the TME activates CD103+ dendritic cells 
(cDC1), promotes T cell priming in lymph nodes and stimulates T cell recruitment into tumors (178, 
236, 771). STING agonists are shown to enhance CTL-mediated anti-tumor immunity and induce 
tumor regression of distant tumors (142). Furthermore, STING agonists in combination with cancer 
vaccines could eradicate established PD-1 blockade-resistant tumors (234). Currently, several STING 
agonists are tested under phase 1/2 clinical trials, in which STING agonists are used in combination 
with immune checkpoint blockade.
IV.V Targeting regulatory T cells
Tregs are the most potent suppressor in the TME due to their multi-faceted suppressive activities to 
myeloid cells and lymphocytes. The increased frequency of Tregs in tumors has also been reported to 
associate with poor clinical outcomes in different cancer types (165, 645). Moreover, depleting tumor-
infiltrating Tregs can reprogram the TME into immunosupportive and unleash anti-tumor responses 
(744).  These findings pave the foundations for Tregs-targeting cancer treatments. CD25, known as the 
interleukin-2 high-affinity receptor alpha chain (IL- regs and 
CD25 expression is critical for Tregs survival (613). Interventions that block CD25 signaling and 
induce antibody-dependent cell death (ADCC) were developed, including daclizumab (an anti-human 
CD25 antibody), and denileukin diftitox (a recombinant fusion protein combining human IL-2 and 
diptheria toxin fragment) (158, 324, 428, 576). However, those clinical data did not provide strong 
clinical benefit mainly because Tregs depletion is limited to the peripheral blood and lymph nodes but 
of anti-CD25 antibody can increase intratumoral Tregs depletion through ADCC and synergized PD-1
blockade (18). However, this type of Tregs-targeting approach remains difficult to be used because the 
systemic loss of Tregs will lead to severe inflammatory responses and autoimmunity. Hence, 
developing anti-CD25 antibody or other Tregs-depleting approaches to specifically target intratumoral 
Tregs without significant impact on other peripheral Tregs is an attractive strategy for cancer 
immunotherapy. Another way to inhibit Tregs functions in the TME is to block Tregs infiltration into 
tumors. CCR4/CCL22 and CCR4/CCL2 chemokine pathway have been revealed to control the 
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infiltration of Tregs into tumors (114, 153, 427). Anti-CCR4 mAb treatment can selectively decrease 
intratumoral Tregs number and induce host anti-tumor immunity (678). In line with these findings, 
anti-CCR4 mAb is under clinical trials, which display potent efficacy to augment immune responses 
(193, 525).
IV.VI Targeting NK cells
The engagement of NK cells represents an attractive immunotherapeutic strategy, due to their strong 
tumoricidal capacity. It has been demonstrated that activated NK cells can express PD-1 (7, 515) and 
CTLA4 (676). Accordingly, anti-PD-1 treatment in multiple myeloma was able to reengage NK cell 
anti-tumor responses (49). The direct impact of CTLA4 on NK cell function remains to be established 
(110, 382). CTLA4 is expressed on some cancer cells and NK cells express CD16 Fc receptor (138).
Therefore, anti-CTLA4 antibodies might induce NK cell-dependent cancer cell killing via ADCC 
(386). Moreover, CTLA4 blockade and subsequent cytokine production by T cells is likely to trigger 
NK cell anti-tumor responses. 
The use of agonistic antibodies represents a promising strategy to boost the effector functions of both, 
NK cells and T cells. Agonist antibodies for 4-1BB (CD137), which is expressed on cytotoxic NK 
cells and T cells, enhances anti-tumor immune activity in murine tumor models (37). Moreover, 4-
1BB antibodies enhance trastuzumab- and rituximab-induced ADCC of mammary tumors and 
lymphomas, respectively (360, 361). However, early clinical trials revealed significant toxicity of 
high dose treatment with 4-1BB antibodies (22). Finally, NK cells express the co-stimulatory 
molecules glucocorticoid-induced TNFR-related protein (GITR, CD357) and CD27 (455), both of 
which are considered as targets for agonist antibodies in cancer therapy. Combining these agonistic 
antibodies with blockade of inhibitory receptors is a promising approach to unleash NK cell 
cytotoxicity. 
Inhibitory KIRs dampen NK cell cytotoxicity upon interaction with self-MHC class I molecules on 
cancer cells. Moreover, inhibitory KIRs are also expressed by some effector CD4+ and CD8+ T cells. 
Hence, KIR-neutralizing immunotherapies have the potential to boost the cytotoxic activity of both T 
cells and NK cells. IPH2102 is a monoclonal antibody that interferes with KIR2DL1, KIR2DL2 and 
KIR2DL3 and enhances NK cell-mediated in vitro killing of cancer cells (595, 712). However, phase 
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1 and 2 clinical trials using anti-KIR as a monotherapy in acute myeloid leukemia (AML) or multiple 
myeloma have shown little clinical efficacy (50, 51, 727). Yet, KIR blockade might show synergy 
with CTLA4 or PD-1 checkpoint blockade which could further enhance NK cell function. 
In addition to genetically engineered T cells, genetic modification of NK cells represents a promising 
immunotherapeutic strategy for cancer (256). The NK cell leukemia-derived NK-92 cell line has been 
successfully engineered to express activating chimeric antigen receptors (CARs) specific for tumor 
antigens (298), including CD19 (59) and CD20 (492) on B cell lymphomas, the glycolipid 
disialoganglioside GD2, on neuroblastoma (204), HER2, on carcinomas (635, 708), epithelial cell 
adhesion molecule (EPCAM), on cancer stem cells (612), prostate stem cell antigen (PSCA) (701)
and CD138, on multiple myeloma cells (331). However, NK-92 cells have some disadvantages that 
limit their clinical utility. NK-92 is a leukemia cell line that is positive for the Epstein–Barr virus 
(EBV) and lack the expression of certain NK cell-activating receptors, including NCRs and CD16. 
Thus, in order to prevent uncontrolled proliferation, NK-92 cells must be irradiated prior to adoptive 
transfer. Alternative approaches have used primary NK cells from peripheral blood or derived from 
pluripotent stem cells (197, 356).
In spite of these encouraging results, there are numerous obstacles to overcome in order to maximize 
the outcome of NK cell-based immunotherapies, including the systemic toxicity of cytokines such as 
IL-2, IL-12 and IL-15 (226, 273), poor NK cell infiltration of solid tumors as well as the elimination 
of factors that suppress NK cell function within the tumor (i.e. Tregs, MDSCs and immunosuppressive 
cytokines such as TGF- te goal to 
enhance NK cell infiltration and performance in solid tumors are desperately needed. For instance, a 
recent study showed that NK cells require HIF-1 for the infiltration of hypoxic tumors and 
subsequent cancer cell lysis (373). Therefore, it is tempting to speculate whether tuning the HIF 
expression in NK cells prior to transfer, e.g. by genetic or pharmacological inhibition of prolyl 
hydroxylases, would be able to increase the infiltration and/or performance of NK cells in solid 
tumors.
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IV.VII Targeting myeloid cells
In the last decade, immunotherapeutic options aiming to kill TAMs, to block their recruitment into the 
tumor or to re-educate their phenotype from a pro-tumor to a tumoricidal and immune stimulatory 
phenotype have been explored (517, 571).
The most advanced approach in clinical trials is probably the use of small molecule inhibitors of the 
tyrosine kinase activity of CSF1R (e.g., PLX3397) or blocking antibodies against the cognate ligand 
CSF1 (e.g., PD-0360324) or the receptor itself (e.g., emactuzumab, cabiralizumab). Besides the
importance of CSF1 for survival and differentiation of macrophages in general, pro-tumor (M2-like) 
macrophages express most of the CSF1R and are more strictly dependent on this pathway (566).
Targeting CSF1/CSF1R pathway can reduce TAM numbers and concomitantly increase the 
CD8+/CD4+ T cell ratio (584), polarize TAMs towards an anti-tumor phenotype (566) or result in a 
specific killing of the CD206high M2-like TAM population and sensitization to anti-CTLA4 (800).
Moreover, anti-PD-1 treatment may promote the secretion of CSF1 and the recruitment of TAMs. 
Thus, in this scenario combination of anti-PD-1 with anti-CSF1R be beneficial (503). Thus, the 
diversity of the targeting agent or, to a larger extent, the context specificity of the tumor type/model 
can underpin the different mechanism-of-action of CSF1(R) blockade alone or in combination with 
ICB. 
Differently from CSF1, CCL2 (also known as MCP1) triggers CCR2-mediated release of monocytes 
from the bone marrow and their recruitment to the tumor (114, 567), where they can differentiate into 
TAMs or MDSCs, induce IL-4 mediated TH2 polarization (269) and CCR4-mediated Tregs recruitment 
(114, 427). CCL2 inhibition of metastasis-associated macrophages (MAMs) in breast cancer 
metastasis is efficient while the treatment is endorsed (60, 567). However, upon treatment withdrawal, 
a rebound of CCL2, together with a boost in IL-6 and VEGF, enhanced macrophage release from the 
bone marrow into the metastatic site with worsening of the metastatic disease outcome (60). This 
study warns some caution on possible therapeutic windows of such an approach. Antibodies or small 
molecule inhibitors of against CCR2 or CCL2 (i.e.PF-6309, Carlumab (CNT088)) have been tested in 
preclinical settings and in phase 1 or 2 clinical trials, alone or in combination (69, 801). Of note, 
Carlumab did not show prolonged inhibition of CCL2 (619).
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Next to strategies aiming to block macrophage differentiation and recruitment, there are other 
strategies aiming to harness one or more macrophage functions. Agonist CD40 antibodies (e.g., 
ABBV-927 and APX005M) are tested in phase 1 and 2 clinical trials with promising results. CD40 
agonists have demonstrated synergistic activity in combination with gemcitabine and resulted in 
complete tumor regression in preclinical models when paired with an anti-PD-1 and/or anti-CTLA4 
(42, 43, 804). Mechanistically, CD40 agonists induce macrophage repolarization from an M2 to an 
M1 phenotype and their cytotoxic effect is T cell independent. However, CD40 activation in DCs is 
important for their maturation and efficient antigen presentation that leads ultimately to a boost in 
CTL infiltration and activation (42, 43). This aspect is important in the clinic when cold tumors such 
as pancreatic cancer need to be converted into a T cell inflamed tumor, prior administration of 
checkpoint inhibitors. Moreover, CD40 activation in innate immune cells converts PD-1high T cells 
into PD-1low T cells, reversing T cell exhaustion and reverting anti-PD-1 refractoriness (507). Despite 
the scarcity of late stage clinical studies, positive results from two trials (NCT03214250 and 
NCT02304393) combining CD40 activating antibodies with anti-PD-1/anti-PD-L1, could place CD40 
agonists at the forefront in the immunoncology space. 
Another key molecule involved in innate immunity and macrophage function is integrin-associated 
protein (IAP or CD47). CD47 is a receptor found to be overexpressed on cancer cells and acts as a 
“don’t eat me” signal to macrophages. CD47 binds the transmembrane signaling protein signal-
) expressed by TAMs (657). The interaction of CD47 with inhibits 
macrophage phagocytosis, allowing cancer cells to escape immune surveillance (228). Moreover, the 
therapeutic effect of CD47 blockade may also rely on dendritic cell but not macrophage cross-priming 
of T cell responses (420). Hu5F9 and TTI-621 are CD47 antagonists currently undergoing clinical 
trials (228).
Tie2-expressing monocytes/macrophages (TEMs) are a highly pro-angiogenic subpopulation of 
myeloid cells in circulation and tumors, where they are closely aligned to tumor vessels expressing 
angiopoietin-2 (Ang2) (131, 133, 162, 451). Moreover, TEMs can express IL-10 and the Tregs
chemoattractant CCL17 (133) and can suppress CTL proliferation and enhance Tregs expansion (131).
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Of note, hypoxia can induce both Ang2 and Tie2 expression (279, 401). Thus, disrupting the 
Tie2/Ang2 signaling pathway is an attractive anti-tumor and anti-metastatic strategy (131, 133, 451).
In sum, as hypoxia and nutrient scarcity in the TME are major factors that polarize TAMs to a pro-
tumor phenotype and that strongly impact on T and NK cell fitness, reduction of hypoxia or 
interventions targeting macrophage metabolism can be an alternative approach to induce anti-tumor 
immunity.
V. Direct and indirect effects of hypoxia on the immune landscape of the tumor 
The family of hypoxia inducible factors (HIFs) are key orchestrators of the adaptive response to 
hypoxia and have a prominent role in the immune system (532, 640). HIF is a heterodimeric 
t - of one of the highly regulated 
s (HIF- - . HIF- -
cell-specific manner and they activate overlapping but also a unique set of genes (532). Upon 
dimerization, HIF binds to hypoxia response elements (HRE) in the genome and drives the 
transcription of genes involved in angiogenesis, lymphangiogenesis, ECM remodeling, metabolic 
reprogramming, cell proliferation, invasion and immunomodulation. 
HIF- -translational level by the O2/PHD/VHL axis. In 
normoxia, O2-sensing prolyl hydroxylases (PHDs) hydroxylate proline residues of HIF-
then be recognized and polyubiquitinated by the Von Hippel Lindau (VHL) E3 ligase and targeted for 
proteasomal degradation (321, 322, 789). In addition, hydroxylation of asparaginyl residues by O2-
sensing factor inhibiting HIF (FIH) prevents the interaction of HIF- oactivators and thus the 
formation of an effective transcriptional complex (381, 439). Of note, the role of FIH expression in 
immune cells is completely underexplored. In some cells, an hypoxia-independent mechanism of 
phosphorylation and dephosphorylation of PHD2 poses another layer of regulation of the HIF 
response (174, 175). In the immune system, the transcription of HIF- 2-
independent signaling pathways (i.e. TLR/NF- B, TCR/PI3K/mTOR and ERK pathways), a process 
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sometimes named pseudo-hypoxia. Importantly, HIF-
status of the cell. PHDs and FIH require Fe2+ - -KG) as cofactors and produce 
succinate as a byproduct of HIF hydroxylation (321, 322, 381, 789). The oncometabolite 2-
hydroxyglutarate (2-HG) competes for the -KG and acts as a competitive inhibitor of 
PHD/FIH (775). Reactive oxygen species (ROS) can also promote HIF-
mechanisms (487). Thus, the activation and metabolic status of the cell can govern HIF stabilization 
even in situations when oxygen is available by modulating PHD/FIH activity or by triggering O2-
independent HIF stabilization. 
Oxygen tension and metabolite fluctuations within the tumor establish distinct niches that profoundly 
shape immune cell localization and phenotype (98). Besides the shortage of oxygen, tumor hypoxic 
areas exhibit a range of other distinctive traits. Hypoxia directly modulates the expression of several 
cytokines and chemokines and induces the expression of CD39 and CD73, fostering the accumulation 
of the immunosuppressive metabolite adenosine. HIF-
which subsequently results in glucose depletion, lactate accumulation and acidification of the TME. 
Poor vessel coverage and perfusion are exacerbated in hypoxic areas, directly affecting immune cell 
trafficking and aggravating the shortage of oxygen and nutrients and the accumulation of metabolic 
byproducts. Thus, the term “tumor hypoxia” can encompass not only oxygen shortage but also the 
effect of the other abovementioned hypoxia-related traits. Moreover, since HIF- stabilization can be 
induced by other stimuli besides hypoxia, an integrative vision on both the effect of cell intrinsic HIF-
required to fully understand how tumor hypoxia 
influences tumor-infiltrating cells.
In sum, bearing in mind the intertwined relationship between oxygen and metabolism, a simplified, 
though more general conclusion might be that i) the normoxic niche is characterized by having higher 
oxygen and nutrient availability and by being rather immunostimulatory and ii) the hypoxic niche is 
characterized by having lower oxygen availability and low pH, and by being rich in lactate and 
adenosine, ultimately favoring immunosuppression. Accordingly, the definition of “metabolic 
immune niches”, taking into account both the relative positioning and skewing of specific immune 
cell subsets, is a potent tool to predict progression and therapy response. For example, more 
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macrophages in the hypoxic regions and perivascular areas of the tumor or more T cells at the edge of 
the tumor are a readout of bad prognosis, whereas abundance of TAMs in more normoxic areas or T 
cells within the tumor core are signs of good disease outcome (17, 99, 100, 242, 243, 402, 702, 761, 
786, 794). A recent study revealed a unique gene signature in TAMs from breast cancer patients and 
identified a crosstalk between cancer cells and TAMs that enhances their pro-tumor functions and 
correlates with aggressiveness and short survival (104). It would be relevant to study whether this 
crosstalk takes place within a particular intratumoral niche. We have recently described a subset of 
podoplanin-expressing macrophages (PoEMs) located in the proximity of lymphatic vessels where 
they foster lymphangiogenesis and lymphoinvasion. From a metabolic point of view, this 
perilymphatic population of TAMs is characterized by high expression of genes related to glucose 
uptake and anaerobic glycolysis (54). In breast cancer patients, association of PoEMs with tumor 
lymphatic vessels correlates with lymph node and distant metastasis (54). Moreover, different T cell 
subsets also exhibit distinctive locations that may have opposite prognostic value (702). While Tregs
are mainly concentrated in hypoxic areas, effector T cells are normally present around blood vessels 
and away from hypoxic areas (293, 379). The presence of Nrp1+ Tregs correlates with poor prognosis 
in melanoma and head and neck squamous cell carcinoma patients (530). In this line, human clinical 
data indicated that higher intratumoral TH2 cells infiltration reduced patient survival rate in pancreatic 
cancer patient as well as other tumor types, whereas these correlations are gone when looking at the 
total T cell population (159).
In this section we will focus on how tumor hypoxia dictates immune cell positioning, in particular 
within the normoxic and the hypoxic niches. Moreover, we will analyze the current knowledge on 
how the HIF pathway and tumor hypoxia regulate different aspects of immune cell function.
V.I Effect of hypoxia on innate immunity
V.I.I Effect of hypoxia on macrophages
Macrophages infiltrate solid tumors in large numbers and contribute to create a microenvironment 
that favors immune evasion, tumor angiogenesis and metastasis. Macrophages in hypoxic tumor
regions express low levels of MHC-II (384, 489) and can interfere with the anti-tumor functions of 
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adaptive immunity (295). Tumor hypoxia promotes the recruitment of myeloid cell populations from 
the bone marrow via several mechanisms. Hypoxia-induced HIF- stabilization drives the 
expression of chemokines such as CCL5 and CXCL12 (also known as SDF1a) by cancer cells (189, 
413) as well as the expression of their cognate receptor CXCR4 on macrophages (632, 674).
Likewise, hypoxia increases cancer cell expression of the myeloid cell chemoattractants VEGF-A and 
the endothelins (ET-1 and ET-2) in a HIF- -dependent fashion (182, 265, 266, 398). The release of 
ATP and other DAMPs from hypoxic dying cells induces the recruitment and entrapment of TAMs to 
hypoxic and necrotic regions via the engagement of nucleotide receptors (P2XRs/P2YRs) and PRRs, 
respectively (120, 202). Finally, we have shown that hypoxia-driven expression of semaphorin3A 
(Sema3A) by cancer cells controls TAMs localization in hypoxic areas (99). Sema3A binds to Nrp-1
and PlexinA1/A4 on TAMs and attracts them to hypoxic tumors through VEGFR1 signaling. Hypoxia 
suppresses Nrp-1 expression on the TAMs surface and then Sema3A-PlexinA1/A4 mediate stop 
signals that ultimately lead to their entrapment in hypoxic areas. Accordingly, macrophage-specific 
deletion of Nrp-1 impaired TAMs recruitment into hypoxic tumors, angiogenesis and tumor growth
and enhanced tumor immunity (99). The relevance of these findings has been underscored by two 
independent groups working in glioma. Genetic KO of Nrp1 in microglia and macrophages, systemic 
pharmacological inhibition of Nrp1 and treatment of patient-derived xenografts with anti-Sema3A 
had strong anti-tumor effect via impairing the recruitment of TAMs and reshaping of the 
inflammatory response (393, 476). The HIF- isoform also plays and important role for the 
infiltration and migration of TAMs via the regulation of chemotactic receptor expression (CSF1R and 
CXCR4) (318). Macrophage-specific deletion of HIF- reduced the tumor infiltration by TAMs and 
improved the outcome of hepatocellular carcinoma and colitis-associated colon carcinoma (318)
(Figure 2).
The HIF pathway plays a central role in macrophage biology: from supporting the pro-inflammatory 
cytokine secretion, antigen presentation and glycolytic metabolism of M1-like macrophages during 
the early stages of tumorigenesis, to fueling the pro-tumor functions of M2-like macrophages in 
established solid tumors. M1 and M2 macrophages differentially express HIF-1 and HIF- , and 
HIF stabilization in macrophages can take place both under normoxia and under hypoxia. Hypoxia via 
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HIF- enhances phagocytosis and antigen presentation in a mechanism involving p38 (11) and the 
production of IFN- and autocrine signaling (2). In M1 macrophages, HIF- is essential to promote 
and sustain glycolysis and energy production (section VII.I.I) (148). Hypoxia strongly impacts the 
macrophage-mediated suppression of adaptive immunity for instance, via the HIF- -mediated 
differentiation of immunosuppressive MDSCs into TAMs and their expression of PD-L1 ligand,
ARG1 and NOS2 (145, 511) and via the induction of Arg1 gene expression in macrophages (426).
Besides hypoxia, TH1 and TH2 cytokines stabilize HIF- - in M1 and M2 macrophages, 
respectively, which oppositely regulate NO homeostasis (684). HIF- induces the expression of 
NOS2 in M1 macrophages, which converts L-arginine into NO and citrulline, whereas HIF-
induces the expression of ARG1 in M2 macrophages, which breaks down L-arginine into L-ornithine 
and urea (684). NOS2-mediated NO production has dual effects on tumor growth depending on the 
stage and context: while it can promote cancer cell killing, it can also stimulate the secretion of ROS 
and RNS, which impair the anti-tumor adaptive immune response (720). L-arginine depletion due to
macrophage ARG1 or NOS2 activity has strong inhibitory effects on T cell mediated anti-tumor
responses (186, 588-591, 684). In this line, macrophage-specific deletion of HIF-
growth of murine breast adenocarcinomas by improving T cell proliferation and function (186, 400).
Moreover, hypoxic macrophages may contribute to the recruitment of neutrophils via the HIF-
mediated upregulation of IL-8 (212).
One of the most well documented consequences of HIF- stabilization in macrophages is the 
promotion of tumor angiogenesis. TAMs have been described to increase in number in premalignant 
lesions just before the angiogenic switch that precedes the transition to malignancy. Depletion of 
macrophages resulted in a reduction in vascular density, causing delayed tumor progression and 
metastasis. In turn, reintroduction of macrophages or VEGF-A led to a significant increase in vascular 
density and enhanced tumor progression (411, 412). In mice lacking VEGF-A specifically in myeloid 
cells the angiogenic switch does not occur, highlighting the role of myeloid-derived VEGF-A in fine-
tuning tumor angiogenesis (675). Loss of VEGF-A expression in myeloid cells resulted in a marked 
increase in pericyte coverage and tumor oxygenation, indicating vascular normalization, which 
surprisingly resulted in a significantly higher tumor burden but it also rendered these tumors 
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vulnerable to chemotherapy (675). Hypoxic areas of tumors are also rich in lactate, which can drive 
VEGF-A expression by TAMs via the stabilization of HIF- (135). HIF- -dependent expression of 
the matrix metalloproteinase MMP9 by hypoxic TAMs contributes to tumor angiogenesis by releasing 
VEGF-A from the extracellular matrix and thus contributing to its bioavailability (189). Hypoxia 
fosters the pro-angiogenic function of TAMs via the hypoxia-driven upregulation of the mTOR 
inhibitor REDD1. In turn, REDD1 tunes down glucose uptake and glycolysis in hypoxic TAMs,
thereby tilting the competition for glucose in favor of glycolytic endothelial cells, which thus acquire 
a motile and pro-angiogenic phenotype (87, 761). Contrary to HIF- , HIF- does not seem to 
contribute to VEGF-A expression in TAMs (3, 205), but it controls the expression soluble VEGF 
receptor 1 (sVEGFR1), which acts as a VEGF trap and, therefore, has an anti-angiogenic function 
(587). In addition to macrophages, Tie2-expressing monocytes (TEMs) represent another myeloid cell 
type that can contribute to tumor angiogenesis (162). Interestingly, hypoxia contributes to Tie2 
expression, which is important for the recruitment and function of these cells (401).
In summary, therapeutic interventions aiming to block the hypoxic response in macrophages could 
potentially re-educate pro-tumor hypoxic TAMs and rewire them into anti-tumor macrophages. 
Importantly, HIF- and other anti-tumor 
immune cells (section VII), and this should raise caution on the use of HIF inhibitors and prompt the 
development of other more selective targets.
V.I.II Effect of hypoxia on neutrophils and MDSCs
Several studies reported that hypoxia induces cancer cell-derived production of neutrophil-attracting 
chemokines (i.e. IL-8, CXCL1, CXCL2 and CXCL5). IL-8 has been found around necrotic and 
presumably hypoxic areas in metastatic lesions from aggressive melanoma patients (377) as well as in 
implanted tumors of human pancreatic cell lines into nude mice (653). In vitro studies revealed that 
hypoxia, acidosis and the hypoxia/ROS/NF- B axis were responsible for the upregulation of IL-8 in 
IL-8-expressing cell lines (377, 477, 653). Interestingly, induction of IL-8 in HIF-1-deficient cancer
cells was accompanied by a strong infiltration of neutrophils (477). Besides cancer cells, hypoxic 
macrophages may contribute to the IL-8-mediated recruitment of neutrophils, although the importance 
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of this contribution within the tumor remains unknown (212). At the time that these studies were 
carried out, neutrophils were regarded as mere bystanders of tumor progression due to their alleged 
short lifespan. Therefore, although the pro-angiogenic effects of IL-8 have been at least in part 
attributed to its CXCR1-mediated effect on endothelial cells (377, 477, 653), further studies are 
required to assess whether IL-8-recruited neutrophils actively contribute to the observed effects of IL-
8. In addition to its role as a chemokine, tumor-derived IL-8 induces the exocytosis of ARG1 by 
neutrophils, thereby contributing to T cell suppression (600). In early stage PTEN-deficient uterine 
tumors, hypoxia-induced cancer cell expression of CXCL1, CXCL2 and CXCL5 promotes the 
recruitment of CXCR2+ anti-tumor neutrophils, resulting in a reduced tumor growth (56).
Intriguingly, in PTEN-deficient murine prostate tumors the YAP-dependent expression of CXCL5 
promoted the recruitment of CXCR+ MDSCs, which in this case favored tumor growth (742). These 
apparently conflicting studies highlight the fact that the pro- or anti-tumor role of neutrophils, as other 
immune cells, likely depends on several environmental factors and thus, on the tumor subtype and 
stage. In the context of tissue inflammation, hypoxia and HIF-
thereby facilitating their adhesion to the endothelium (364) and, on the other hand, via the stimulation 
of Sema7A expression by endothelial cells, which facilitates neutrophil transmigration by engaging 
with PlexinC1 on neutrophils (482). Whether these mechanisms are also at stage in the context of
tumor hypoxia needs further investigation (Figure 2).
Hypoxia influences many aspects of neutrophil biology including neutrophil lifespan, metabolism and 
phenotype (148). Neutrophil apoptosis is tightly controlled to avoid excessive pro-inflammatory 
immune reactions. Hypoxia-induced activation of HIF- -life via the 
activation of NF- B and the secretion of CCL4/MIP- (738, 739). Besides, HIF- -mediated 
metabolic reprogramming towards glycolysis is essential for neutrophil survival (608). In line with 
this, loss of PHD2 in neutrophils promoted neutrophil survival, enhanced neutrophil chemotaxis and 
increased their functional capacity (608). In contrast, hypoxia-induced PHD3 expression in 
neutrophils is essential for hypoxic neutrophil survival, but not for other neutrophil functions, in a 
HIF-independent mechanism that involves the pro-apoptotic molecules Siva1 and Bcl-XL (737). A 
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recent study revealed that HIF-
neutrophils, but is not required for chemotaxis, phagocytosis and respiratory burst (693). Thus, since 
neutrophils will likely encounter hypoxia in the TME, HIF- -
will likely elongate the half-life of tumor-associated neutrophils (TANs). Tumor hypoxia induces PD-
L1 expression in MDSCs in a HIF- HIF- (511). The seminal study by 
Fridlender et al. revealed that TGF- stimulated the recruitment and activation of “N1” anti-
tumor neutrophils (233). Since TGF-
that hypoxic TANs might be polarized towards an “N2” phenotype. Finally, neutrophils’ respiratory 
burst consumes important amounts of molecular oxygen, placing neutrophils as a potential contributor 
to perpetuate tumor hypoxia (85).
Of note, many of the abovementioned studies used models for inflammation-related diseases. Given 
that neutrophils encounter hypoxia in the TME, it would be of outmost importance to shed light into 
the role of hypoxia and the HIF pathway in neutrophils in the context of tumor biology. Furthermore, 
since most studies used the LysM promoter, which is more active in macrophages than in neutrophils 
(1), we recommend to use neutrophil-specific promoters such as MRP8 (544) or Ly-6G (292).
V.I.III Effect of hypoxia on dendritic cells (DCs)
The effect of hypoxia and HIFs on the activation, maturation and function of DCs has been addressed 
in several in vitro settings and murine models of inflammation. Yet, these studies have reached 
contradictory conclusions (767). Furthermore, there is still a significant gap of knowledge regarding 
its effects on DC recruitment, position and function in the context of the tumor. 
Unlike the positive effect of hypoxia on macrophage phagocytosis, culture of human immature DCs 
under hypoxia represses their antigen uptake capacity, characteristic of immature DCs, in a 
mechanism that does not involve HIF- (200, 524). Given the impact of antigen presentation by 
TIDCs to CTLs on the effectiveness of CTL-mediated tumor rejection, it would be relevant to unravel 
whether tumor hypoxia can affect this process. In addition, hypoxia fuels the migratory capacity of 
immature and mature DCs through the upregulation of chemokine receptors while it simultaneously 
represses cytokine expression (218, 359, 581). Several HIF- -dependent and independent 
mechanisms have been proposed. In contrast, other authors reported that hypoxia can impair the 
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motility of monocyte-derived DCs by modulating the expression of metalloproteinases (796) and their 
inhibitors (570). A recent report demonstrated that stimulation of TLRs under normoxia induces 
glycolytic metabolism in DCs partially via the stabilization of HIF-
essential for the oligomerization of CCR7 and the migration of DCs towards the lymph nodes (270).
Moreover, inhibition of glycolysis by 2-DG injection in vivo impaired the migration of DCs to the 
lungs in a model of HDM-induced allergic asthma model (270). Several inflammatory signals alone 
or in synergy with hypoxia can stabilize HIF- and induce the expression of costimulatory molecules 
(200, 328, 572, 581). In this line, hypoxia-differentiated DCs had an enhanced T cell stimulatory 
ability in vitro that required HIF- and mTOR (572), supporting the idea that hypoxia rather favors 
the functions of mature DCs. However, other authors reported that hypoxia did not alter the T cell 
stimulatory capacity of DCs (200). Altogether, in the context of inflammatory hypoxia in vitro, HIF-
stabilization following hypoxia and/or TLR stimuli seems to trigger the first steps required for DC 
maturation: migration from the hypoxic site, usually rich in molecules that dampen the full maturation 
of DCs (i.e. VEGF) (238), to maturation-permissive environments such as the lymph nodes and 
expression of T cell stimulatory molecules. Importantly, in vivo studies using murine models of 
inflammatory diseases indicate that HIF- in DCs limits CD8+ T cell expansion (281) as well as TH1
inflammatory responses (280) and is essential for the induction of Tregs (227). Mechanistically, HIF-
in DCs impairs the production of IL-12, necessary for CD8+ T cell expansion and TH1 responses 
(280, 281), while it promotes the production of IL-10 and TGF- , potent inducers of Tregs (227).
Finally, HIF- negatively regulates the development of plasmacytoid DCs and genetic deletion of 
HIF- in myeloid cells augmented infiltration of PyMT-MMTV tumors by pDCs (759). It still 
remains unclear whether this is a direct result of the lack of HIF- in pDCs or an indirect result of 
the lack of HIF- in other myeloid cells. 
The discrepancy between the abovementioned studies highlights the importance of taking into account 
the whole complexity of the environment in which dendritic cells, in this case, carry out their 
functions. While hypoxia is a common trait of inflammatory sites and tumors, the cytokine and 
metabolic milieu are notably different. For instance, hypoxia in the TME is commonly accompanied 
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by glucose deprivation. Thus, further studies are required to shed light into the important question on 
how TIDCs are affected by the global composition of the TME.
V.I.IV Effect of hypoxia on innate lymphoid cells (ILCs)
The knowledge about the effect of hypoxia on innate lymphoid cell function tumors is still scarce and 
most of studies so far have focused on the NK cell subset. High numbers of NK cells within the tumor 
predict outcome in various types of cancers. It has been shown that the preoperative activity of NK 
cells predicts distant metastasis after tumor removal (363). The existing pre-clinical data suggests that 
NK cells primarily kill circulating cancer cells but show very low killing activity against established 
solid tumors (130, 272, 730). Nevertheless, more recent studies indicate that NK cells are capable of 
controlling solid tumor growth, particularly during early tumorigenesis (385). The cancer cell-killing 
efficiency of NK cells in solid tumors seems to depend rather on the activation state of NK cells, 
which can be modulated by the availability of oxygen. Hence, it is much more difficult to explain the 
link of NK cell density and outcome in solid tumors, given its dynamic oxygen gradients. 
Hypoxia in hepatitis C-infected livers has been shown to compromise the anti-viral NK cell response
(770). In the cancer setting, Sceneay et al. reported that myeloid immune suppressor cells indirectly
inhibition NK cell function in the hypoxic primary TME and metastatic niches (626). Furthermore,
several reports suggest a direct suppression of NK cell function by hypoxia via multiple mechanisms. 
For instance, hypoxia decreases the expression of NKG2D on the surface of NK cells. This is partially 
driven by the release TGF- -containing tumor microvesicles in response to hypoxia (33, 512, 621). In 
a similar fashion, tumor microvesicles that deliver miR-210 to NK cells decrease the release of 
cytotoxic granules and the expression of the degranulation marker CD107a (512). From a therapeutic 
point of view, it will be key to reveal mechanisms that allow the reversal of hypoxia-induced NK cell 
inhibition. In this line, the study by Sarkar et al. suggests that hypoxic suppression of NK cell 
performance can be reversed by exogenous IL-2 treatment (621). In contrast, a transition of normoxic, 
pre-activated NK cells to an hypoxic environment leads to robust proliferation and enhanced effector 
function via stabilization of HIF-
adoptive NK cell transfer, where NK cells can be stimulated prior to transfer (349).
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Recently, it has been shown that NK cells infiltrate into hypoxic areas in murine tumor models. NK 
cell-specific deletion of HIF- reduced overall intratumoral NK cell densities and decreased overall 
NK cell cytotoxicity. Moreover, while HIF- -proficient NK cells were predominantly found in 
hypoxic areas, loss of HIF- induced the accumulation of NK cells in normoxic areas, inverting this 
situation (373). Curiously, specific deletion of HIF- s impaired tumor growth 
independently of their cytotoxic activity, but because it resulted in non-functional angiogenesis likely 
resulting from the decrease in sVEGFR1-expressing NK cells especially in hypoxic areas.
Intriguingly, HIF- deficiency in NK cells gave rise to increased metastasis despite impaired growth 
of primary tumors. Whether hypoxia is the ultimate cause of HIF-
demands further clarification. In this setting it is not understood yet to which extend the loss of HIF-
in NK cells compromises infiltration, survival or proliferation in hypoxic tumors. Nevertheless,
this study strongly indicates that in addition to NK cell numbers, the positioning of NK cells within 
the oxygen gradient of tumor might be a prognostic factor. Noteworthy, boosting the hypoxic 
response in NK cells should have the opposite effect, increased cytotoxicity and vascular stabilization. 
Therefore, the HIF pathway could represent a promising target to enhance NK cell performance in the 
TME (Figure 2).
In addition to the impact of hypoxia on NK cell function, it is important to take into account the NK 
cell-extrinsic effects on a target cell, e.g. its susceptibility to lysis by NK cells. For instance, hypoxia 
leads to HIF- -dependent downregulation of the activating NKG2D ligand MICA in cancer cells 
(778). Moreover, hypoxic cancer cells engage autophagy, which results in the degradation of cytolytic 
Granzyme B and impaired NK cell-mediated lysis (30). Moreover, hypoxia-induced autophagy blunts 
NK cell-dependent cancer cell killing via the degradation of the membrane connexin 43 in the cancer 
cell (698). There is also data showing that VHL-deficient clear cell renal cell carcinoma cells acquire 
resistance to NK cell-dependent killing, involving the accumulation of inositol 1,4,5-trisphosphate 
receptor type 1 (ITPR1), an intracellular channel that mediates calcium release and ER stress-induced 
apoptosis (461, 462). Therefore, targeting ITPR1 could reinstate cancer cell elimination by NK cells.
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In summary, it becomes clear tumor hypoxia rather contributes to tumor escape from NK cell-
mediated immunosurveillance. Therefore, dissecting the critically involved and hypoxia-associated 
pathways in the TME will likely yield attractive immunotherapeutic targets.
V.II Effect of hypoxia on adaptive immunity
V.II.I Effect of hypoxia on CD4+ T cells
Hypoxia modulates the expression of several T cell attracting chemokines by cancer cells and other 
immune cells. Hypoxic cancer cells, via HIF- secrete the chemokine CCL28 that recruits 
CXCR10+ Tregs into tumors (208). Cancer cell-derived VEGF-A has been shown to regulate Tregs
chemotaxis by binding to Neuropilin-1 (Nrp1) on their surface. Consequently, a T cell-specific 
deletion of Nrp1 prevents Tregs infiltration into melanomas, breaking down an important mechanism 
for immune evasion, enhances the infiltration and activation of CD8+ T cells and limits tumor growth 
(285). Whether other Nrp1 ligands also mediate the recruitment of Tregs or other T cell subsets into the 
tumor or into hypoxic tumor niches remains unknown. Tumor-associated neutrophils (TANs), an in 
particular N2 TANs, produce CCL17 and promote the recruitment of Tregs (471). Since N2 TANs 
arise in response to TGF- (233), a cytokine highly abundant in hypoxic regions of the tumor, it 
would be interesting to unravel whether this chemotactic signal also affects intratumoral Tregs
positioning. Although a direct link between hypoxia and CXCL9/10 expression has not been 
described, hypoxia could indirectly modulate the availability of these important T cell attracting 
chemokines through its effects on CXCL9/10-expressing cell types. Moreover, further investigations 
are required to assess whether hypoxia also impacts the trafficking of other CD4+ T cell subsets
(Figure 2).
Given that the thymus and the secondary lymphoid organs tend to have lower oxygen tension (0,5-
4,5%) than the bloodstream, we can conclude that activation of naïve T cells in secondary lymphoid 
organs takes place under hypoxia (83). After activation, CD4+ T cells undergo differentiation into 
various T effector or regulatory subsets. Hypoxia and HIF-
divergent roles have been described suggesting, again, that i) combined environmental conditions 
such as hypoxia and cytokine and metabolic milieu can fine-tune a different response than each 
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condition alone and that ii) hypoxia-induced HIF- -
different effects (174).
HIF- TH17 and Tregs differentiation and the presence of other cytokines, namely 
TGF- and/or IL-6, are crucial to tilt the balance (Figure 3). A protocol mimicking the fluctuations in 
O2 levels that accompany T cell activation in vivo supports this notion, which consists of priming of T 
cells in under mild hypoxia (5% O2), as occurs in the lymph nodes, followed by reoxygenation
mirroring T cells entry in the normoxic bloodstream (316). TGF- instructs the differentiation of both 
TH17 and Tregs (799). In the 
absence of other cytokines, TGF- - regs
differentiation in vitro. The addition of the TH17-polarizing cytokines IL-6, IL-21 and IL-23, in 
contrast, es its Foxp3-imposed suppression, therefore 
promoting TH17 polarization (799). Moreover, hypoxia-driven HIF-
differentiation of Tregs in a mechanism mediated by TGF- -6
and TGF- H17 polarization (128). In this line, Dang et al. 
unraveled that HIF- H17-polarizing conditions, both in hypoxia and in 
normoxia, enhances TH17 and opposes Tregs -17 
transcription and the proteasomal degradation of Foxp3 (156). Shi et al. described that TH17-
polarizing conditions induce an mTORC1-driven stabilization of HIF-
checkpoint to induce glycolysis. This metabolic shift towards glycolysis is required to support of 
TH17 metabolic demands while it blunts Tregs development  (652). Noteworthy, the effect of HIF-
stabilization under hypoxia was not tested. Interfering with any of the steps of the mTORC1/HIF-
H17 polarization, including loss of HIF- irs TH17 
differentiation and tilts the balance towards the formation of Tregs, which accordingly confers 
protection against TH17 -mediated neuroinflammation (156, 652). Supporting this, hypoxia via HIF-
glycolysis-driven migratory capacity of Tregs and their tumor infiltration, but it tunes 
down its OXPHOS-driven immunosuppressive capacity (473). In glioblastoma, Tregs-specific deletion 
of HIF- s to a decreased infiltration of Tregs and to an extended survival, thus indicating that the 
infiltration defect overrules the potential enhanced immunosuppressive activity (473). Activation 
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under hypoxia followed by reoxygenation potentiates TH17 polarization, but not TH1 and Tregs, in a 
hypoxia/mTORC1/HIF- -driven mechanism (316). Interestingly, hypoxia/reoxygenation and TCR 
stimulation synergistically induce the expression of the HIF- -210 in TH17 cells, 
which acts as a negative feedback loop to tune down HIF- H17 differentiation. In a 
TH17-driven model of inflammatory colitis, T cell-specific deficiency of miR-210 fostered TH17 
formation as well as the conversion of TH17 cells into TH1-like cells, therefore worsening the disease 
severity (743). In conclusion, the differentiation of activated CD4+ T cells into TH17 or Tregs in 
response to hypoxia and TGF- - concentrations and on the presence or the absence 
of TH17-polarizing cytokines (128, 799) (Figure 3). HIF- either induced by hypoxia and/or by 
other stimuli such as TCR ligation, is at the crossroads of this fate decision via the regulation of key 
transcription factors, cytokines and cell metabolism (128, 156, 652, 799) (section VII.II).
The HIF pathway also regulates the balance between Tregs and TH1 (Figure 3). VHL expression in 
Tregs is essential to maintain their identity after differentiation and their immunosuppressive functions 
(395). Genetic deletion of VHL specifically in differentiated Tregs and the subsequent HIF-
stabilization promotes their conversion to IFN- -producing TH1-like effector cells by inducing a 
glycolytic metabolic program and by HIF-binding to the IFN-
activation of TH1 cells (395). In vivo, VHL loss in Tregs increases the numbers of TH1 cells in almost 
all organs as well as the number of activated/memory CD4+ and CD8+ T cells in the spleen and lymph 
nodes, resulting in a severe lethal inflammation in young adult mice (395). In the TME, hypoxia via 
HIF- s the production of IFN- regs, which induced Tregs fragility and enhances the 
success of anti-PD-1 therapy (530). In the lung, PHD-mediated oxygen-sensing by CD4+ T cells and 
the subsequent HIF- , which 
ultimately facilitates tumor colonization of the lung (129). PHD isoforms redundantly limit TH1
differentiation and favor the induction of Tregs, partially due to the repression of the HIF-driven 
glycolytic metabolism and IFN- production (129). Pharmacological blockade of PHD in ex vivo
cultured CD4+ T cells prior to adoptive T cell transfer improves the efficiency of this immunotherapy. 
These findings suggest that adding a PHD inhibitor to established clinical expansion protocols for 
human ACT could potentially improve the tumor regression rate (129).
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Many of the studies addressing the role of hypoxia in T cell differentiation were carried out in the 
context of inflammatory hypoxia, in which antigen presentation is usually intact, a situation that is 
often impaired in the TME. Moreover, the cytokine and metabolic milieu of tumor hypoxia greatly 
differs from that of inflammatory hypoxia and tissue-specific environments. Although it is tempting to 
speculate that immunosuppressive signals in the TME will likely overrule the hypoxia-driven 
stimulation of anti-tumor T cell subsets (see next sections for further discussion), how the integration 
of the metabolic and cytokine signals in the TME shapes the function of specific CD4+ T cell subsets 
demands further clarification.
V.II.II Effect of hypoxia on CD8+ cytotoxic T cells (CTLs)
Until recently, little was known regarding how hypoxia/the HIF pathway regulates the pathways
orchestrating the recruitment of CD8+ T cells in the tumor. Palazon et al. have now shown that tumor-
infiltrating CTLs are an important source of the HIF-1 target gene VEGF-A. In murine tumor 
models, CTL-derived VEGF-A contributes to the permeabilization of the endothelium and enables 
CTL recruitment. Accordingly, ablation of HIF-1 or VEGF-A in T cells resulted in a specific defect 
in CTL transendothelial migration and homing to the tumor, vascular normalization and accelerated 
tumor growth (534) (Figure 2). Furthermore, T cell specific ablation of HIF-1 , but not of VEGF-A,
was accompanied by an increase in tumor-infiltrating Tregs, supporting the observations discussed 
above that HIF-1 blunts Tregs development (156, 316, 652).
As mentioned above, CD8+ T cell activation in lymphoid organs takes place under hypoxia (83) and 
the HIF pathway is important for the maintenance of CTL effector functions. In vitro hypoxia-driven 
HIF-1 stabilization in CTLs is required for their expression of effector molecules (i.e. IFN- TNF-
and GzmB) (534), costimulatory receptors (i.e. OX40, GITR, and 4-1BB) (185, 532-534) and 
exhaustion-related markers (i.e. PD-1 and CTLA4) (185, 534), whereas HIF-2 is dispensable (534).
In this line, two studies highlighted the role of HIF negative regulators VHL and PHD in CTL
function. Loss of VHL in CD8+ T cells promoted their effector capacity not only by an induction of 
glycolytic metabolism, but also by a HIF-dependent regulation of a set of effector molecules and 
activation-associated co-stimulatory and inhibitory receptors (185). Interestingly, enhanced HIF
activity due to VHL loss prolonged the survival of effector CD8+ T cells by impairing their terminal 
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differentiation and freezing them into a previous state which retains their effector functions without 
being short-lived. Adoptive transfer of VHL-deficient OT-I CTLs exhibited an enhanced ability to 
control OVA-expressing B16 tumors compared to ACT of VHL-proficient OT-I CTLs, suggesting 
that enhanced activity of HIFs may be a potent strategy to sustain the effector function of CTLs in a 
context where prolonged antigen exposure induces CTL exhaustion (185). Similar to the positive 
effect on TH1 differentiation (Figure 3), loss of all three PHD isoforms in CD8+ T cells unleashed 
IFN- production and protected mice from metastatic colonization in the lung, although the value of 
PHD inhibition prior to ACT of CTLs was not assessed (129). The nature of the signal that triggers 
HIF-1 stabilization in tumor-infiltrating CTLs still remains unclear.
Tumor hypoxia can negatively impact the anti-tumor function of CTLs. Similar to NK cells, hypoxia 
drives cancer immune evasion by decreasing the susceptibility of cancer cells to immune cell-
mediated killing in a HIF- -dependent manner. Cancer cells undergo autophagy in response to 
hypoxia, which renders them resistant to lysis by cytotoxic T cells and NK cells (30, 510, 513).
Hypoxia via HIF- uces the expression of PD-L1 on cancer cells and on myeloid cells to favor 
immune escape (36, 511). VEGF-A expressed in the TME can induce the expression of PD-1 and 
other inhibitory checkpoints on tumor CTLs and induce T cell exhaustion (733). Moreover, hypoxia 
can promote the infiltration and suppressive function of Tregs. Thus, although hypoxia promotes CTL 
function in vitro, it is known that their anti-tumor function is highly impaired in the highly hypoxic 
TME and that CTLs are mostly found in well oxygenated areas (293). This suggests that hypoxia-
related or tumor-related factors either prevent the stabilization of HIF-
immunostimulatory effect.
VI. Tumor metabolism: beyond cancer cell metabolism
Due to high nutrient consumption and compromised tumor vascular supply, the tumor environment is 
frequently poor in nutrients and oxygen and cancer cells have to compete with neighbor cells for 
nutrients. Our understanding on the complexity of the metabolic networks (Figure 4A) and the 
different crosstalks between tumor compartments have represented a step-forward from the original 
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concept of “glucose-dependency of the cancer cells” introduced in the 20s by the German physiologist 
Otto Warburg (753). Warburg found that, even in the presence of oxygen, unlike the majority of 
normal cells, cancer cells prefer to metabolize glucose via glycolysis, a less efficient pathway for 
producing ATP when compared to OXPHOS (752), ascribing this phenomenon to an impairment of 
mitochondrial respiration. However, numerous studies have shown that mitochondrial respiration is 
intact in many tumors and that OXPHOS suppression by glycolysis stimulation is rather an adaptation 
to hypoxic conditions during tumor development. Supporting this idea, a metabolic zonation within 
glioblastoma tumors has very recently been reported, revealing progressive changes in the metabolic 
profile of cancer cells relative to their distance from the blood vessels that were associated with
aggressiveness and therapy resistance (375). It is yet unknown whether and how metabolic zonation 
impacts on tumor stromal cells. Increased glucose consumption during tumorigenesis has been useful 
for clinical detection and monitoring by fluorodeoxyglucose positron emission tomography (FDG-
PET) (5) but it is clear that this type of diagnostic outcome can also be inferred to the fact that 
extensive inflammation in general displays an augmented incorporation of radiolabeled glucose (677).
The new evidence is that cancer cells can even live when starved from glucose and rely on additional 
means of energy supply, including the tricarboxylic acid cycle (TCA cycle, wherein carbon sources 
other than glucose can be channeled), fatty acid -oxidation (FAO), or even opportunistic modes of 
nutrient acquisition, involving uptake of macromolecules or cells/cell remains, under metabolically 
unfavorable conditions (548).
The mechanistic target of rapamycin (mTOR) and the AMP-activated protein kinase (AMPK) are one 
of the most influent signaling pathways controlling both cancer and immune cells function and 
metabolism (415, 484, 625). mTOR is an evolutionarily conserved serine/threonine kinase composed 
by two complexes, mTORC1 and mTORC2, which are distinguished by the scaffolding proteins 
Raptor and Rictor, respectively (625). The PI3K/Akt pathway is a major trigger of mTOR activation. 
By inhibiting TSC1/2, Akt releases the activity of the small GTPase Rheb that, in turn, when in its 
GTP-bound state stimulates mTORC1 kinase activity (625). mTORC1 drives anabolic metabolism, 
including lipid, glutamine and glucose metabolism, while it inhibits catabolic processes, namely 
autophagy (625). Activation of mTOR drives glycolytic metabolism essentially through HIF-
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c-Myc (81) as well as de novo fatty acid biosynthesis (FAS) via upregulating the transcription factors
sterol regulatory element-binding proteins (SREBPs) (415). How mTOR orchestrates metabolic 
activities that shape immune effector responses depends on each cell type, nutrient availability in the 
microenvironment and on the specific tissue (415, 757). AMPK is a highly conserved serine/threonine 
--sensing capability of AMPK can be attributed to its ability to detect and react to 
fluctuations in AMP:ATP ratio. High AMP concentrations promote the phosphorylation of AMPK in 
-subunit that leads to its activation. Active AMPK acts as a metabolic master switch that 
regulates several intracellular systems including the inhibition of glucose and anabolic metabolism 
(i.e. FAS, protein synthesis, amino acid uptake and de novo synthesis of amino acids) and the 
activation of catabolic metabolism (i.e. oxidative metabolism and mitochondria biogenesis) (287, 
519). Moreover, AMPK activation suppresses mTOR and HIF- In the next sections we 
will mention how mTORC1, mTORC2 and AMPK are differentially implicated in immune cell 
metabolism and function. However, for a more in-depth discussion of the implication of mTOR and 
AMPK signaling in cancer cell or in immune cell metabolism, we refer the reader to more extensive 
recent reviews (287, 415, 484, 519, 625).
Importantly for this review is the concept that the metabolic fingerprint in cancer cells will define the 
composition of the milieu to which stromal cells are exposed. In this way, changes in the metabolic 
state of cancer cells may induce phenotypic changes in other cells in their vicinity, including tumor-
associated fibroblasts, endothelial cells and immune cells. Thus, stromal cells can be reprogrammed 
by cancer cells to acquire either pro-tumor or anti-tumor phenotypes. On the other hand, the opposite 
is also true: metabolism of stromal cells can also re-shape the metabolic behavior of cancer cells (481, 
785). Finally, also stromal cells can enter in competition for the same metabolite so that their 
phenotype is tightly linked and a consequence of the “appetite” of neighboring cells.
Notably, while the technologies are quite advanced to calculate the percentage of oxygen in precise 
areas of the tumor (e.g., through paramagnetic resonance) (673), the technologies to detect and 
quantify metabolites in tumor sections or by in vivo imaging are blooming (181, 479). Remarkably, 
one of the major current caveats is the use of in vitro cultures is that the metabolite composition of 
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culture media and the oxygen tension of the incubators is far from physiological. The use of new 
medium formulations that aim to mimic physiological concentration in plasma (88) or in tumors (718)
could greatly contribute to reproduce immune cell biology more faithfully. The future research should 
aim to design the metabolic topography of the tumor, with the detailed identification and localization 
of metabolites in the tumor milieu in order to increase our prediction on the function of the different 
immune cells in these niches (196).
VI.I Glucose, lactate and glutamine metabolism in cancer cells
Transformed cells reprogram their cellular metabolism to support cancer initiation, progression and 
aggressiveness (719). In 2011, Hanahan and Weinberg proposed this metabolic adaptation has one of 
an emergent hallmark of cancer (284). Since then, an explosion of studies in cancer cell metabolism 
have expanded our knowledge on how tumor-associated metabolic alterations have an impact at 
various stages of tumorigenesis (548).
Several oncogenic mutations drive alterations in cancer cell metabolism that allow them to survive in 
the harsh conditions of a malignant tumor and sustain their high proliferation needs. For example, in 
lung cancer, the copy number of mutant KRAS proportionally correlates with increase glucose uptake 
and the channeling of glucose carbons into the TCA cycle (347). In line with this, another study has 
found that paired colorectal cancer cell lines differing only for the mutational status of their KRAS or 
BRAF genes, displayed enhanced expression of glucose transporter-1 (GLUT1) and increased 
glycolysis when one of these two genes was mutated; it followed that glycolysis blockade hindered 
preferentially the growth of mutant colorectal cancer cells (790). Mirroring the pro-glycolytic effect 
of (proto)-oncogenes, loss of oncosuppressors such as PTEN in melanomas confers a glycolytic 
signature which results in increased glucose consumption, enhanced lactate production and reduced 
susceptibility to immunotherapeutic interventions as adoptive T cell transfer (102). As mentioned in 
the section above, hypoxia is a common trait of solid tumors and it drives the expression of PD-L1 on 
cancer cells (36). Importantly, PD-L1-mediated immune evasion is not only due to its binding to PD-1
on T cells, but PD-L1 in cancer cells also favors their glycolytic and glutaminolytic flux and therefore 
fosters metabolic competition in the TME (116). Although the yield of ATP production per molecule 
of glucose of aerobic glycolysis is much lower than that of OXPHOS, this metabolic switch meets the 
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energy requirements and underlies numerous advantages for cancer cells (40). The increased rate of 
glycolysis and branching metabolic pathways such as the pentose phosphate pathway (PPP) provide 
precursors for macromolecular biosynthesis (i.e., fatty acids and membranes, amino acids and 
proteins, etc.) and reducing equivalents in the form of NADPH required for rapid proliferation, 
together with nucleotide production (504). Importantly, the upregulation of glycolysis triggers the 
accumulation of extracellular lactate (299), which results in an acidic microenvironment that is 
harmless for cancer cells but fatal to normal cells (253). Although lactate was thought to be a mere 
waste product of glycolysis, developing evidences indicate that lactate could be used as a metabolic 
fuel for cancer cells. In vivo human experiments using isotope-labelled lactate have shown that in 
human lung tumors, lactate contributes more carbon to the TCA cycle than that of glucose (213, 313)
(Figure 4B).
As for glucose uptake and glycolysis, oncogenic events have also been associated with a major boost 
in glutamine metabolism, such as MYC oncogene, the third most commonly amplified gene in human 
cancer (791), or mutations in the catalytic subunit of PI3K (286), encoded by PIK3CA, mutated in a 
wide variety of human cancers including 30% of colorectal cancers (CRCs) (617). These
observations lead to the concept that cancer cells can rely on other sources to fuel carbons to the TCA 
cycle. Therapeutically speaking, the inhibition of these compensatory pathways may lead to synthetic 
lethality of cancer cells (719). Several studies have shown that glucose deprivation will foster 
- -KG), through a 
process known as glutamine anaplerosis (710, 781). Overall, glutamine can highly contribute to the 
core metabolic functions of cancer cells in different ways: energy formation, biomass assimilation and 
redox control (164). Glutamine contributes to ATP production by cancer cells through TCA cycle 
intermediates, NADH and FADH2, which offer electrons for the mitochondrial electron transport
chain. Also, although poor tumor vascularization induces hypoxia and inhibits OXPHOS, glutamine is 
redirected towards biosynthetic fates that do not require oxygen for the production of citrate, acetyl-
CoA and lipids by reductive carboxylation (6). Glutamine transported into cells provides carbon and 
nitrogen required for the biosynthesis of glucosamine-6-phosphate, purine and pyrimidine nucleotides 
and non-essential amino acids, as aspartate and alanine (6). Interestingly, glutamine may be 
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exchanged to facilitate the uptake of a broad range of essential amino acids by LAT1/SLC7A5 (548)
(Figure 4B).
VI.II Fatty acid metabolism and TCA cycle in cancer cells
Despite their voracity for glucose and glutamine, cancer cells have to deal in vivo with nutrient 
scarcity and with highly abnormal tumor vessels (548). To overcome these obstacles, cancer cells 
acquire alterations that will promote the use of alternative energetic pathways. 
The TCA cycle is used as a source of numerous precursors to support proliferation. Furthermore, 
metabolites from the TCA cycle participate in the glycerol-phosphate and malate-aspartate shuttle 
systems responsible for moving reducing equivalents across the mitochondrial membranes that are 
required for biosynthesis. Glycerol-3-phosphate is a side product of glycolysis and is involved in lipid 
synthesis, while aspartate is used to synthesize proteins and nucleotides. 
Although less studied, adaptations in lipid metabolism have also been pointed as one of the metabolic 
rewiring of transformed cells being important for cancer progression (140) (Figure 4B). Fatty acid 
metabolism constitutes another source of anabolic substrates and reducing equivalents for cancer 
cells. Fatty acid -oxidation (FAO) is an important route for acetyl-CoA, NADH and FADH2 and 
ATP production that will sustain cancer cell survival and proliferation. Metastasis formation and cell 
survival also rely on FAO (48). In human carcinomas, the fatty acid transporter CD36 identifies a 
unique subset of metastasis-initiating cells that respond to dietary lipids and CD36 expression
correlates with poor prognosis (543). In mouse models, blockade of CD36-mediated fatty acid 
uptake restrains the appearance of metastasis or the shrinkage of already existing metastasis (543).
In breast cancer, regulation of lipid metabolism by JAK/STAT3 pathway promotes cancer stem 
cell self-renewal and chemoresistance (749). On the other hand, de novo fatty acid synthesis (FAS),
or lipogenesis, is also needed to produce new phospholipid bilayers (154). When tumors grow in areas 
with reduced blood vessel density the access to lipids in the circulatory system is reduced. Thus, by 
engaging FAS cancer cells are less dependent on the circulatory system around the tumor and can 
proliferate even in avascular conditions (575). Some cancer cells have the ability to store 
triacylglycerides in lipid droplets that can be used as an energy source (48). These lipid droplets 
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within cancer cells are now considered as hallmarks of cancer aggressiveness (48) and resistance to 
chemotherapy (569).
In conclusion, what Warburg and followers postulated at the beginning of the twentieth century,  that 
enhanced glycolysis is due to mitochondrial dysfunction, has been now disproven by the experimental 
observation that most cancer cells maintain functional mitochondria (636). These organelles are 
essential for the production of cytoplasmic CoA, for citrate synthesis in TCA cycle, an important 
source of acetyl groups for protein acetylation and FAS (81), to restore the NAD+ pool to support the 
high glycolytic flux (636) and, of course, mitochondria are key to sustain the electron transport chain, 
ending in ATP production.
VII. Immune cell metabolism
The emerging role of immunometabolism as an important regulator of immune system function has 
been widely investigated in the last decade. Immune cell activation leads to enormous alterations of 
several signaling pathways accompanied by a shift in energetic and metabolic demands to which 
immune cells need to respond and adapt. For instance, resting immune cells obtain most of their 
energy from FAO or the TCA cycle, linked to the generation of ATP via OXPHOS (55, 550), while 
after activation, interferon- - -stimulated macrophages (M1-like) as well as T cells
rapidly switch to aerobic glycolysis to face the increased demand for energy and biosynthetic 
precursors for proteins, lipids and nucleic acids (436, 505, 717). mTOR and AMPK play a central role 
in the orchestration of immune cell metabolism and highly contribute to the differentiation or 
polarization into specific immune cell subsets (415, 519). While mTOR is mostly required by anti-
tumor effector immune cell subsets (i.e. M1-like macrophages, DCs, TH1 and TH17 CD4+ T cells and 
effector CD8+ T cells), AMPK supports pro-tumor immune cell subsets (i.e. Tregs) but also the 
formation of memory T cells. Overall, it is conceivable that different stimulus from the TME, namely 
scarce nutrient availability, low oxygen levels and the secretion of numerous cytokines and 
chemokines, may induce the activation of AMPK in immune cells, which in turns will lead to a 
metabolic switch to OXPHOS and consequently an induction of the immunosuppressive phenotype of 
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these cells. Therefore, the activation of AMPK in immune system usually correlates with increased 
tumor growth, aggressiveness and immune evasion (55).
Importantly, recent studies have brought to light an important caveat in the study of metabolism: the
use of inhibitors and their potential unknown off-target effects. For instance, most of the studies on 
the FAO pathway relied on treatment with different doses of etomoxir to inhibit CPT1a, rate-limiting 
enzyme, and reached contradictory conclusions (715). Divakaruni et al. and Raud et al. have used 
genetic models to prove that the effects observed upon etomoxir treatment are not actually due to 
CPT1a inhibition, but rather due to off-target effects including suppression of OXPHOS and depletion 
of intracellular CoA levels (184, 573, 715). In the next section, we will dissect more in detail what is 
known and established regarding which metabolic pathways predominate in each immune cell 
subtype and how metabolism affects the balance between them. Nevertheless, it would be wise to 
keep in mind that new techniques in the metabolism field are blooming and therefore will likely 
challenge some of the current paradigms.
VII.I Metabolism and innate immunity
VII.I.I Macrophage metabolism
Macrophages are terminally differentiated innate immune cells that display high secretory, phagocytic
and antigen-presenting abilities in response to tissue damage and infection. Given that macrophages 
provide first-line protection and possess critical functions to modulate tissue homeostasis and 
repair, they must maintain plasticity to adapt their functions to the biological need. Thus, it is 
reasonable to postulate that macrophages engage distinct metabolic programs during M1 and M2 
activation to support their distinct functional specialties. In recent years, emerging evidence revealed 
that M1 macrophages enhance anabolic metabolism, including aerobic glycolysis, the PPP and FAS,
while M2 macrophages engage catabolic metabolism, namely FAO and OXPHOS (452, 520, 521)
(Figure 5A,B).
TLR signaling during M1 activation promotes aerobic glycolysis by boosting HIF-1 and mTOR 
activity, which is central for the metabolic reprograming of M1 macrophages. These signaling 
cascades drive a metabolic switch towards increased glycolysis, FAS and the PPP (232, 345, 593).
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Inhibition of aerobic glycolysis or ablation of glucose transporter 1 (GLUT1) expression in 
macrophages blunts M1 polarization and the production of pro-inflammatory molecules while it
promotes the secretion of anti-inflammatory cytokine IL-10 (469, 686). Evidences showed that 
alveolar macrophages with lack of Raptor have a reduction in glucose uptake, leading to a decrease in 
M1 polarization and pro-inflammatory responses (172), while macrophages deficient in TSC1 and 
TSC2 increase glycolysis, mitochondrial content, OXPHOS and FAS in an mTORC1-dependent 
manner, and consequently an increase in pro-inflammatory response and M1 polarization (172, 415).
Furthermore, aberrant activation of AMPK during LPS stimulation could also impair macrophage M1 
activation and stimulate production of anti-inflammatory cytokines (609). In addition to glycolysis 
and fatty acid metabolism, M1 and M2 macrophages display distinct activities on running TCA cycle. 
M1-like macrophages are proposed to have two recurrent and typical TCA cycle “break points” in 
which citrate and succinate accumulate (330) (Figure 5A). The first break point occurs at the level of 
isocitrate dehydrogenase (IDH), leading to the accumulation of citrate, whereas the second break 
point occurs at the level of succinate dehydrogenase (SDH), which allows for succinate buildup (141).
The accumulation of succinate, either due to increased glutamine anaplerosis and oxidation in the 
TCA cycle or increased flux through the GABA shunt, can stabilize HIF- and hence promote the 
transcription of pro-inflammatory and glycolytic genes, such as IL-1 , NOS2, GLUT1 and PFKFB3 
(294, 523, 686). It also follows that the increase in citrate efflux from the mitochondria sustains the 
NADPH levels necessary for FAS and ROS and NO production, through the actions of isocitrate 
dehydrogenase and malic enzyme (141, 319). Moreover, citrate can be used to fuel itaconate synthesis 
by mitochondrial aconitase 2 (ACO2) and cis-aconitate decarboxylase, also known as immune-
responsive gene 1 (IRG1) (764). Itaconate is a signal metabolite with bactericidal activity (764) that 
increases following inflammatory stimuli. Itaconate is able to inhibit SDH activity and therefore to 
prevent the generation of ROS by the reverse electron transport (141, 380). During an inflammatory 
stimulus such as LPS, succinate accumulates so much in macrophages, that his SDH-mediated 
oxidation produces a large amount of coenzyme Q. Electrons are then forced back through complex I 
of OXPHOS, generating a large amount of ROS that activates s the 
production of pro-inflammatory signals such as IL- -6 and IL-18 (38, 469, 764). Therefore, the 
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production of itaconate provides a negative feedback mechanism to tune-down M1 activation by 
turning off SDH hyper-activity and enhancing NRF2-mediated anti-oxidant and anti-inflammatory 
responses (380, 470). Using murine models of peritoneal tumors, Weiss et al. showed that itaconate 
was highly abundant in peritoneal macrophages of tumor-bearing mice and that it promotes tumor 
growth (760). In addition to these findings, macrophage-specific deletion of glutamine synthetase 
(GS), the enzyme that generates glutamine from glutamate, has been shown to cause glutamate 
rerouting to the GABA shunt with accumulation of succinate at the TCA cycle (535). Most of the 
findings in the field of macrophage metabolism are either in vitro or in contexts other than cancer. 
The latter observation on GS deletion has actually been translated in mouse tumor models where we 
have shown that succinate accumulation following genetic deletion of glutamine synthetase directly 
and indirectly (through HIF-1) sustains a rewiring of TAMs into an M1-like phenotype, which leads 
to increased T cell recruitment and activation but also tumor blood vessel normalization, with 
increased perfusion, reduced permeability and prevented cancer cell dissemination (535). In addition 
to metabolic checkpoints controlled by the production of metabolites, the regulation of the electron 
transport chain (ETC) complex assembly also influences macrophage functions. Activating 
macrophages with living bacteria or bacterial products induce massive ROS production to stimulate 
pro-inflammatory activity by impairing the formation of the ETC supercomplex (245). In contrast,
LPS-triggered NO production plays a negative feedback mechanism to resolve persistent M1 
activation by blunting ETC function and OXPHOS activity (469, 714). A recent study demonstrated 
that macrophage-associated VSIG4, a B7-related protein identified as a negative regulator of T cell 
activation (732), could act as a M1 checkpoint inhibitor that reprograms pyruvate mitochondrial 
metabolism by reducing the conversion of pyruvate to acetyl-CoA, resulting in a reduction in ROS 
secretion and inhibits the pro-inflammatory responses of macrophages (404). In this line, LLC murine 
tumors were significantly smaller in VSIG4-deficient mice (410).
In contrast to M1 macrophages, M2 macrophages engage catabolic metabolism and possess low 
glucose flux but a high rate of FAO (Figure 5B). Expression of carbohydrate kinase like protein 
(CARKL) in M2 macrophages contributes to the reduced PPP flow (291). Moreover, M2 
macrophages engage a PGC-1 -dependent metabolic switch to sustain their OXPHOS activity and 
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FAO (722). Targeting FAO or PGC-1 impairs M2 marker gene expression in macrophages 
stimulated with IL-4 (722). Moreover, CD36-mediated fatty acid uptake and subsequent liposomal 
lipolysis support both OXPHOS and M2 marker gene expression in IL-4-stimulated macrophages 
(308). Recent studies by Divakaruni et al. and Nomura et al. using a genetic deletion of CPT1a or 
CPT2 and pharmacologic models challenged this idea (184, 514). Divakaruni et al. suggest that high 
doses of etomoxir, considered a CPT1a inhibitor, impair the in vitro IL-4 mediated M2 polarization of 
macrophages due to the depletion of the intracellular free CoA pool but independently of expression 
of CPT1a or CPT2 (184). It still remains unknown how these mechanisms are at play in TAMs. 
Interestingly, several recent works reported that glycolysis plays a crucial role in M2 polarization 
even though IL-4-stimulated macrophages have only a slight increase of glucose metabolism 
compared to naïve macrophages (309). Activation of ATP citrate lyase (ACLY), an enzyme of FAS,
and OXPHOS in M2 macrophages also stimulate production of acetyl-CoA, which directly impacts 
the expression of certain M2 marker genes via histone acetylation (147). Furthermore, impaired 
cholesterol efflux in macrophages leads to an elevated lipid content accompanying with M2-skewing 
phenotype (586, 643). However, uptake of modified low-density lipoprotein (LDL) in macrophages 
has also been reported to stimulate pro-inflammatory activity and M1 activation (301). Similar to 
LDL-modulated macrophage polarization, uptake of high density lipoprotein (HDL) has also been 
shown to promote both M1 and M2 phenotypes in macrophages (160, 620). Although it remains 
unclear why cholesterol metabolism could lead to distinct immune responses in macrophages, these 
studies uncover that the composition of lipid species and metabolic fate of those uptaken lipids may 
orchestrate macrophage polarization by modulating functions of nuclear receptors, such as PPAR and 
LXR (549). In contrast to the broken TCA cycle displayed by M1 macrophages, M2 macrophages 
have an intact TCA cycle and highly depend on glutaminolysis, which supports epigenetic 
reprogramming of M2 macrophages through the production of -ketoglutarate (330, 417).
M2 macrophages express high levels of PFKFB1 instead of PFKFB3 to reduce glucose influx (593)
while TAMs may rather rely on PFKFB3 (761). A recent study in mouse tumor models has shown 
that accumulation of intracellular lactic acid could stimulate M2 activation by promoting HIF-
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stability, leading to VEGF production and tumor angiogenesis (135). Mirroring this, we have shown 
that an increase in glucose uptake and glycolysis directly in TAMs (by the genetic deletion of the 
mTOR inhibitor REDD1) does not change the polarization of macrophages (M1 and M2-like markers 
and functions) but rather subtracts glucose to the neighboring endothelium, breaking endothelial 
glycolysis and resulting in a more quiescent, less leaky tumor vasculature (87), which overall 
prevented cancer cell intravasation and metastasis (761). PFKFB3 knockout in REDD1-deficient 
macrophages completely abrogated this protective effect and restored a dysfunctional tumor 
angiogenesis and metastasis (761). Whether the reduced glucose uptake by REDD1-deficient 
macrophages alleviates the competition for glucose between TAMs and cancer cells or other stromal 
cells (i.e. pericytes and immune cells) and whether TAM-derived lactate following glycolysis can 
“signal” to other stromal cells or cancer cells remain to be elucidated (Figure 5B).
Together, these findings reveal that metabolic processes utilized by macrophages support metabolic 
demand and tailor immune responses by intervening signaling cascades and epigenetic programs. 
Furthermore, the emerging evidence suggest that targeting metabolism may be an attractive approach 
to fine-tune macrophage immune response in different diseases and further highlight the possibility 
that macrophages may control their surrounding neighbor cells through their metabolic processes 
(452, 535, 761).
VII.I.II Neutrophil and MDSC metabolism
Although mounting evidence shows the crucial role of TANs/MDSCs in the TME, the metabolic 
programming of these neutrophils is still not fully characterized (Figure 6). Neutrophils contain 
relatively few mitochondria and the energy required for neutrophil chemotaxis and activity is mostly 
derived from glycolysis (366, 592). Chacko and co-workers characterized the bioenergetic profile of 
human neutrophils and observed that these cells were unresponsive to mitochondrial respiratory 
inhibitors, indicating that they have a minimal requirement for OXPHOS and are primarily glycolytic 
(109). This observation has been underscored by Sadiku et al, who demonstrated that PHD2 
inactivation and subsequent HIF- increased glycolytic flux and glycogen stores and 
promoted aberrant neutrophilic responses (608). Moreover, it has been described that the PPP,
namely glucose-6-phosphate dehydrogenase (G6PD) activity, is essential to sustain the NADPH
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required by NADPH oxidase (NOX) to form ROS and fuel the respiratory burst (264). Glucose uptake
and a shift toward PPP are essential for NETs formation (28, 336). Yet, a recent study has reported 
that glutamate and proline can maintain the ability of intratumor immature low-density neutrophils 
(but not in high-density neutrophils) to form NETs even under glucose deprivation, thereby 
supporting their pro-metastatic function (306).
MDSCs activate AMPK and rely on fatty acid uptake and FAO to support their immunosuppressive 
functions (282, 304). In this line, Rice et al. have recently described that tumor-elicited immature c-
Kit+ neutrophils acquire an oxidative metabolic profile (i.e. high FAO and OXPHOS) that supports 
NOX2-mediated ROS production and T cell suppression (582). In tumor models and cancer patients,
FATP2 is upregulated exclusively in PMN-MDSCs in response to GM-CSF/STAT5 signaling (723).
Uptake of arachidonic acid by FATP2 is required for the synthesis of PGE2 and for the 
immunosuppressive functions of PMN-MDSCs. Selective blockade of FATP2 by lipofermata 
reinvigorates anti-tumor adaptive immunity, delays tumor growth and promotes tumor regression in 
combination with immunotherapy (723). Interestingly, bone marrow neutrophils from mice with early 
stage tumors (termed PM-LCs after “PMN-MDSC-like cells”) displayed an increased spontaneous 
motility and lacked immunosuppressive activity, a trait that is lost as tumors progress. An increase in 
glycolysis and OXPHOS with a concomitant elevation in ATP production and the establishment of an 
autocrine ATP/ADP signaling through purinergic receptors account for the superior migratory 
features of these non-immunosuppressive PM-LCs (546) (see section IX.I for further details on 
purinergic signaling).
Very little is known regarding amino acid metabolism in neutrophils. High expression levels of ARG1
and NOS2 are a hallmark of MDSCs/N2 neutrophils and are crucial to deploy their 
immunomodulatory functions. For instance, IL-8 mediated exocytosis of neutrophil-derived ARG1
depletes arginine levels in the TME (600), impairing T cell proliferation, and production of NO by 
NOS2 drives CD8+ T cell suppression (132). Further studies are required to shed light into whether
arginine metabolism controls neutrophil functions per se, in addition to the abovementioned effect on 
T cell suppression (Figure 6).
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Taken together, these studies reveal that tumor progression and the acquisition of 
neutrophils/MDSCs’ immunosuppressive features are concomitant with a dynamic evolution of their
metabolism and nutrient usage, going from glucose-fueled glycolysis and OXPHOS to fatty acid-
fueled FAO in the early and late stages, respectively. Moreover, this metabolic evolution might likely 
be dictated by the microenvironment of the organs where they are located, namely the bone marrow, 
blood or tumor. Further investigations dissecting how the environment modulates the metabolism of 
neutrophils and MDSCs and how these metabolic programs impact their function will help to develop 
immunotherapies targeting these cell types. 
VII.I.III Dendritic cell metabolism
Dendritic cells (DCs) are professional antigen-presenting cells and express a variety of pattern 
recognition receptors (PRRs). Upon activation via PRR ligation, DCs undergo transcriptional and 
translational changes that allow them to process the antigen, migrate generate immunomodulatory 
molecules and mount specific immune responses. Noteworthy, in vitro differentiation of bone 
marrow-derived DCs (BMDCs) does not technically allow to generate pure DC subsets, and this 
limitation needs to be taken into account when drawing conclusions (recently revised in (254, 755)). 
More studies or technical advances are required to further detail subset-specific metabolic traits that 
reflect what occurs in vivo.
Activated DCs rely on glycolysis and the PPP to support their demands to produce energy, 
membranes and inflammatory mediators and their migratory capacity. In response to TLRs ligation, 
DCs immediately upregulate glucose uptake and lactic acid production, mediated by the PI3K/Akt
pathway (367) (206). Furthermore, the deletion of TSC1 and 
concomitant activation of mTORC1 in DCs increased glycolysis, mitochondrial respiration and lipid 
synthesis in part mediated by Myc, highlighting the importance of these master regulators for BMDC 
maturation (751). Glycolysis feeds the PPP to produce NADPH as well as the TCA cycle to produce 
mitochondrial citrate (206). Intriguingly, a recent study further revealed that TLR4 signaling 
stimulates glycogen metabolism to fuel citrate production and early glycolysis in DCs, thereby 
supporting early effector functions of TLR-activated DCs (695). Citrate is then exported to the 
cytoplasm where, together with NADPH, fuel FAS (206). Unlike in macrophages, where citrate is 
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used for the production of various mediators, in DCs the citrate flux into FAS is required for the 
expansion the endoplasmic reticulum (ER) and the Golgi apparatus (206) (Figure 7A). This 
uniqueness of citrate utilization in DCs has been suggested to be a critical event for supporting the 
maturation and specialized biological functions in activated DCs (206, 254, 755). In some NOS2-
expressing DCs, mTORC1/HIF- -driven NO production by NOS2 impairs electron transport chain 
(ETC) activity and thereby sustains aerobic glycolysis (207). This circuit seems to be sensitive 
glucose and likely to several amino acids (387). Importantly, most DCs are NOS2-deficient and rely 
on other mechanisms to sustain glycolysis, which may involve type I IFN, HIF-
and may still partially maintain OXPHOS (206, 254, 270, 328, 387, 540, 755). Yet, exogenous NO 
could also promote HIF- stabilization, raising the possibility that other NO-producing cells can 
shape DC metabolism (387). Guak et al. recently demonstrated that glycolytic metabolism is also 
essential for the oligomerization of CCR7 and the migration of DCs towards the lymph nodes, while 
mitochondrial metabolism is dispensable (270). The mechanism linking glycolysis to CCR7 
oligomerization demands further investigation.
Although in general glucose metabolism and FAS enhance the pro-inflammatory features of DCs, 
several studies have suggested that inhibition of these pathways actually enhances DC-induced T cell 
activation (8, 387, 578). In a B16 melanoma model, mTOR inhibition prior to DC vaccine enhanced 
their anti-tumor efficiency (8). Lawless et al. propose a metabolic competition between interacting 
DCs and T cells in which both cell types engage contrasting metabolic states (glycolytic T cells and 
non-glycolytic DCs) to maximize the pro-inflammatory functions of both immune cells.  
Mechanistically, glucose limitation within the DC-T cell synapse inhibits the mTORC1/HIF- NOS2 
circuitry in DCs, consequently tuning down glycolysis (387). Whether this favorable and synergic 
metabolic competition also takes place in the TME or in the tumor draining lymph nodes remains 
unknown. 
In addition to glucose metabolism, type I interferon can enhance mitochondrial activity and FAO 
which support maturation of plasmacytoid DCs (pDCs) (773) (Figure 7B). In contrast to how fatty 
acid metabolism support pDC maturation, in tumor-bearing mice as well as in cancer patients a 
tumor-derived unknown factor induces lipid accumulation in cDCs and impairs their ability to process 
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tumor antigens and to effectively activate T cells. Both activation of FAS and lipid uptake via the 
upregulation of Msr1 expression contribute to the accumulation of lipids (296). Normalization of lipid 
abundance in DCs by pharmacological inhibition of FAS by TOFA, an ACC inhibitor, synergized 
with DC vaccination in murine tumor models (296). In this line, ROS-mediated activation of XBP1, 
an ER stress-induced transcription factor, elevated FAS and triggered the accumulation fatty acids and 
tolerogenic phenotype in tumor-infiltrating DCs (TIDCs) with markers of cDC2s (151). In a model of 
ovarian cancer, targeting XBP1 in TIDCs enhanced their anti-tumor function and enhanced the 
survival. However, it remains unclear whether TIDCs lose their ability to oxidize fatty acids and how 
accumulation of fatty acids could drive tolerogenic phenotypes. Moreover, DCs can also modulate 
their function and activity by sensing extracellular metabolites such as succinate (606), short chain 
fatty acid (660), adenosine/ATP (406) and lactic acid (501). It remains largely unexplored how amino 
acids can influence activation, maturation and functions in DCs (Figure 7A,B).
VII.I.IV Innate lymphoid cell (ILC) metabolism
In the bone marrow, NK cells develop and mature to fully differentiated naïve NK cells and this 
maturation process seems to be associated with distinct metabolic changes. In contrast to terminally 
differentiated cells, immature NK cells exhibit higher expression of certain nutrient receptors, such as 
the transferrin receptor CD71 and the amino acid transporter SLC3A2/CD98 as well as increased 
glucose uptake (445). It is likely that this metabolic profile is a prerequisite for the adequate 
proliferation and differentiation of immature NK cells. 
Mature non-activated NK cells have a relatively low glucose uptake and show increased expression of 
genes that are involved in FAO and OXPHOS (346). Long-term cytokine stimulation increases 
glycolysis and OXPHOS (346, 445). mTORC1 plays a pivotal role in the development and 
differentiation of murine NK cells since it drives the increase in glycolysis during cytokine-induced 
NK cell activation (188, 445, 728). The increase in glucose metabolism is a prerequisite for the 
production of IFN- and granzyme B (GzmB) and, therefore, for the acquisition of effector functions
(188). Moreover, mTOR-driven glycolysis is required to direct the lytic granules of activated NK cells 
towards the synapse with cancer cells (468). In ILC3s, unlike their counterpart TH17, mTORC1/HIF-
-driven glycolysis is accompanied by an increase in mROS, which acts as a loop to sustain HIF-
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and (176). Although way less is known about the metabolism of human NK cells, the role for 
glucose metabolism and mTORC1 as master regulator of human NK cell effector function has been 
confirmed (344, 444, 445, 468). Despite its undisputed role as a key metabolic regulator, the precise 
mechanisms of mTORC1-mediated NK cell metabolism remain mostly unknown. In light of the 
studies highlighting the involvement of c-Myc, SREBPs and HIF- on T cells metabolism and 
function (discussed below), it can be speculated that these transcription factors might also play a role 
in NK cell metabolism. It has been recently shown that SREBP transcription factors are required to 
induce a unique metabolic program in cytokine-triggered NK cells. Despite SREBPs are known for 
their crucial role in regulating lipid synthesis, in the context of NK cell activation SREBPs were 
essential to increase glycolysis and OXPHOS and to support NK cell effector function (23). SREBP1c 
induces the use of the citrate-malate shuttle (CMS) via the expression of Slc25a1 and Acly. The CMS 
contributes to the formation of mitochondrial NADH donors for OXPHOS, of cytosolic NAD+, a 
cofactor of glycolysis, and cytosolic acetyl-CoA, which could potentially be used for acetylation
reactions rather than for FAS (23). A recent study demonstrated that an NK cell-specific deletion HIF-
in response to NK cell receptor ligands under normoxic and 
hypoxic conditions (373). Therefore, it would be interesting to see whether HIF- -dependent 
metabolic changes contribute to this phenotype (Figure 8).
Less is known regarding to which extent amino acids and fatty acids can fuel the metabolic demands 
of activated NK cells. Loftus et al. have recently reported that c-Myc accumulation, but not HIF- , is 
crucial for the proper activation and IFN- and GzmB production of cytokine-stimulated NK cells 
(IL-2/IL-12). While mTORC1 promotes the translation of c-Myc minutes after IL-2/IL-12 
stimulation, prolonged c-Myc levels are sustained by the SLC7A5-mediated import of long neutral 
amino acids (LNAAs) (i.e. methionine, phenylalanine, tyrosine, arginine and/or tryptophan) in 
exchange for intracellular glutamine (424). These data could at least partially explain the 
underperformance of NK cells in glutamine-deprived environments such as the TME. Although 
glutamine underwent glutaminolysis and glutamine anaplerosis in this setting, these pathways were 
not involved in the modulation of IFN- and GzmB levels. This suggests that the use of glutamine 
metabolism inhibitors could have therapeutic benefits by impairing cancer cell metabolism, promoting 
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macrophage M1 skewing as well as by increasing glutamine availability in the TME and thereby
fueling NK cell anti-tumor functions (424, 535, 768). Further research is required to shed light on 
which LNAA is responsible for the regulation of c-Myc, how other activation queues modulate amino 
acid metabolism in NK cells and on the relevance of NK cell amino acid metabolism in vivo (Figure 
8).
A recent study has demonstrated that obesity promotes the uptake of lipids, the accumulation of lipid 
droplets and lipid metabolism by NK cells both in mice and in human, which results NK cell paralysis 
and impaired their tumor killing capacity. The lipid-induced activation of the PPAR / pathway and 
the concomitant inhibition of mTOR-mediated glycolysis and the activation of lipid oxidative
metabolism in activated NK cells downregulates IFN- and GzmB and prevents the transport of the 
lytic granules to the tumor synapse (468). The presence of free fatty acids during the in vitro
activation of NK cells prior to adoptive cell transfer or diet-induced obesity impaired the anti-tumor 
functions of NK cells in murine tumor models (468). This study supports the idea that reducing 
dietary fat intake may help to fuel NK cell mediated anti-tumor functions and raises caution towards 
the untargeted use rapamycin (Figure 8).
NK cells are part of the ILC family, yet, very little is known about metabolism of other ILC subsets 
and its functional impact. In analogy to naïve NK cells, quiescent ILC2 and ILC3 cells predominantly 
use OXPHOS rather than glycolysis prior to activation (763). A recently published study by Li et al. 
suggests that hypoxia and the HIF signaling pathway directly impacts on the late stage of maturation 
and function of ILC2 cells via the regulation of the IL-33-ST2 pathway (407). This very elegant study 
suggests that the VHL-HIF-
differentiation of ILC2 cells located in peripheral organs such as the intestine, lung or adipose tissue. 
VHL promotes maturation of ILC2s by restraining the HIF- -driven glycolytic flux and by altering 
the epigenetic control of ST2 gene and downstream targets. This study highlights that the metabolic 
status of ILC precursors actively participates in the regulation of their maturation and is not just a 
“default” metabolic state during low energy-demanding states. In lung inflammation, activated ILC2 
express high levels of arginase-1 (ARG1) and metabolize extracellular L-arginine. ARG1 expression 
in ILC2 is required to sustain proliferation and acts as a metabolic checkpoint as it fuels polyamine 
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biosynthesis and enhances aerobic glycolysis (480). Of note, ARG1-deficient ILCs did not reroute 
arginine towards other pathways, namely NOS2 (Figure 8). Arg1 gene expression can be induced by 
hypoxia (426), however this raises the question of how ARG1 activity is regulated under hypoxia in 
ILC2 context, and how the HIFs participate in that regulation. Further research on ILC2 and ILC3 is 
desirable to extend our knowledge how their function and metabolism are modulated by hypoxia and 
the HIF signaling pathway.
In summary, the metabolism NK cells as well as other ILC subsets remain largely unexplored but 
holds great promise for therapeutic exploitation of in a variety of diseases including cancer. 
VII.II Metabolism and adaptive immunity
T cells engage distinct metabolic programs during activation, proliferation and differentiation. In the 
quiescent state, naïve T cells mainly rely on FAO and OXPHOS to support their low metabolic 
demands (Figure 9A). Upon TCR and co-stimulatory receptor engagement, activated T cells rewire 
their metabolism in order to meet the energetic and anabolic requirements to support their rapid
proliferation and effector function (520). Activated T cells increase glucose and glutamine uptake, 
aerobic glycolysis, the PPP, OXPHOS, glutaminolysis and FAS while they suppress FAO. Moreover, 
the TCA cycle is also used as a source of intermediates for nucleotide, protein and lipid synthesis
(Figure 9B).
CD28 co-stimulatory receptor engages signaling cascades to activate the PI3K/AKT pathway and 
increase the glycolytic flux that, in turn, activates mTOR activity (231, 564). Raptor-mTORC1 
signaling couples glycolysis, OXPHOS, FAS and cholesterol synthesis to the TCR-induced exit from 
quiescence (784). TSC2 deficiency increases glycolysis, decreases FAO and stimulates effector T 
cells (561). Accordingly, TSC1 deficiency in T cells leads to reduced mitochondrial membrane 
integrity and increases ROS. mTOR activation also increases HIF- and Myc expression. HIF-
upregulates the transcription of the glucose transporter GLUT1 and the glycolytic enzyme lactate 
dehydrogenase A (LDHA) and boosts the activity of pyruvate dehydrogenase kinase 1 (PDK1),
thereby augmenting glycolytic and glutaminolytic metabolism (350). The tremendously increased
glycolytic flux becomes an important source of ATP and fuels the PPP and serine biosynthesis 
pathway that provide intermediates for nucleotide and fatty acid synthesis (747). It has been shown 
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that glycolysis is specifically required for effector cytokine production and expansion rather than 
supporting survival and development of memory T cells (300, 679). Production of 
phosphoenolpyruvate (PEP), a metabolic intermediate of glycolysis, inhibits SERCA and maintains a
Ca2+ cytoplasmic pool necessary to sustain NFAT signaling upon T cell activation (300).
Overexpression of phosphoenolpyruvate carboxykinase 1 (PCK1), the enzyme that converts TCA-
derived oxaloacetate into PEP, prior to adoptive cell transfer of CD4+ or CD8+ T cells circumvented 
the requirement for glucose and boosted their IFN- in the TME, which suppressed tumor 
growth and prolonged survival in a murine model of melanoma (300). Moreover, several works report 
that when the glycolytic flux is low, glycolytic enzymes acquire other roles and can regulate cytokine
production, indicating that the switch to aerobic glycolysis also modulates T cell effector functions 
(115, 457, 552). These mechanisms may partially underlie the dysfunction of effector T cells in the 
glucose-deprived TME. Noteworthy, OXPHOS is still required not only as a source of ATP, but also 
to maintain low levels of mitochondrial ROS that sustain NFAT signaling and T cell expansion upon 
activation (642) (Figure 9B).
Apart from changes in glucose metabolism, T cell activation is also coupled with increased amino 
acid metabolism. Myc stimulates glutaminolysis to fuel polyamine biosynthesis, which is essential for 
the activation-induced metabolic reprogramming of T cells (747). While low levels of mitochondrial 
ROS are required for proper T cell activation, high levels are detrimental (641, 642). Upon activation, 
glutathione (GSH), generated in part from glutamate by glutamate cysteine ligase (GCLC), buffers 
ROS levels and allows low ROS-dependent NFAT activation and mTORC1 to drive c-Myc 
expression and the shift towards glycolysis and glutaminolysis (440). In certain circumstances such as 
hypoxia, glutamine anaplerosis feeds the reductive carboxylation of -ketoglutarate -KG) into 
citrate, which is subsequently exported to the cytoplasm and fueled into FAS (463). The parallel 
increase in FAS and in the PPP coordinately sustain nucleotide and lipid synthesis while maintaining 
the redox balance (463, 747). Moreover, glutamine anaplerosis also contributes to the formation of the 
TCA intermediate oxaloacetate. In proliferating cancer cells, oxaloacetate is a precursor for aspartate 
generation and supports protein and nucleotide synthesis (163). Whether a similar mechanism is also 
used by activated T cells to sustain their proliferation rate remains to be clarified. Other amino acids 
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are also important for the proper activation of T cells. The system L transporter, SLC7A5, which 
controls the uptake of leucine and other long neutral amino acids (LNAAs), is coupled to mTOR 
activation, sustained c-Myc expression, amino acid transporter expression, T cell activation and clonal 
differentiation. SLC7A5-null T cells are unable to activate mTORC1 and c-Myc and therefore fail to 
reprogram their metabolism upon TCR stimulation (659). Moreover, T cell proliferation requires the 
uptake of extracellular L-arginine to sustain the expression of certain TCR components (591) and cell 
cycle progression (589). In consequence, depletion of this amino acid by the high ARG1 and NOS2 
activity in myeloid cells, as is often observed in the TME, leads to T cell anergy (186, 588, 590, 684).
So far, little is known regarding the metabolic fates of arginine in T cells. However, a few studies 
point towards specific roles of arginine and arginine-related enzymes in T cell differentiation (782),
death (729) and memory acquisition (249, 729), which will be further discussed in the next sections
(Figure 9B).
In addition to the general metabolic regulation and reprogramming upon activation, different subsets 
of effector and regulatory T cells engage unique metabolic pathways in order to support their 
specialized functions (Figures 10,11) and the acquisition of T cell memory is also associated to a 
wave of metabolic reprogramming that differs from activation (Figure 9C and section VII.II.III). In 
the next sections, we will describe how metabolism controls CD4+ T cell differentiation and effector 
function, CD8+ T cell function and T cell memory acquisition. 
VII.II.I CD4+ T cell metabolism
The differentiation of activated CD4+ T cells into effector TH1, TH2 and TH17 cells or into Tregs cells
engages different molecular mechanisms and is linked to a metabolic rewiring to adapt to their
distinct usage of glucose, amino acid and lipid metabolism. In general, effector T helper cells 
predominantly engage aerobic glycolysis and FAS while Tregs mostly rely on FAO and OXPHOS
(251, 652) (Figures 10,11).
TH1, TH2 and TH17 differentiation requires an increase in glucose uptake and aerobic glycolysis, 
while Tregs preferentially use FAO (435, 467). TH1 cells require enhanced glucose metabolism to fuel 
their effector function through the posttranscriptional and epigenetic regulation of IFN- by glycolytic 
enzymes and metabolites (115, 300, 552). Chang et al. unraveled a new function of glyceraldehyde-3-
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phosphate dehydrogenase (GAPDH) as a metabolic checkpoint: GAPDH sequesters IFN-
binding its 3’-UTR region and inhibits its translation. Since aerobic glycolysis engages GAPDH 
enzymatic function, upon CD4+ T cell activation IFN- is freed from GAPDH inhibition and 
promptly translated (115). Moreover, the expression of lactic acid dehydrogenase A (LDHA) relieves 
the burden of mitochondria as an energy house to burn acetyl-CoA for ATP production. Hence, citrate 
can be exported to maintain high concentrations of cytosolic acetyl-CoA, which is used to acetylate 
histones of the promoter of IFN- , fueling IFN- transcription and maintaining TH1 immune 
response (552). Notably, TH2 cells have a higher OXPHOS rate than other T helper subsets, 
suggesting that glycolysis-derived pyruvate is rather directed to feed the TCA cycle than used to 
produce lactate (783). TH17 cells, oppositely to TH1 and Tregs, express high levels of pyruvate 
dehydrogenase kinase 1 (PDHK1 or PDK1). PDHK1 activity halts the entry of pyruvate in the TCA 
cycle and diminishes the formation of mitochondrial ROS, which is crucial to support TH17 
differentiation (250). Knockdown or inhibition of PDHK1 selectively suppresses TH17 cells while 
sparing TH1 and increasing Tregs, through a mechanism at least partially involving ROS-mediated 
inhibition of IL-17 production (250).
Different transcription factors support these changes in glycolytic activity. Tregs exhibit better 
peripheral tolerance through metabolic adaptation. In low glucose and high lactate conditions, Foxp3
suppresses c-Myc expression to turn glycolysis off. Concurrently, Foxp3 induces OXPHOS and 
increases the NAD+/NADH ratio to resist lactate-mediated suppression of T cell function and 
proliferation (16). IRF4 controls TH1 metabolism and effector function (438). HIF- -
studied transcription factor controlling the balance between TH17 cells and Tregs (652) (section V.II.I).
TH17 differentiation requires HIF- to engage glycolytic activity and to promote IL-17 expression 
(652). Moreover, HIF- Tregs
development through binding Foxp3 and targeting it for proteasomal degradation (156) as well as 
through the inhibition of pyruvate entry in the mitochondria and OXPHOS-driven 
immunosuppressive capacities (473). Foxo1-mediated transcription also skews CD4+ T cell metabolic 
process into reduced glycolytic but enhanced OXPHOS (506, 529). Foxo1 is a pivotal regulator of 
Tregs cell function and Tregs-specific deletion of Foxo1 induces the development of a fatal 
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inflammatory disorder (529). Unexpectedly, tumor-infiltrating Tregs downregulated Foxo1 target 
genes and forced expression of Foxo1 selectively in Tregs was sufficient to deplete them, thereby 
activating effector CD8+ T cells and inhibiting tumor growth (429) (Figures 10,11).
The catalytic subunit mTOR is required for effector T cell differentiation and its deficiency leads to 
the differentiation of Tregs (166). While mTORC1 signaling participates in TH1, TH2 and TH17
differentiation, mTORC2 is exclusively involved in TH2 differentiation (167, 378, 783, 784).
PI3K/Akt pathway and Rheb/mTORC1 signaling is required for the differentiation of TH1 and TH17 
cells in vitro through the induction of the transcription of T-bet and , respectively (167), and 
the translocation of to the nucleus (378). Deletion of Rheb in CD4+ T cells impairs the 
development of experimental autoimmune encephalitis (167). In contrast, Rictor/mTORC2 signaling 
is involved in GATA3 transcription and TH2 cell development both in vivo and in vitro (167).
Furthermore, in vitro as well as in a model of TH2-mediated asthma, Rheb-independent 
Raptor/mTORC1-driven or RhoA/mTORC2-driven glycolytic program positively regulates GATA3, 
IL-2Ra, IL-4Ra and IL-4 and is therefore crucial for TH2 differentiation, but not for TH1 and TH17 
(783, 784). It still remains unknown how these mechanisms may dictate the differentiation of T cells 
towards a specific subset within the TME.
FAS is strongly required for effector CD4+ T cells but dispensable for Tregs differentiation. Deletion of 
acetyl-CoA carboxylase 1 (ACC1) in CD4+ T cells blocked FAS and interfered with the metabolic 
flux of glucose-derived carbon via glycolysis and the TCA cycle, which strongly impaired the 
differentiation of effector CD4+ T cells in vitro, in particular TH17, and induced the differentiation of 
Tregs (53). In the EAE model, T cell specific ACC1-deficient mice had lower CD4+ T cell infiltration 
in the spinal cord, lower percentage of TH1 and TH17 cells and higher percentage of Tregs and were 
protected against EAE (53). Moreover, ACC1 controls the DNA binding ability of and 
therefore, the transcription of downstream genes (203). In humans, obesity upregulates ACC1 
and thereby promote TH17 differentiation (203). Instead, Tregs rely on the uptake of exogenous fatty 
acids, that enter in the mitochondria via CPT1a to sustain their high rate of FAO (53, 250, 467). In a 
recent study, Raud et al. proved that CPT1a is dispensable for T cell homeostasis and for the 
differentiation and suppressive function of Tregs. The inhibiting effect of high doses of etomoxir on 
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Tregs differentiation are due to CPT1a-independent off-target effects that reduce the levels of TCA 
cycle intermediates and OXPHOS (573). Surprisingly, Pacella et al. revealed that expansion of 
activated Tregs in the context of the tumor is not only sustained by FAO of extracellular lipids, but also 
by a strong increase in glycolysis that concomitantly fuels FAS (531). This way, Tregs may impose a 
competition for glucose as a mechanism to exert their immunosuppressive functions in the TME. This 
finding has recently been reinforced by the work of Liu et al. that identifies the establishment of a 
metabolic competition for glucose during the crosstalk between human effector T cells and Tregs,
which causes DNA damage and the senescence of effector T cells (419). A recent study in a mouse 
model of glioblastoma has suggested that activation of different metabolic routes may serve distinct 
purposes in Tregs function, and that HIF- is involved in this switch (473). While hypoxia and HIF-
-driven glycolysis is important for tumor-infiltrating Tregs migration, FAO and mitochondrial 
metabolism are essential to sustain their immunosuppressive ability. Inhibition of Tregs migration via 
genetic deletion of HIF- or inhibition of FAO by etomoxir increases the lifespan of glioblastoma-
bearing mice in a mechanism that seems to involve reactivation of anti-tumor CTLs (473). In addition 
to FAS, fatty acid uptake is required for the proliferation of CD4+ T cells after antigen stimulation. 
Mechanistically, TCR-activated mTORC1 signaling in CD4+ T cells controls fatty acid biosynthesis 
through SREBP1 activation and fatty acid uptake through PPAR- activation (15). Lipids are 
necessary to generate membranes and also important for posttranscriptional modifications (423).
Thus, it would be attractive to study whether lipid synthesis could also influence the function of 
transcription factors involved in T cell differentiation (Figures 10,11).
The amino acid transporter SLC1A5/ASCT2 facilitates glutamine uptake, which is required for TCR-
stimulated mTORC1 activation and T cell effector function. Glutamine deprivation or the deficiency 
of SLC1A5/ASCT2 limits TH1 and TH17 differentiation (333, 500) and drives the formation of Tregs
(355, 465). The glutamine- - -KG)
is required for T-bet expression and the activation mTORC1 signaling to support TH1 differentiation, 
and to further inhibit Tregs generation (355). The predominance of Tregs upon glutamine restriction can 
be mimicked by targeting the glutamine-dependent nucleotide synthesis pathways and abrogated by 
inhibiting glutamine synthetase (GS), suggesting that Tregs have a superior capacity to produce 
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endogenous glutamine in conditions of low extracellular glutamine (465). However, it still remains 
-KG to support T-bet and TH1
differentiation. TH17 differentiation under TH17 polarizing conditions requires the silencing of the 
Foxp3 promoter, which is achieved through the GOT1-mediated transamination of glutamate into -
KG and subsequently into R-2-hydroxyglutarate (R-2-HG) by IDH1/2. In turn, R-2-HG maintains the 
hypermethylation and silencing of the Foxp3 promoter by antagonizing the TET1/2 demethylases 
(774). In line with the observation that glutamine metabolism is preferentially increased in TH17 cells 
(250), Johnson et al. have recently shown that glutaminase (GLS) activity sustains TH17 and restrains 
TH1 and CTL development and effector function. Mechanistically, GLS is required to neutralize ROS 
by glutamate-derived glutathione as well as to inhibit IL- -KG-mediated 
changes in chromatin accessibility (333). Interestingly, while chronic or complete GLS deficiency
impairs overall effector T cell function in vivo, transient GLS inhibition prior to adoptive cell transfer 
of CAR-T cells improved their effector function against B cell leukemia cells, indicating that transient 
GLS inhibition has the potential to enhance anti-tumor TH1 responses in vivo (333). Intriguingly, 
these studies indicate that glutamine- -KG controls on one hand the TH1/Tregs balance in 
favor of TH1, and on the other hand the TH1/TH17 balance in favor of TH17. Therefore, it is logic to 
speculate that other factors, likely cytokines or the enzymes and pathways that convert glutamate into 
-KG, are crucial to determine whether glutamine-derived -KG induces or inhibits TH1 polarization.
Other amino acids are also essential for CD4+ T cell differentiation. Leucine uptake via SLC7A5 is 
required to support the global metabolic rewiring during TH1 and TH17 differentiation but dispensable 
for the formation of Tregs, and its involvement in TH2 differentiation was not tested (659). Isoleucine 
uptake via SLC3A2, a branched-chain amino acid transporter, is involved in the in vivo maintenance 
of Tregs through their metabolic reprogramming (315). It would be interesting to assess whether 
tumor-infiltrating Tregs use this mechanism to maintain their tumor-promoting functions. NOS2 
expression is induced after in vitro T cell activation and mediates the nitration of tyrosine residues of 
, which impairs -mediated IL-17 transcription (782). The severity of autoimmune 
encephalitis was increased in NOS2-deficient mice and correlated with an increased number of TH17 
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and TH1 cells, although the involvement of other NOS2-expressing cells was not further investigated
(782) (Figures 10,11).
Interestingly, immune modulators and defense mechanisms can also affect T cell metabolic rewiring 
and phenotypic rewiring upon TCR activation. Complement binding to the complement regulatory 
receptor CD46 on T cells stimulates their proliferation and differentiation, and it does so partly by 
promoting GLUT1 and SLC7A5/LAT1 expression that respectively enhance glucose and amino acid 
uptake during TH1 responses (362).
In conclusion, the metabolic profile of effector T cells resembles that of cancer cells in several 
aspects, anticipating the harsh metabolic competition observed between them in the TME. Moreover, 
Tregs have a unique ability to adapt harsh metabolic environment and the preference to oxidize fatty 
acids may provide advantage for them to survive and function in inflammatory microenvironments, 
such as infectious loci and tumors, where the nutrient availability is scarce. Most of the advances 
regarding how metabolism is involved in T cell differentiation and effector function were carried out 
in the context of in vivo inflammation or in vitro conditions of polarization, that consist in the 
extrapolation of single or few cytokines’ effects on a certain, isolated cell type – a condition that is 
never found in vivo where cells are connected and exposed to multiple stimuli. Therefore, given that 
the unique composition of the TME likely differs from the environment of the currently studied 
models, it is of outmost importance to further investigate how the metabolic and immunomodulatory 
signals in the TME integrate and regulate T cell function.
VII.II.II CD8+ cytotoxic T cells (CTL) metabolism
Like CD4+ T cells, naïve CD8+ T cells maintain low metabolic rate and mostly rely on OXPHOS for 
ATP generation and fuel nutrients for cell survival and homeostasis (Figure 9A). Upon TCR 
stimulation, CD8+ T cells undergo a metabolic switch from OXPHOS to glycolysis. Similar to CD4+
effector T cells, CTLs increase GLUT1 expression to promote inflammatory phenotype and 
expansion (637). Moreover, TCR signal triggers the activation of mTORC1 and the expression of 
HIF- to sustain glucose uptake and glycolysis (221). TCR signaling promotes pyruvate 
dehydrogenase kinase 1 (PDHK1 or PDK1) rapid activation, inhibiting pyruvate import into 
mitochondria and facilitating lactic acid production (457). Similar to the glycolysis-independent 
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function of GAPDH in CD4+ T cells (115), in CTLs with low glycolytic flux lactate dehydrogenase 
(LDH) binds to and represses the translation of IFN- TNF- and IL-2 mRNA. Consequently, 
engagement of LDH in aerobic glycolysis upon PDHK1 activation enhances cytokine production 
without affecting the cytotoxic function of effector CTLs (457) (Figure 12).
Glutamine metabolism is also critical for T cell survival and effector function upon activation. 
Mitochondria can generate biosynthetic intermediates through glutamine metabolism (94).
Glutaminolysis promotes CD8+ T cell differentiation and effector function by modulating histone and 
DNA methylation through S-2-HG synthesis (706). Treatment of CD8+ T cells with S-2-HG prior to 
adoptive cell transfer results in an improved anti-tumor effect (706). GLS-deficient stimulated CTLs
expressed more effector proteins but were more prone to exhaustion, while transient GLS inhibition 
prior to adoptive cell transfer of anti-viral CD8+ T cells improved their effector function vaccinia 
virus (333). Given its effect on TH1 and CTLs, it would be relevant to assess the potential of transient 
GLS inhibition to enhance anti-tumor TH1 and CTL responses in vivo. In addition to glutamine, 
activated T cells also increase the uptake of other amino acids, including leucine and phenylalanine. 
CTLs upregulate the System L transporter, SLC7A5, which mediates uptake of large neutral amino 
acids. The deficiency of SLC7A5 impairs leucine uptake, which results in inability to engage 
metabolic reprogramming and declined effector function upon antigen stimulation (659).
Furthermore, serine is also an essential amino acid supporting T cell proliferation. Mice fed with a 
serine-restricted diet show impaired antigen-specific CD8+ T cell expansion and pathogen clearance 
(432). Moreover, increasing L-arginine concentrations or enforcing mitochondrial fusion in CTLs
promotes OXPHOS and IFN- -tumor 
ability in vivo (249).
Activation of CD8+ T cells induces FAS via the mTOR/SREBP pathway, which is required to meet 
the heightened lipid requirements of proliferation and effector function (348). Moreover, CTLs 
readily uptake extracellular fatty acids (522) and also rely on FAS for their expansion (394). In 
metabolically challenging environments such as the TME, concurrent hypoglycemia and hypoxia 
trigger the PPAR- -mediated FAO to preserve CTL effector function (795). Further promoting FAO
by fenofibrate improves CTL anti-tumor immunity (795). Inhibiting cholesterol esterification in T 
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cells can increase cholesterol level, which enhances T cell receptor clustering and the formation of the 
immunological synapse (787). Remarkably, CTLs derived from the draining lymph nodes of murine 
models of PD-1 blockade therapy show concomitant expression of mTOR and AMPK, as well as their 
downstream transcription factors PGC- T-bet (112). An activation of the mitochondria and an
increased generation of mitochondrial ROS in hypoxia underlies this unique co-expression of mTOR 
and AMPK (112). Of note, the dynamic of mitochondria also affects CD8+ T cells differentiation. 
CD28 signal induces mitochondrial engagement and cristae remodeling to the metabolic capacity by 
the expression of CPT1a and transient FAO activation, which is essential for T cell effector functions 
and memory T cell differentiation (353) (Figure 12).
VII.II.III Memory T cell metabolism
The generation of memory CD8+ and CD4+ T cells also requires metabolic reprogramming. Different 
from effector T cells, memory CD8+ T cells rely on fatty acid-fueled OXPHOS during quiescent 
status, and they are prone to rapidly switch their metabolism to glycolysis upon re-encountering
antigens (271) (35). Upon antigen activation, CD8+ T cells undergo asymmetric division and hence 
asymmetric segregation of c-Myc that will predict whether they remain as short-lived effector cells or 
develop into long-lived memory cells. The daughter cell proximal to the APC contains high c-Myc 
levels, more amino acid transporters and increased mTORC1 activity; whereas the distal daughter cell 
displays less mTORC1 and more AMPK. This asymmetric distribution of mTOR/AMPK activities 
leads to higher glycolytic activity in proximal cells, which supports effector functions. On the other 
hand, the distal cells increase OXPHOS to persist as long-lived memory cells (562, 726). As a 
consequence, decreasing glucose metabolism by the hexokinase inhibitor 2-deoxyglucose (2-DG) 
during in vitro priming enhances the formation of long-term memory T cells (679). In mouse 
melanoma models, T cells primed in vitro in the presence of 2-DG prior to ACT accumulate at higher 
numbers in the tumor and show an increased fitness, resulting in a more potent and long-term anti-
tumor activity (679) (Figure 9C). In addition to metabolic regulations orchestrating differentiation of 
memory CD8+ T cells, the uptake of acetate in memory CD8+ T cells can drive GAPDH acetylation 
for catalyzing the rapid recall immune response upon acute infection (32).
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Memory T cells have an enhanced mitochondrial biogenesis and fuel OXPHOS via an increased flux 
of FAO (716). Interestingly, memory T cells use extracellular glucose to synthetize the fatty acids and 
rely on their expression of the lysosomal acid lipase (LAL) to conduct lipolysis to fuel FAO and 
OXPHOS, engaging in what has been termed “fatty acid futile cycle” (522). A similar skewing 
towards memory T cells can also be produced by Akt inhibition that leads to an increase in FAO in 
activated T cells (150). Pharmacological inhibition of Akt in human TILs is able to induce a memory 
phenotype in both CD4+ and CD8+ T cells (150), indicating that this pathway is used by both CD4+
and CD8+ T cells subsets, and not only in CTL. Of note, the previous studies drawn their conclusions 
thanks to the use of the CPT1a inhibitor etomoxir. In contrast, Raud et al. have combined genetic and 
pharmacological models as well as human samples from patients with inherited deficiencies in FAO 
to report that ACC2/CPT1a are dispensable for T cell memory formation, and that the previously 
described effects of high doses of etomoxir were due to the off-target effects affecting other 
mitochondrial processes that still require further validation (573). IL-7 induces expression of the 
glycerol channel aquaporin 9 (AQP9) in memory CD8+ T cells can support fatty acid esterification 
and triglyceride (TAG) synthesis and storage, which serves as a central component of IL-7-mediated 
memory CD8+ T cells survival (152). Memory T cells upregulate the cytosolic phosphoenolpyruvate 
carboxykinase (PCK1) to increase the conversion of oxaloacetate (OAA) into phosphoenolpyruvate 
(PEP). Interestingly, the OAA used as substrate by PCK1 derives from citrate produced both from 
glucose and from glutamine. PEP is used to synthetize glycogen that subsequently undergoes
glycogenolysis to generate glucose-6-phosphate, ensuring a high PPP flux and high levels of PPP-
derived reduced glutathione to maintain survival of memory T cells (433). It is tempting to speculate 
that the channeling of the OAA produced in the first step of FAS into gluconeogenesis may represent 
a way to economize resources and to ensure a slow release of glycogen-derived antioxidants to sustain 
their own survival. CD8+ tissue resident memory T cells (TRM) have also been reported to elevate 
their fatty acid metabolism and OXPHOS. A recent study revealed that TRM increase lipid uptake 
through high expression level of fatty acid binding proteins 4 and 5 (FABP4 and FABP5) and the 
deficiency of FABP4/5 impairs long-term maintenance of TRM cells (538). A recent study highlighted 
a characteristic metabolic feature of effector memory T cells (TEM) consisting in their inability to 
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upregulate fatty acid metabolism in low glucose environments, which confers them the unique ability 
to sustain IFN- production in nutrient-poor environments such as the TME (195). In activated T 
cells, NOS2-derived NO forms peroxynitrite adducts and shortens T cell survival. Therefore, deletion 
of NOS2 or inhibitors of the NOS2-peroxynitrite pathway enhance memory responses and block post-
activation death in mouse and human T cells at least in part via the upregulation of anti-apoptotic 
molecules (729). It would be interesting to elucidate whether NO, either autocrine or from other cell 
types, can impair memory T cell formation in the TME (Figure 9C).
VIII. Targeting hypoxia and metabolism to tackle immune evasion and enhance
immunotherapy
Immunotherapy with immune checkpoint inhibitors (ICIs) has shown dramatic and long-lasting 
responses in subsets of cancer patients and in some cancer types (699). Yet, the overall response rate 
remains about 30% (699). The efficacy of immunotherapy is compromised by cancer cell-intrinsic 
pathways that make them invisible to the cytotoxic immune cells, mechanisms impairing the access of 
immune cells to the tumor or to certain regions within the tumor and the establishment of an immune-
restrictive TME. As explained in the previous parts of this review, hypoxia and metabolism strongly 
modulate immune cells and, therefore, can also strongly impact on the clinical outcome of 
immunotherapy. We propose four main metabolism/hypoxia-based therapeutic approaches aiming at 
reinvigorating the anti-tumor immune response via i) altering the recruitment (i.e., turning “cold” 
tumors into “hot” tumors) and the location of specific immune cell subsets within different tumor 
niches to foster anti-tumor immune phenotypes, ii) promoting cancer cell immune-recognition, iii)
rewiring immune cell fitness so to improve their function in a restrictive TME, and iv) rewiring the 
TME into an immune permissive milieu that favors anti-tumor immune responses (Figure 13).
VIII.I Altering immune cell recruitment and positioning
As the tumor vasculature is morphologically abnormal and dysfunctional, some anti-angiogenic 
agents, at specific dosages (260), can “normalize” instead of pruning blood vessels in the tumor, and 
thus reduce tumor hypoxia. In doing so, recruitment of immune cells in response to hypoxia-driven 
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chemokines is affected. As normalized vessels are more perfused and are more permissive to T cell 
rolling (260), T cell recruitment will be further affected (260).  Finally, if hypoxic areas are 
reoxygenated, immune cells located in those areas might be re-educated. In hypoxic areas lactate 
accumulation usually takes place and increases the recruitment of MDSCs to the tumor (314).
Some targeted therapies directed against the chemokines responsible for the recruitment of pro-tumor
immune cells have been proposed. For instance, cancer cell-derived Sema3A binds to neuropilin-1
(Nrp-1) and PlexinA1/A4 on tumor associated macrophages (TAMs), attracting TAMs to hypoxic 
tumors through VEGFR1 signaling, and hypoxia-induced downregulation of Nrp-1 is responsible for 
their entrapment in hypoxia. In gliomas, genetic KO of Nrp1 in microglia and macrophages, systemic 
pharmacological inhibition of Nrp1 and treatment of patient-derived xenografts with anti-Sema3A 
had strong anti-tumor effect via impairing the recruitment of TAMs and reshaping of the 
inflammatory response (99, 393, 476). Moreover, Nrp1 expression by tumor-infiltrating Tregs
regulates their chemotaxis and stability within the tumor via VEGF-A and Sema4A signaling, 
respectively (168, 285). Loss of Nrp1 as well as hypoxia-driven HIF-1 induce IFN- expression by 
Tregs and thus Tregs fragility, which is required for the success of PD-1 blockade (530). Whether loss 
of HIF-1 would revert Tregs fragility was not tested, but another study showed that HIF-1 -deficient 
Tregs are more capable of suppressing CTLs in vitro (473). Yet, loss of HIF-1 impaired Tregs
migratory capacity and tumor infiltration in glioblastoma-bearing animals, prolonging their survival.
Thus, it would be promising to explore which combinational therapies targeting these pathways that 
could synergistically induce tumor regression. While HIF inhibitors could also impair the anti-tumor 
function of other cells, anti-Nrp1 therapy could potentially impair the suppressive functions of Tregs
and macrophages and its combination with anti-VEGF-A and immunotherapy could inhibit Tregs
infiltration and angiogenesis and further reinvigorate CTLs.
Among the numerous obstacles to overcome in order to maximize the outcome of NK cell-based 
immunotherapies is the poor infiltration of solid tumors by NK cells. Hence, strategies to address this 
challenge with the ultimate goal to enhance NK cell infiltration in solid tumors are a promising 
therapeutic avenue. Recently, it has been shown that NK cells infiltrate into hypoxic areas in murine 
Downloaded from www.physiology.org/journal/physrev at Hauptbibliothek Univ Zurich (130.060.047.189) on September 17, 2019.
Riera-Domingo et al. (revised version) 83 
tumor models and NK cell-specific deletion of HIF-1 reduced overall intratumoral NK cell densities
and particularly the number of NK cells in hypoxic areas (373). Consequently, tuning the HIF 
expression in NK cells prior to transfer, e.g. by genetic or pharmacological inhibition of PHDs, should 
foster the infiltration of NK cells in solid tumors.
VIII.II Promoting cancer cell immune-recognition
In addition to mediating resistance to conventional chemotherapy and radiotherapy, it is becoming 
clear that tumor hypoxia counteracts the success of modern immunotherapies. 
One crucial mechanism of immunosuppression is the expression of PD-L1 on cancer cells, 
macrophages, MDSCs and dendritic cells, which is strongly induced by hypoxia in a HIF- -
dependent manner (36, 511, 536). Beyond inducing T cell dysfunction upon binding to PD-1 on T 
cells, PD-L1 on cancer cells sustains their glycolytic metabolism via activation of Akt/mTOR 
signaling and fosters the establishment of an immunosuppressive TME (116). Consequently, blocking 
PD-L1 under hypoxic conditions enhances the activation of T cells (511). Mechanistically, the 
upregulation of PD-L1 in hypoxia is achieved by cooperative binding of HIF-
M2 (PKM2) to the PD-L1 promoter. Therefore, the inhibition of PKM2 in macrophages, MDSCs and 
cancer cells results in a decrease of PD-L1 expression (536). Moreover, in neuroendocrine 
pheochromocytomas and paragangliomas, the expression of PD-L2 shows a strong association with 
HIF- (558). In summary, it becomes conceivable that hypoxia gives rise to an immunosuppressive 
microenvironment which can overcome the effect of checkpoint blockade by increasing PD-L1/ PD-
L2 expression on stromal cells and cancer cells. Thus, the combination of PD-L1/PD-L2 blockade and 
HIF- tion may represent a novel approach to improve the outcome of checkpoint 
immunotherapy. Yet, since HIF- underlies the metabolism of several anti-tumor immune cells, is 
important to assess whether the effect on these cells would balance out the anti-tumor effects of HIF 
inhibition.
Another emerging checkpoint that blunts both innate and adaptive immune responses is CD47 (418).
This membrane protein is able to negatively modulate T cell activation and cytokine production by 
interacting with the signal regulatory protein-
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-phagocytic signal (325, 418, 420, 526). High levels of CD47 
have been detected in various tumor types and its expression shows correlation with HIF target gene 
expression as well as patient survival (118, 211, 325, 442, 793). Furthermore, it was demonstrated 
that CD47 expression in triple-negative primary breast cancer cells is induced by hypoxia in a HIF-
1 -dependent manner. Besides being involved in the ‘don’t-eat-me’ signal, CD47 contributed to 
maintain a cancer stem cell phenotype (793). Hence, CD47 has become a target for cancer 
immunotherapy and the benefit of CD47 blockade is currently tested in several clinical trials (418).
CD47 blockade in the context of adaptive immunity yields increased cancer cell lysis and IFN-
release by CD8+ T cells (420, 668, 703). In tumors that are resistant to CD47 blockade, CpG treatment 
could be beneficial to overcome the “don’t-eat-me” signal of CD47 via metabolic rewiring of 
macrophages and to promote macrophage-mediated phagocytosis of CD47-expressing cancer cells, 
altogether leading to tumor shrinkage and prolonged survival (416). A very recent study hints towards 
another potential mechanism of resistance to CD47 blockade. In the context of chronic infection, 
where T cell exhaustion is considerable, a new subset CD8+ T cells that express has been 
discovered, in which the expression of inhibitory receptors is counterbalanced by the expression of 
co-stimulatory receptors (498). Hence, + CD8+ T cells retain their proliferative capacity, IFN-
expression and cytolytic function. Accordingly, CD47-expressing cells are more susceptible to CD8+
T cell-killing in vivo (498). It still remains unknown whether this subset of + CD8+ T cells also 
exists in tumors and if so, it would raise caution towards the use of CD47 blockade since it could 
negatively affect CTL-mediated anti-tumor immunity.
Expression of HLA-G, the non-classic major histocompatibility complex (MHC) class I molecule, is 
important for the maintenance of immune homeostasis and tolerance in healthy adult tissues. 
However, there is increasing evidence that HLA-G contributes to tumor immune escape and, hence 
represents an immunotherapeutic target (93, 601). HLA-G exerts its immunosuppressive effect by 
direct binding to inhibitory receptors CD85j on monocytic cells, B cells, T cells, and NK cells; to 
CD85d on dendritic cells, monocytes, and macrophages; and to CD158d on NK cells (9, 92). Elevated 
expression of HLA-G has been reported in various malignancies with a high a high tumor grade 
where it leads to immune escape (368, 408, 707, 779). Consequently, the expression of HLA-G on 
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cancer cells is associated with a poor prognosis (13, 274, 486). Interestingly, the HLA-G promoter 
and non-promoter regions contain several hypoxia responsive elements (HREs) and, in HLA-G-
negative cancer cells, hypoxia leads to an upregulation of HLA-G mRNA and protein in HIF- -
dependent fashion (215, 247, 777). Given the immunosuppressive function of HLA-G on cytotoxic T 
cells and NK cells, HLA-G expression in hypoxic cancer cells may drive immune evasion and, hence, 
represents a novel immune checkpoint molecule. Noteworthy, glucose deprivation in combination 
with hypoxic stress leads to increased surface expression of HLA-E cancer cells (623). Therefore, it 
will be interesting to investigate the impact of hypoxia on other MHC-I molecules in a cancer cell
context.
VIII.III Rewiring immune cell fitness and function
VIII.III.I Repolarization of TAMs
Several strategies have been proposed to re-educate TAMs into anti-tumor M1-like macrophages. 
Targeting glutamine metabolism is an attractive strategy due to its potential anti-tumor effects on 
cancer cells, macrophages, CD4+ T cells and NK cells (333, 417, 424, 535, 768), although it can 
interfere with CD8+ T cell differentiation, proliferation and cytokine production (94, 706). Glutamine 
synthetase (GS) deletion in macrophages prevents metastasis dissemination in a murine tumor model 
via a metabolic rewiring of TAMs into an M1-like phenotype, resulting in increased T cell 
recruitment and activation and tumor blood vessel normalization (535). Since glutaminolysis-derived 
-KG is important for M2 polarization, glutaminase (GLS) could be a potential target to repolarize 
TAMs into M1, although this approach still needs to be tested in the context of cancer (417). A subset 
of podoplanin-expressing perilymphatic TAMs (PoEMs) stimulate lymphangiogenesis, 
lymphoinvasion and metastatic dissemination (54). Given that PoEMs express higher levels of 
glucose uptake and glycolysis-related genes compared to non-PoEMs, it would be interesting to 
explore whether this population could be targeted with metabolic reprogramming therapies (54).
Macrophage-associated VSIG4 has been proposed as a M1 metabolic checkpoint inhibitor. Targeting 
VSIG4 could a potential strategy to re-polarize TAMs into anti-tumor M1 macrophages via the 
alteration of their metabolism (404). CpG treatment of macrophages activates FAS, FAO and 
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cholesterol biosynthesis to increase membrane fluidity and to overcome the “don’t-eat-me” signal of 
CD47 (416). Treatment of murine model of pancreatic cancer resistant to CD47 blockade with CpG 
allows the engulfment of CD47-expressing cancer cells and induces a macrophage phenotype switch, 
overall resulting in a relevant anti-tumor response and thus improving the overall survival (416).
VIII.III.II Enhancing DC function
Abnormal lipid accumulation is arising as a characteristic trait of tumor-associated DCs (TIDCs) and 
impairs their ability to process tumor antigens (151, 296). This accumulation is triggered by a tumor-
derived factor that still remains unknown. Strategies aiming at normalizing lipid abundance in TIDCs 
have proved to be beneficial in murine tumor models. For instance, pharmacological inhibition of 
FAS by TOFA, an ACC inhibitor, reverted this effect and synergized with DC vaccination (296).
Furthermore, silencing of XBP1, an ER stress-induced transcription factor, tuned down FAS and lipid 
accumulation, leading to a suppression of the tolerogenic phenotype of TIDCs and dampening tumor 
progression (151).
VIII.III.I Enhancing NK cell cytotoxicity
mTORC1 is a critical player in NK cell metabolism. In addition to its involvement in the development 
and differentiation of murine NK cells, mTORC1 is a crucial driver of glycolysis during NK cell 
activation (188, 445, 728). Moreover, SREBP transcription factors are required for metabolic 
reprogramming of NK cells during activation by increasing the citrate malate shuttle, glycolysis and 
OXPHOS (23). Therefore, boosting these pathways in should enhance the tumoricidal function of NK 
cells. Yet, SREBP activators for clinical use are currently not available and current mTOR-based 
therapeutic strategies aim at mTOR inhibition in cancer cells (see above) and, therefore, are likely to 
interfere with NK cell activation in the TME.
NK cells require the uptake of glutamine to sustain the import of other essential long neutral amino 
acids (LNAA) through SLC7A5 and to ensure the c-Myc-driven production of IFN- and GzmB. 
Targeting glutamine metabolism in cancer cells in order to increase glutamine availability in the TME 
might unleash NK cell anti-tumor functions in tumors where NK cell activation can take place (424).
While transient inhibition of glutaminase (GLS) prior to ACT of CD4+ T cells favors TH1 and CTL 
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responses (333), and could induce macrophage to M1 phenotype (417), it can also impair CTL
function (94, 706). Thus, the overall effect of these therapies should be carefully evaluated and might 
strongly be influenced by the immune cell composition and the degree of T cell or NK cell-mediated 
responses in each tumor type. Another interesting observation is that obesity promotes uptake and 
accumulation of lipids by NK cells, resulting in NK cell paralysis. Therefore, reducing dietary fat 
intake has been proposed to foster NK cell-mediated anti-tumor responses (468).
Noteworthy, HIF-
demonstrated, NK cell-specific deletion HIF- cancer cell
killing. Moreover, it was shown that HIF- (373).
-dependent metabolic changes in NK cells have not been fully elucidated yet, it is 
tempting to speculate that boosting HIF activity could enhance infiltration and cytotoxicity of NK 
cells as well as tumor vessel normalization.
VIII.III.I Enhancing T cell effector and memory function
Several strategies have been envisaged to rewire T cell metabolism in order to cope with the 
metabolic restrictions imposed in the TME. First, promoting effector function may have beneficial 
effects but a major caveat of this approach is that effector T cells are typically short-lived, which can 
translate in a failure to control tumor growth and metastasis in the long term. Therefore, a growing 
interest towards inducing T cell memory has arisen, which could potentially entice cancer cell killing 
in the short-term while creating a reservoir of long-lived memory T cells ensuring a protective long-
term effect.
Overexpression of phosphoenolpyruvate carboxykinase 1 (PCK1) in tumor-specific T cells or prior to 
ACT has been shown to sustain T cell anti-tumor responses in a glucose-deprived TME (300). In 
addition, PD-1 alters T cell metabolic reprogramming by inhibiting glycolysis, required by effector 
CD4+ and CD8+ T cells, and promoting lipolysis and FAO, required for Tregs (116, 547). Therefore, 
PD-1 blockade can improve the metabolic fitness of tumor-infiltrating T cells and may be one of the 
underlying mechanisms that contributes to the therapeutic benefits of PD-1 blockade. Combined 
targeting of TIGIT and PD-1 further enhances CD8+ T cell activation and function to improve 
survival rate (547). Additionally, targeting costimulatory receptors can also alter T cell metabolism. 
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For example, agonistic anti-4-1BB antibody treatment activates glucose and FAO to support CTL
proliferation and a memory-like state (125). 4-1BB activation also promotes PGC- -dependent 
mitochondrial function, which further provides metabolic support to improve the response of anti-PD-
1 and ACT (458). Similarly, glucocorticoid-induced TNFR-related protein (GITR) agonism 
upregulates nutrient uptake, lipid stores and glycolysis in CTLs to support their proliferation, and 
further increases IFN- -1 blockade treatment (607).
In contrast to sustaining metabolic fitness of effector T cells in vivo, modulating metabolism of T cells 
during in vitro expansion for ACT therapy can also improve therapeutic benefits. Treating T cells 
with the glycolysis inhibitor 2-deoxyglucose or with an Akt inhibitor during in vitro TIL expansion 
has been shown to promote memory T cell formation and to elicit stronger anti-tumor responses (150, 
679). Since ACT-refractory melanoma patients exhibit higher glycolytic activity in cancer cells (102),
combining glycolysis inhibition by an LDHA inhibitor with ACT elicit superior therapeutic potential. 
Hypoxia and low glucose TME causes a metabolic switch in CTLs through enhancing PPAR-
signaling and FAO that have been suggested to preserve CTL effector functions. In murine melanoma 
models, applying the PPAR- CTL metabolism can increase the 
therapeutic effect of PD-1 blockade (795). Modulating the signaling domain CAR T cells also 
represents a promising strategy to enhance their persistence and metabolic fitness. The inclusion of 4-
1BB domain in CAR T cells enhances FAO and mitochondrial biogenesis, promoting the outgrowth 
of T cells with memory phenotype. In contrast, CAR T cells with CD28 domains increase glycolysis 
and form short-lived effector T cells (343). Of note, modulating cholesterol metabolism in T cells 
through inhibition of ACAT1, a cholesterol esterification enzyme, can improve the formation of the 
immunological synapse efficiently to increase their effector function. The ACAT1 inhibitor 
avasimibe, already in clinical trials for the treatment of atherosclerosis, exhibits anti-tumor effect and 
shows better efficacy in combination with anti-PD-1 therapy (787).
CTLs lose their mitochondrial fitness due to impaired mitochondrial biogenesis, which weakens T cell 
anti-tumor responses. Overexpression of PGC- -specific T cells boosts mitochondrial 
activity and biogenesis and improves T cell anti-tumor activity (116, 628). In vivo treatment with the 
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PGC- agonist bezafibrate can increase OXPHOS and FAO and synergize with PD-1 blockade for 
tumor suppression (112, 127). Mitochondrial dynamics also regulate metabolic reprogramming in T 
cells through controlling mitochondrial fusion and fission. Preventing mitochondrial fission by 
treating in vitro expanded tumor-specific T cells with a mitochondria fission inhibitor, Mdivi-1, could 
enhance T cell anti-tumor responses by skewing expanded T cells to acquire memory phenotype (73).
Interestingly, it has also been reported that tumor-specific T cells with lower mitochondrial membrane 
potential, a subset with decreased oxidative stress, can elicit superior anti-tumor responses (680).
Two studies have proposed therapeutic approaches intervening T cell glutamine metabolism, which 
would synergize with their effects on macrophages, NK cells and cancer cells (333, 417, 424, 535, 
768). Transient glutaminase (GLS) inhibition, but not chronic inhibition, unleashes TH1 and CTL 
development and effector function in vivo by the activation of IL-2/mTORC1 signaling. Transient 
GLS inhibition prior to adoptive cell transfer of CAR-T cells improved their effector function against 
B cell leukemia cells (333). Moreover, glutaminolysis drives the synthesis of the epigenetic regulator 
S-2-HG and thereby promotes CD8+ T cell differentiation and effector function (706). Treatment of 
CD8+ T cells with S-2-HG prior to ACT results in an improved anti-tumor effect (706).
Tumor-infiltrating T cells often commit to T cell exhaustion due to chronic antigen persistence, a 
dysfunctional state in which they express lower amounts of effector molecules and higher levels of 
co-inhibitory receptors and reduce their proliferative capacity (762). It would be interesting to explore 
the link between the metabolic stress in the TME and the commitment to T cell exhaustion, anergy or 
senescence. The findings of this question would be vital for preventing the engagement of T cells into 
these distinct dysfunctional programs and for developing more effective interventions to reinvigorate 
dysfunctional T cells in the TME.
VIII.IV Rewiring the TME: metabolic competition and immunomodulatory metabolites
In the tumor context, the high energy demand of malignant cells as well as active stromal cells, a poor 
vascular flow and defective lymphatic drainage will result in a shortage of key metabolites and in the 
abundance of waste products. This makes the TME a harsh metabolic environment and installs a tight 
competition for vital nutrients. Not only this, but also the by-products (that have high chances to be 
stagnant inside the tumor) have a negative impact on neighboring cells such as immune cells (750).
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An example is how the high demand of cancer cells for glucose creates a competition with T cells that 
ultimately are hampered in their activation. It follows that melanomas from patients with higher 
glycolytic activity, respond less to ACT (102). Also, endogenous T cell tumor infiltration is reduced 
in melanoma and NSCLC patients with a high expression of glycolysis-related genes. It is not only 
the glucose competition itself that will reduce glucose availability to T cells but also because high 
glycolysis by cancer results in the decrease of immunostimulatory signals (e.g. IRF1, CXCL10) and 
in the increase of immunosuppressive metabolites (e.g. lactate) (102). Therefore, either glycolysis 
inhibition or LDHA blockade can, for a short period, precondition the TME and increase the 
effectiveness of the ACT (102). If on one hand, metabolism rewiring modulates the success of 
immunotherapy, on the other hand anti-PD-L1 blocking antibodies themselves can bind to cancer 
cells and decrease their glycolytic flux, thus harnessing glucose competition and further increasing T 
cell cytotoxicity (116). Other types of competition rather than glucose have been suggested also for 
other metabolites e.g., glutamine in the context of cancer cell-cancer-associated fibroblast crosstalk
(785). Moreover, low glutamine levels favor the differentiation of naïve T cells into Tregs (355, 465),
which could at least partially underlie the thrive of the immunosuppressive Tregs at the expense of 
other anti-tumor CD4+ subsets. 
Glycolysis-driven acidification and lactate accumulation are one of the hallmarks of tumors (311, 
596). Lactate is not only a waste product of glycolysis but has been considered a metabolic fuel (221, 
322), a signaling molecule in angiogenesis (135, 605, 724) and an immunosuppressive metabolite that 
impairs immunosurveillance by CTLs (214, 225) and NK cells (314, 431). Acidic conditions lower 
the T cell secretion of IL-2, TNF and IFN-
the cytotoxic potential of CTLs (64, 82). Likewise, IL-2-dependent activation and cytotoxicity of NK 
cells are diminished under acidic conditions (222, 223, 491, 644). Moreover, extracellular sodium 
lactate and lactic acid can selectively regulate CD4+ and CD8+ T cells migration (276). Lactate was 
also reported to inactivate cytokine release (i.e. IL-12) from DCs and to inhibit the differentiation and 
activation of monocyte-derived dendritic cells (262, 288). Recently, Colegio and co-workers showed 
that cancer cell-derived lactate sustains the pro-tumor M2-like phenotype of TAMs by inducing 
macrophage expression of VEGF-A and ARG1 in a HIF- -dependent manner (135). In melanomas, 
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an acidic tumor milieu due to the high glycolytic rate of melanoma cells fosters TAM skewing 
towards an M2-like phenotype and consequently anti-tumor T cell evasion (58).
Cancer cells cope with lactate accumulation by increasing the transfer of lactate and protons (H+)
across the plasma membrane into the extracellular space. The major enzymes involved in this process 
are the monocarboxylate transporter MCT1 and MCT4, which are both upregulated hypoxia, though 
MCT4 is considered the most hypoxia-induced lactate transporter (277, 351, 542). Furthermore, 
enhanced CO2 production by cancer cells is a major contributor to the acidification of the TME. The 
molecules of CO2 coming out of the PPP and the TCA cycle are converted into bicarbonate (HCO3 )
and H+ by carbonic anhydrases (CA) and the extracellular H+ drastically lowers the 
microenvironmental pH (453, 639, 683). Noteworthy, the major enzyme for pH regulation under 
hypoxic conditions is carbonic anhydrase IX (CAIX), a HIF- -regulated gene (453, 545). Hence, 
major contributors to tumor acidification, MCTs and CAIX, are upregulated in response to hypoxia 
and thus they are attractive targets to trigger an anti-tumor immune response, particularly in hypoxic 
tumors. Interestingly, a recently developed CAIX-targeting antibody against its enzymatic activity 
reduces acidification and induces antibody-dependent cell-mediated cytotoxicity in renal cell 
carcinoma via NK cells, macrophages and the complement system (117). Yet, a phase 3 clinical trial 
with girentuximab, a chimeric monoclonal antibody against CAIX, had no clinical benefits in patients 
with clear cell renal cell carcinoma (111). However, the impact of girentuximab on 
immunosuppression is not clear. It is possible that the simultaneous blockade of CAIX and immune
checkpoint inhibitors might yield superior therapeutic outcome.  
The acidic microenvironment is responsible for the selection of acidic-resistant phenotype, a powerful 
proliferative advantage. Initially thought as a metabolic waste, lactate the end product of glycolysis 
can be a paracrine signaling molecule (311, 596). Acidosis often precedes angiogenesis, since lactate 
increases the production of the VEGF and its receptor VEGFR2 by cancer cells and endothelial cells, 
respectively (605). Moreover, lactate can stabilize HIF in endothelial cells independently of hypoxia 
via the pyruvate-mediated inhibition of PHD activity and consequently promote angiogenesis (666).
The impact of lactate on angiogenesis could be also explained by induction of IL-8 production by 
endothelial cells, through NF- (724). Lee et al. showed that under hypoxic conditions,
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the stabilization of N-Myc downstream-regulated gene 3 (NDRG3) protein expression by lactate 
binding promotes angiogenesis and cell growth apparently via the ERK1/2 signaling pathway (392).
Low extracellular pH together with hypoxia results in cell death escape through activation of 
intracellular pathways for instance the extracellular-signal-related kinase (ERK1/2) (157). The 
activation of ERK1/2, acidification and hypoxia also lead to the increased release and activation of 
acidic proteases such as cathepsin B (604), MMP2 and MMP9 (157, 341) which are responsible for 
the degradation of the extracellular matrix of the tumor, facilitating invasion and metastasis (89, 90).
Other hypoxia-driven immunosuppressive metabolites that abundantly occur in tumors are adenosine
and kynurenine. Adenosine is produced by the action of CD39/CD73 and can bind to several 
receptors expressed in different levels across the different immune cell types. Noteworthy, there is 
preclinical evidence that suggest that targeting the adenosine receptor A2AR enhances
immunotherapy (434) and clinical trials that with drugs that target A2AR or CD73 are currently on 
the way (409). Hence, it seems conceivable that such compounds are able to boost the outcome of 
immunotherapies in hypoxic tumors. Tryptophan metabolism has gained new attention in tumors 
since it influences immune evasion. Indoleamine 2,3-dioxygenase (IDO) catabolizes the essential 
amino acid tryptophan into the immunosuppressive metabolite kynurenine (602). While in one hand 
the expression of IDO in APCs is related with tumor progression and poor responses to 
immunotherapies, on the other hand the generation of kynurenine, a ligand for endogenous aryl 
hydrocarbon receptor (AhR), induces Tregs differentiation and suppress DCs immunogenicity (466, 
508). How purinergic signaling and tryptophan metabolism impact immune cell function and the 
strategies envisaged to revert it are revised in detail in sections IX.I and IX.II, respectively.
In sum, the metabolic competition and crosstalk inherent in the TME between cancer cells and 
immune cells is crucial and determinant for metabolic alteration that will determine the pro- or anti-
inflammatory function of immune cells. Thus, future studies pinpointing metabolic targets common to
both tumor and immune cells will lead to a multi-pronged attack to successfully open new strategies 
to eradicate cancer. Thus, it is important to define metabolic signatures (that can be strictly dependent 
or not to the activation status of oncogenes and oncosupressors, as aforementioned) in order to predict 
or improve the response to immunotherapies.
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IX. Two examples of metabolic and hypoxia-based immunotherapies 
IX.I Nucleotide metabolism
Nucleotides are not only building blocks for nucleic acids and crucial components of cellular 
metabolism, but also potent signaling molecules when released into the extracellular milieu. 
Nucleotides are released from stressed or dying cells either passively, due to cell lysis, or actively, 
through membrane channels, by exocytosis of vesicles or as part of the content of exosomes. ATP, 
UTP and its derivatives act as immunomodulators via P1 and P2 purinergic excitatory receptors 
expressed on several immune cells. Extracellular ATP is degraded through the action of membrane-
bound ectonucleotidases, which dephosphorylate ATP into adenosine (177). There are two main 
ectonucleotidases responsible for ATP degradation in the TME: the ectonucleoside triphosphate 
diphosphohydrolases (ENTPDases) including CD39 (also known as NTPDase 1), which sequentially 
dephosphorylates ATP into ADP and AMP, and CD73 (also known as 5-NT), which 
dephosphorylates AMP into adenosine. Adenosine signaling is terminated when it is removed from 
the extracellular space by the activity of adenosine deaminase, which converts it to inosine, by 
cellular uptake through nucleoside transporters or by phosphorylation and conversion to AMP due to 
intracellular adenosine kinases (177). Notably, the metabolic master regulator AMPK is sensitive to 
changes in the AMP:ATP ratio, linking the action of CD39/CD73 with intracellular metabolic 
reprogramming. 
Phosphorylated nucleotides and adenosine elicit opposing responses on immune cells. ATP, UTP, 
UDP and UDP-glucose signal through ionotropic P2X receptors or metabotropic P2Y receptors, 
inducing chemotactic and excitatory effects on immune cells. Inversely, adenosine binds to four P1 G-
protein-coupled receptors, namely A1R, A2AR, A2BR and A3R. These receptors differ between them 
for their tissue distribution, affinity for adenosine, the type of G protein they are coupled with, and the 
downstream pathway (61, 62, 122, 155). A2A and A2B receptors are mainly involved in the control 
of immunity and inflammation; they are coupled to Gs proteins and trigger cAMP formation (61, 122, 
155). In contrast, A1 and A3 receptors are coupled to Gi/o proteins and their activation reduces the
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intracellular levels of cAMP; they can elicit pro-inflammatory responses depending on the context 
(61, 62, 122, 155). Reduced ATP signaling and increased activation of A2A and A2B adenosine 
receptors serves to limit the extent and duration of inflammation (106). Thus, ATP dephosphorylation 
into adenosine via the action of CD39 and CD73 dictates which kind of immune response is deployed. 
ATP and UTP act as “find me” signals that promote the recruitment of monocytes, dendritic cells and 
neutrophils (120, 124, 202). Through binding to P2X7R on dendritic cells, ATP induces the activation 
of the inflammasome and the maturation of pro-inflammatory cytokines such as IL-1 and IL-18, 
which are required for the polarization of IFN -producing CTLs (27). T cells express several ATP 
receptors, including P2X1R, P2X4R and P2Y12R (746). In effector T cells, TCR ligation induces the 
Ca2+-mediated activation of the transcription factor NFAT and the translocation of ATP receptors 
P2X1R, P2X4R to the membrane (769). Besides driving IL-2 secretion and T cell proliferation, NFAT 
promotes the translocation of pannexin-1 at the immune synapse, contributing to a controlled release 
of ATP (769). Signaling of autocrine ATP together with ATP from other sources through P2X1R, 
P2X4R and P2Y12R is required to sustain NFAT activation and IL-2 secretion, thereby enhancing 
effector T cell activation and proliferation and preventing anergy (630, 769). Similarly, activation-
induced ATP release by T cells and autocrine ATP signaling through P2X4R is required for the 
secretion of effector cytokines such as TNF- and IFN- (443). IL-6 induces ATP synthesis and ATP 
release by Tregs (629). Autocrine stimulation of the P2X7R by ATP in Treg impairs their 
immunosuppressive functions and results in Treg conversion to TH17 cells (629) or in Tregs apoptosis 
(24). In contrast with the general anti-tumor immune responses elicited by ATP, signaling of ATP 
through P2YRs and P2X7Rs in cancer cells has been associated with cancer cell proliferation and 
dissemination but also, in some instances, with inhibition of proliferation and induction of apoptosis 
(reviewed in (177)). Thus, treatment regimens aiming at promoting ATP signaling must be evaluated 
with care.
Hypoxia is one of the most important inducers of CD39, CD73, A2AR and A2BR expression and, 
thus, plays a decisive role in the outcome of purinergic signaling. As mentioned in the previous 
sections, HIF- may have a immunostimulatory effect on T cells and macrophages (156, 535).
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However, many of these effects can be ascribed to the hypoxia-independent activation of HIF- in 
the context of inflammatory diseases, where the antigen load is high (156). In the TME, oppositely, 
the detrimental effect of hypoxia on the anti-tumor T cell response is likely due to the hypoxia-driven 
accumulation of adenosine. Thus, in most cases the adenosine-mediated immunosuppressive effect 
overrules the cell autonomous/direct immunostimulatory effect of HIF-1/hypoxia in T cells (156, 267)
or in M1-like macrophages (535). An exception is represented by endometrial cancer, wherein CD73 
deletion accelerates tumor progression, suggesting that in this case adenosine has an anti-tumor effect 
by promoting epithelial integrity and limiting invasiveness (67). Mechanistically, adenosine usually 
antagonizes the molecular pathways triggered by ATP. Macrophages express A2A and A2B 
receptors. Adenosine binding to A2ARs promotes macrophage polarization into M2-like phenotype 
and the expression of anti-inflammatory IL-10 by macrophages, dendritic cells and neutrophils (105).
Deletion of A2ARs in myeloid cells reduced tumor growth and metastasis due to the activation of 
CTLs and NK cells (105). Activation of A2BRs in macrophages and DCs induces the production and 
secretion of VEGF-A and IL-6 and thereby promotes angiogenesis, TH17 polarization and fibrosis 
(667, 765). Moreover, A2BR signaling in DCs impairs their maturation and their capacity to present 
antigen and activate T cells (766). Adenosine inhibits neutrophil chemotaxis directly by binding to 
A3Rs or indirectly by impairing the secretion of neutrophil chemoattractants (106). Furthermore, it 
inhibits their oxidative capacity (682) and their transendothelial migration (681). Given the dual role 
of neutrophils in cancer progression, the consequences of impaired neutrophil infiltration and function 
on tumor growth and metastasis formation remain unclear and should be further investigated. 
Adenosine signaling through A2ARs in effector T cells mainly impairs T cell activation and 
proliferation by constraining NFAT activation and IL-2 secretion (78). The cytotoxic functions of 
CTLs and NK cells is also impaired by activation of A2ARs (44, 475). On the other hand, adenosine 
signaling through A2ARs in Tregs induces the expression of CTLA4, PD-1, Foxp3 and CD39/CD73, 
which helps to maintain their identity and their immunosuppressive functions (106).
Given the immunosuppressive effects of the adenosine signaling, the effects of A2AR blockade in 
tumor immunotherapy have been investigated. Several A2AR antagonists tested for safety and 
tolerability firstly in patients with Parkinson disease are currently studied in cancer, alone or in 
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combination with PD-1 or PD-L1 inhibitors, such as PBF-509, NIR178, MK-3814 (399). CPI-444 has 
been evaluated in a phase 1a/1b study in combination with the anti-PD-L1 antibody Atezolizumab in 
patients with advanced solid tumors. Clinical activity was observed in all tumor types both as a single 
agent and in combination with Atezolizumab and the disease control rate was 45% in the overall 
patient population (229). Clinical trials are also ongoing for an A2BR antagonist (PBF-1129) and for 
two monoclonal antibodies against CD73, namely MEDI9447 and BMS-986179 (399). MEDI9447 
has been evaluated in a phase 1/2a trial in combination with anti-PD-L1 therapy in patients with 
advanced solid tumors and in a phase 2 study in combination with antibodies against PD-L1, CTLA4 
and OX40 in relapsed ovarian cancer patients. Agents targeting CD39 are under development in 
preclinical studies. Overall, in the next coming year, we will understand which combination and 
which tumor type are suited for this type of approach and if adenosine signaling can be targeted in 
those patients that have shown resistance to checkpoint inhibitors.
IX.II Tryptophan metabolism and indoleamine 2,3-dioxygenase (IDO)
Indoleamine (2,3)-dioxygenase (IDO) is an enzyme that catabolizes tryptophan to kynurenine and is 
highly expressed in cancer cells, myeloid cells and endothelial cells. Tryptophan is essential for 
supporting T cell proliferation. Tryptophan-deprived T cells will be halted at a mid-G1 arrest point 
and lose their effector functions as a result of the activation of the serine/threonine-protein kinase 
GCN2 and the inhibition of mTOR activity (464, 495, 689). In addition, kynurenine can promote Tregs
differentiation by activating aryl hydrocarbon receptor (AhR) signaling cascades (466, 508). In 
physiology, kynurenine can accumulate in the placenta and induce Tregs cells that may help to prevent 
rejection of the semiallogenic fetus. In cancer, IDO-induced tryptophan depletion and kynurenine 
accumulation may facilitate the establishment of an immunosuppressive microenvironment and
promote immune evasion of cancer cells. In support of this notion, it has been reported that active 
IDO is widely expressed in the TME of different cancer types (709). Expression of IDO by 
immunogenic mouse cancer cells transfected with a construct containing the mouse cDNA of Indo 
(the gene encoding IDO) prevents their rejection when these cells were implanted in pre-immunized 
mice (i.e., mice that received a cell vaccine for this tumor) while systemic administration of an IDO 
inhibitor could prevent this rejection (709). Among all the cells, it has been recently reported that IDO 
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production in DCs is induced by hypoxia and this increase was dependent on adenosine A3 receptor 
(A3R) activation, but not on A2AR or A2BR (see section IX.I). Consistently, A3R blockade in 
hypoxia inhibited IDO induction in DCs (664). IDO activity in a subset of pDC in tumor draining 
lymph nodes is responsible for the activation of Tregs and the hindrance of TH17 presumably through 
the inhibition of IL-6 expression. In a murine tumor model, the combination of an IDO inhibitor with 
an anti-tumor vaccine unleashed the conversion of Tregs into TH17 cells that enhanced CD8+ T cell 
activation and anti-tumor function (648). IDO is not only expressed and active in many antigen-
presenting cells, whereby it promotes peripheral tolerance to tumor-associated antigens, but it is also 
expressed by cancer cells themselves. IDO enzymes and IDO-related enzymes such as the tryptophan 
2,3-dioxygenase (TDO) are active in many tumors, providing a direct defense against T cell attack 
and  facilitating survival, growth, invasion, and metastasis of malignant cells (559). In many studies, 
high IDO expression in tumor or in tumor-draining lymph nodes associates with a poor disease 
outcome (259).
To reverse IDO-mediated immune evasion, different IDO inhibitors are under clinical trial, alone or in 
combination with immune checkpoint inhibitors (711). While the recent results of a phase 3 clinical 
trial have shown that the selective oral IDO inhibitor Epacadostat failed to improve the efficacy of the 
PD-1 checkpoint inhibitor Keytruda when the two drugs were used together to treat patients with 
newly diagnosed melanoma, other proof-of-concept trials are ongoing in patients with unresectable or 
metastatic melanoma, non-small-cell lung cancer, kidney cancer, bladder cancer and squamous cell 
carcinoma of the head and neck. In these studies, Epacadostat combined with the CTLA4 inhibitor 
Ipilimumab, or the PD-1 inhibitors Keytruda or Opdivo, improved response rates compared to the 
checkpoint inhibitors alone. Thus, IDO blockade may alleviate the immunosuppressive features of the 
TME and further reinforce therapy efficacy of other cancer immunotherapies. It results that IDO 
activity has been also tested as a putative predictive biomarker for resistance to immunotherapy (66).
In a cohort of twenty-six NSCLC patients, of which 14 of them (54%) presented early progression 
kynurenine to tryptophan ratio before treatment significantly 
correlated with resistance to anti-PD-1 treatment.  Vice versa, taken as a therapeutic target, IDO-
based strategies will need a better patient stratification. For example, the initial mouse work with IDO 
Downloaded from www.physiology.org/journal/physrev at Hauptbibliothek Univ Zurich (130.060.047.189) on September 17, 2019.
Riera-Domingo et al. (revised version) 98 
inhibitors takes advantage of cancer cells with “induced” IDO expression (709). Thus, it is important 
to understand if the metabolic target itself, namely IDO, is present and/or which agent can be 
administered in combination in order to promote a higher dependency of the tumor on IDO as an 
immune suppressive cue. As hypoxia induces Indo transcription, it is possible for example that a 
combination with agents that modulate the level of oxygen in the tumor by their effect on the tumor 
vasculature (namely anti-angiogenic therapy; see (97, 224)) might induce IDO expression and render 
the tumor immune evasion more dependent on this pathway. Another recent study has shown that 
activated CTLs promotes IDO expression and the tryptophan transporter SLC1A5 in stem cell-like 
immune evasive melanoma cells (421). It follows that higher tryptophan uptake and IDO activity end 
up in increased release of kynurenine in the extracellular milieu. In turn, kynurenine is transported 
inside the T cells where it binds to the cytoplasmic transcription factor aryl hydrocarbon receptor 
(AhR) that induces the transcription of PD-1. Consistently, kynurenine plasma levels were strongly 
correlating with PD-1 expression in breast and colon cancer patients, but not in healthy individuals.
Therapeutically, inhibiting IDO in cancer cells or the AhR in CTLs can reduce immune evasion and 
lead to novel combinatorial regimens (421).
X. Preclinical evidence for response, resistance and refractoriness to immune checkpoint 
inhibitors 
X.I Clinical response to immune checkpoint blockade
Immunotherapy by immune checkpoint inhibitors (ICIs) constitutes an important breakthrough in 
cancer therapy. In recent years, the number of clinical approvals has been increasing at an 
extraordinary rate, due to the demonstrated efficacy across different solid and hematologic 
malignancies. Several ICIs entered the FDA accelerated approval program, making these new drugs 
available to the patient earlier, which was justified by the efficacy and safety of ICIs in phase 1 trials 
(329). However, in parallel, there are also reports of negative results, evidencing the limitations of this 
therapeutic approach.
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X.I.I Biomarkers of response
Unfortunately, there is still a long way before we can accurately predict response to the approved 
ICIs. Regarding anti-CTLA-4 antibodies, even though some biomarkers of response have been 
identified, none of them has yet been included in the clinical routine. Regarding blockage of the PD-
1/PD-L1 axis, only PD-1 expression has been identified as a relevant predicted biomarker. However, 
it is believed that the full picture is much more complex, with many more players involved (690).
Another biomarker used to predict response to the approved ICIs, is the “mutational load” of the 
tumors. However, there is still no cut-off value defined to apply in the clinics. In a recent study, a 
comprehensive immunogenomic analysis of TCGA data was compiled for more than 10,000 tumors 
across different cancer types, which may become a valuable resource for future studies (694). Another 
related biomarker is the presence of microsatellite instability (MSI), which was found to predict 
response to ICIs in colorectal cancer. Hence, PD-L1 expression together with MSI analysis is 
currently being used in gastrointestinal cancers.
Tumor size is a common parameter analyzed to evaluate cancer therapeutic response, although in this 
type of immunological treatment, initially some patients could even present an increase in tumor size, 
due to infiltration of inflammatory cells (pseudoprogression). Thus, this parameter cannot be used in
the same way to predict response, as with other types of treatment.
X.I.II Overcoming resistance
Many patients still do not benefit from ICIs treatment and other approaches are being attempted, such 
as combinations of drugs which will lead to maximal therapeutic benefit, but with minimum adverse 
events (4). One of the approaches is the combination of different T cell ICIs in one treatment. The 
rational for this combination comes from the fact that blockade of one of these T cell immune 
checkpoints alone might induce the expression of other co-inhibitory receptors, rendering cancers 
resistant to therapy (4). Other immunostimulatory approaches include therapeutic vaccines, cytokines, 
oncolytic virus therapy and adoptive T cell transfer (see section IV for a further explanation on these 
therapies). Combinations of ICIs and chemotherapy or radiotherapy have also shown therapeutic 
benefits, since chemotherapy and radiotherapy in some cases are able to stimulate the function of 
different immune cells besides exposing cancer cell antigens upon cancer cell killing (240, 758).
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Another approach is the combination with targeted therapies, in which case its success depends on 
each combination.
X.I.III Adverse effects
ICI therapy has been described to induce immune-related adverse events, which is a consequence of 
overstimulation of the immune function. The side effects associated with either CTLA4 or PD-1/PD-
L1 antibodies, can go from cutaneous (rash and pruritus) and gastrointestinal (diarrhea), to more 
difficult to handle auto-immune conditions, including Crohn’s disease, Hashimoto’s thyroiditis, 
autoimmune hepatitis, uveitis and hypophysitis (4). Thus, this is another issue that has to be taken into 
consideration when using ICI therapy.
X.II Preclinical studies 
Many pre-clinical studies have been set up on the use of ICIs, before and after the approval of the ICI
Ipilimumab (anti-CTLA4) for human metastatic melanoma treatment in 2011. As mentioned above, 
despite the great success of ICIs in different cancer types, there are still many patients who do not 
benefit from this therapeutic strategy. Our knowledge is still very limited regarding the markers of 
response and refractoriness to ICIs, which justifies further investment in pre-clinical studies.
As one would expect from the clinical studies, by far, the great majority of preclinical studies 
available were conducted in melanoma models (Table 2). Nevertheless, there is a considerable 
amount of studies in other models, including the ones with clinical approval of ICIs, such as head and 
neck (Table 3), lung (Table 4), hematological (Table 5), renal and urothelial (Table 6), but also in 
other “less immunogenic” cancers such as breast (Table 7), central nervous system (Table 8) and 
digestive system cancers (Table 9).
In general, most preclinical studies show that single agent ICI therapy has limited effectiveness in 
melanoma models (Table 2). Thus, several combinations have been explored, including combinations 
with adoptive T cell transfer, cancer vaccines, oncolytic virus, regulatory T cell targeting, HDAC 
inhibitors, heparanase KO, IDO inhibitors, STING activator, targeted therapy, chemotherapy, 
radiotherapy and surgery. In general, the different combinations led to improvement of the anti-tumor 
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effects compared to either drug alone. These studies are aligned with the results of clinical studies in 
which ICIs were found to be more effective than control interventions, in terms of tumor progression 
and survival (340). Peculiarly, head and neck cancer and especially the squamous cancer cell subtype 
(HNSCC) is an excellent model for immunotherapeutic interventions due to its high mutation load, 
high T cell infiltration, PD-L1 overexpression and, importantly, in human papillomavirus (HPV) 
positive cases, there is potential to use targeted therapy against HPV viral proteins which serve as 
tumor antigens (805) (Table 3). In lung tumors, PD-L1 blockade showed some efficacy in preclinical 
models, but there are unsuccessful cases reported (Table 4). This is reinforced by clinical evidence, 
where important clinical response with ICIs has been seen in some patients with non–small cell lung 
cancer (NSCLC). Nevertheless, further efforts should be put on improving the selection of patients 
and optimize patient response (290). Particularly in hematological tumors, the oncogenic role of PD-
1/PD-L1 axis in Hodgkin lymphoma and initial clinical trials showed very good response rates and a 
durable response. As a result, many clinical trials are testing PD-1 blockade either alone or in 
combination with other therapeutic approaches, with promising results (460) (Table 5). In renal 
cancer, several trials are ongoing with ICIs combination with anti-angiogenic therapies (VEGF 
pathway inhibitors) which are showing encouraging results (25) (Table 6). Even though breast cancer 
is considered as “immunologically silent” and thus not so promising in terms of response to 
immunotherapy interventions, many pre-clinical studies have been set up using ICIs alone or in 
combinations (Table 7). In clinical studies, PD-1/PD-L1 blockade showed variable percentage of 
response in triple negative breast cancer (TNBC) but a subset of patients experienced durable 
responses. Also, there is early evidence for positive results for combination with chemotherapy and 
many clinical trials are ongoing with different combinations (560). An interesting number of 
preclinical studies also exist in central nervous system tumors, especially in glioma models (Table 8). 
In a recent meta-analysis, the authors concluded that there are significant anti-tumor effects with anti-
PD-1 antibody, while either IDO or CTLA4 blockade have little efficacy (246). Many studies also 
exist in digestive cancers, mainly in colon models, followed by liver, gastric, pancreas, GIST (gastro-
intestinal stromal tumors) and esophageal cancer. Even though there is evidence for anti-tumor effects 
with ICIs alone, as for the other tumors, the different combinations also enhanced ICI efficacy (Table 
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9). Regarding gynecological cancers, most studies are in ovarian cancer, followed by cervical cancer, 
in which ICI combinations also showed effectiveness (Table 10). A similar scenario was also 
observed for prostate cancer.
As stated above, the metabolic crosstalk between cancer cells and immune cells plays a crucial role in 
the regulation of the immune response. Although we have been able to stimulate the activity of 
immune cells by targeting the inhibitory immune checkpoint proteins, immune cells will not be able 
to thrive and enter inside a tumor without a favorable metabolic environment. Thus, it would make 
sense to explore combinatory strategies to target both features. However, only a few metabolic targets 
have been explored so far, and this could partly explain cases of treatment resistance. Future studies 
should envisage to investigate this issue, aiming to improve the response to immunotherapy.
 
XI. Conclusive remarks
Cancer cells are equipped with different immunosuppressive mechanisms to oppose anti-tumor 
immune responses. They may mock tumor-associated antigens in several ways and reduce tumor 
immunogenicity to avoid T cell recognition. Further, cancer cells upregulate PD-L1/L2 expression to 
provide a co-inhibitory signal to suppress T cells anti-tumor functions. The combined use of 
checkpoint inhibitors against PD-1 and CTLA4 (or other immunotherapeutic regimens) shows great 
clinical promise in patients with advanced cancer. However, single compound treatment often remains 
unresponsive and therapeutic success by combining checkpoint inhibitors with other anti-cancer drugs 
is only achieved in a fraction of patients (and needs to be closely monitored to an increased toxicity of 
the combination regimen). This implies that other mechanisms of T cell suppression are still at play 
that can overrule checkpoint inhibition, or that that other targets may play an important role in 
preconditioning the tumor to (better) respond to conventional immunotherapies. Along this line, it has 
become evident that tumors may differ in the composition, phenotype and intratumoral localization of 
immune cells, and this diversity strongly influences the success of immunotherapy.
In the last decade, immunometabolism has emerged as a key player in the tumor-associated immune 
response. Metabolism can influence antigen presentation, immune cell function and trafficking and 
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the expression of immune checkpoints. Moreover, metabolism greatly contributes to the harsh 
conditions of the TME that ultimately suppresses immune cell functions and T cell fitness. Recent 
studies have shown that cancer cells can also metabolically exhaust tumor-infiltrating T cells, since 
they are competing for the same nutrients. Oncogenic mutations enable cancer cells to drastically alter 
their metabolism in order to sustain their uncontrolled growth in hypoxic and/or nutrient-deprived 
environments. From a historical perspective, aerobic glycolysis was considered as the main metabolic 
pathway used for cancer cell energetics and building blocks, but recent reports made clear that 
functional mitochondria are also required for cancer cell growth. Therefore, recently developed 
therapies target the aberrant metabolism of cancer cells in order to block their energetic or anabolic 
supply. On the other hand, different immune cell subsets and phenotypes require distinct metabolic 
features enabling their functional activity. For example, the rule of thumb establishes that memory T 
cells and Tregs rely on FAO and OXPHOS, while CTLs and other effector anti-tumor immune cells 
prefer aerobic glycolysis and glutaminolysis. Yet, we need to move beyond this dogmatic view and 
expand our knowledge on i) how immunometabolism is regulated at the tumor site, where the 
complexity of the TME will likely tailor unique “tumor niche-associated” metabolic programs for 
particular immune cell subtypes displaying particular phenotypes, ii) how and if the immune system 
displays different metabolic vulnerabilities according to the primary tumor tissue of origin or the 
genetic marks of the primary tumor types and iii) whether different metastatic sites may be 
characterized by specific immunometabolic checkpoints. Importantly, metabolism-based therapeutic 
strategies may hamper the lifespan of cancer cells yet produce a detrimental effect on the anti-tumor 
immune system and thus, create a situation of non-cell autonomous drug resistance. Thus, it will be 
relevant to investigate which therapeutic targets would either be directed at a unique vulnerability or 
at a shared vulnerability with similar anti-tumor effects in different cell types. Alternatively, research 
on new drug delivery methods could provide the means to selective modify the metabolism of a 
specific immune cell subset or phenotype. One could also speculate that the metabolic signatures of 
tumors responding or refractory to checkpoint inhibition might differ, and thus also the relative 
availability of glucose, glutamine, fatty acids, oxygen levels or other nutrients. Therefore, future 
research should aim to determine the differential metabolism in tumors resistant versus refractory to 
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checkpoint inhibitors, in order to identify the targetable metabolic pathways in cancer cells that could 
have an additive effect to checkpoint inhibition. 
In the last 30 years, several efforts were made to target cancer cell metabolism. The current principle 
of immune metabolism moves far beyond the original concept springing 90 years ago from the ideas 
of Otto Warburg to study metabolism to specifically tackle cancer cells. Immunometabolism keeps 
into account that cancer cells are embedded in a context of immune cells and other cells. However, 
the in vitro to in vivo disconnect had limited the success of preclinical and clinical translation with 
only a handful of targets that have made to the clinic. Technical advances, such as the use of new 
medium formulations more faithfully resembling physiological concentrations will be extremely 
useful to reduce this disconnection. A step beyond will be to design a metabolic topography of the 
tumor, with the detailed identification and localization of metabolites in the tumor milieu in order to 
increase our prediction on the function of the different immune cells in these niches. 
Looking at metabolic dynamics and interplay within the tumor to trigger the immune system and 
integrating human and mouse datasets, current research in immunoncology will be able to re-purpose 
the armamentarium of metabolic drugs currently used in preclinical and clinical settings for the 
treatment of diseases other than cancer, or that so far have been conceived to target cancer cell 
metabolism. This new branch of research will thus hold the opportunity to disclose certainly novel 
biology. It will also allow efficient target identification and lead compounds with an 
immunotherapeutic effect when used alone or that synergize with or sensitize the tumor to currently 
available drugs such as immune checkpoint inhibitors. Hopefully, the intertwined, in vivo embedded, 
study of immunometabolism will pave the way to a new era of successful preclinical phases and 
clinical translation.
In conclusion, it is becoming clear that targeting the immune landscape and metabolic pathways can 
achieve positive endpoint only when the tumor is considered as a heterogeneous entity: how do 
oncogenic mutations modify metabolism? How is the molecular target regulated within the tumor? 
How is the general immune landscape of the tumor? Which are the metabolic alterations that define 
the composition of an immunosuppressive TME? Which of the cancer cell compartments and their 
crosstalk drives these metabolic alterations? Can we “normalize” the TME to sustain T cell fitness 
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and effector functions? Are the different metabolic features of the metastasis (vs. the primary tumor) 
impacting on a diverse immune response? These and other questions will lead to a more thorough 
cohort selection and ultimately to precision medicine where each cancer patient can be treated with a 
specific cocktail of drugs.
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XII. Figures
Figure 1. The immune system in cancer 
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Immune cells are dynamic by nature and therefore may adopt an anti- or pro-tumor phenotype in 
response of the environment they encounter. Here we offer a classification of the main tumor-
infiltrating immune cell lineages (in rows) based on their most usual anti- or pro-tumor effect (green 
left and red right columns, respectively). When their role is still unclear they are grouped in the 
middle column (orange). Within each cell, the main transcription factors are indicated in white, 
upstream cytokines to each cell type/phenotype are indicated by a blue arrow and downstream 
cytokines are indicated by a blue arrow (for TH17, the brackets indicate that only in certain cases). 
The mostly used markers for the identification of each cell are indicated underneath, with the icon of a 
mouse or a human for murine and human markers, respectively. Shared markers are indicated with 
both icons. In some instances, the specific antibody clone is specified in brackets. Abbreviations: M1 
or M2 macrophage (M1 or M2); conventional dendritic cells 1 or 2 (cDC1 or cDC2); plasmacytoid 
dendritic cells (pDC); N1 or N2 neutrophils (N1 or N2); myeloid-derived suppressive cells (MDSCs); 
NK cells (NK); innate lymphoid cells type 1, 2 and 3 (ILC1/2/3);  CD4+ T helper cells type 1, 2 and 
17 (TH1/2/17); CD8+ T cells (CD8 T); and CD4+ regulatory T cells (Treg).
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Figure 2. Hypoxic instruction of immune cell positioning 
 
Hypoxic cells secrete several cytokines and chemokines and establish a gradient that shapes the 
recruitment or the exclusion of several immune cell subsets in hypoxic areas. When the involvement 
of hypoxia-inducible factor 1 alpha (HIF-1 ) or HIF-2 has been described, it is indicated within 
each cell. Dendritic cells are not included in this figure due to the fact that the impact of hypoxia on 
the positioning of dendritic cells has not been described. 
Abbreviations: C-X-C chemokine receptor type 1, 2 or 4 (CXCR1/2/4); C-X-C chemokine ligand type 
1, 2, 5, 12 (CXCL1/2/5/12), C-C receptor 10 (CCR10), C-C ligand 5/28 (CCL5/28), pattern 
recognition receptor (PRR), (P2XR), (P2YR), vascular endothelial growth factor A (VEGF-A), 
(soluble) vascular endothelial growth factor receptor 1 (sVEGFR1 or VEGFR1), neuropilin-1 (Nrp1), 
semaphoring 3/7A (Sema3/7A), interleukin-8 (IL-8), damage-associated molecular pattern (DAMP), 
tumor growth factor beta (TGF- ), endothelin 1/2 (ET-1/2), granzyme B (GzmB), interferon gamma 
(IFN- ), TNF receptor apoptosis-inducing ligand (TRAIL).
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Figure 3. Hypoxia, HIF and cytokine-mediated control of CD4+ T cell subset plasticity 
Hypoxia, HIFs and cytokines (i.e. TGF- and IL-6) control TH17/Treg and TH1/Treg balance through 
several mechanisms. HIF-1 , induced either by hypoxia or by other stimuli, is a central orchestrator 
of these balances. Hypoxia and TGF- can potentially induce both TH17 and Treg development and is
the presence or absence of IL-6 what skews the balance towards TH17 or Treg, respectively. The 
modulation of glycolysis, ROR t, IL-17 and Foxp3 underlie these events. Furthermore, VHL and 
PHDs are necessary to maintain Treg identity and in their absence, HIF-1 promotes TH1
differentiation via induction of glycolysis and IFN- .
Abbreviations: interleukin-6/17/22/23 (IL-6/17/22/23), tumor growth factor beta (TGF- ), interferon 
gamma (IFN- ), Von Hippel-Lindau (VHL), prolyl hydroxylases (PHDs), mammalian target of 
rapamycin complex 1 (mTORC1), ROR-related orphan receptor gamma t (ROR t).
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Figure 4. General metabolic pathways and metabolic pathways in cancer cells
 
(A) Glycolysis consists in the conversion of glucose to pyruvate. G6P, an intermediate of glycolysis, 
can be rerouted to the PPP pathway to generate ribose-5-P and NADPH, which are required for 
nucleotide synthesis, maintenance of the redox balance and for FAS. Pyruvate can be either 
converted to lactate and secreted or enter in the mitochondria and feed the TCA cycle. Fatty 
acids and glutamine can also undergo anaplerotic reactions and feed the TCA cycle by engaging 
in FAO and glutaminolysis, respectively. The TCA cycle generates reducing equivalents 
(NADH, FADH2) that can enter the ETC and contribute to the synthesis of ATP and mROS. 
Moreover, the TCA cycle also serves as a source of metabolic intermediates such as citrate, that 
is shuttled from the mitochondria to the cytoplasm to fuel FAS. FAS is essential to generate 
membranes as well as lipid mediators. Glutamine metabolism serves other purposes besides 
glutamine anaplerosis, such as for instance the synthesis of glutathione, ornithine or -KG and 
epigenetic regulators. Finally, arginine can be converted into ornithine or to NO by the action of 
ARG1 and NOS2, respectively, which is crucial for several immune responses.
(B) Cancer cell increase glycolysis, lactate uptake and conversion to pyruvate, PPP, FAO, FAS, 
glutaminolysis, glutamine anaplerosis and arginine metabolism. Moreover, cancer cells maintain 
intermediate levels of the TCA cycle and OXPHOS.
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Increased fluxes are indicated by a wider color band and/or thicker arrows, while reduced fluxes are 
indicated by a thinner color band and/or a dotted arrow. A transparent color band and a question 
mark next to the name of the pathway indicate that the contribution is still unclear. Abbreviations: 
pentose phosphate pathway (PPP), fatty acid oxidation (FAO), fatty acid synthesis (FAS), 
tricarboxylic acid cycle (TCA cycle), oxidative phosphorylation (OXPHOS), glucose transporter 1 
(GLUT1), glucose-6-phosphate (G6P), phosphoenolpyruvate (PEP), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), lactate dehydrogenase A (LDHA), monocarboxylate transporter (MCT), 
nicotinamide adenine dinucleotide phosphate (NADPH), coenzyme A (CoA), -ketoglutarate ( -
KG), oxaloacetate (OAA), flavin adenine dinucleotide (FADH2), nicotinamide adenine dinucleotide 
(NADH), electron transport chain (ETC), mitochondrial reactive oxygen species (mROS), acetyl-
CoA carboxylase (ACC), ATP citrate lyase (ACLY), adenine triphosphate (ATP), solute carrier 
family 1 member 5 (SLC1A5), glutaminase (GLS), glutamine synthetase (GS), glutamic-oxaloacetic 
transaminase 1/2 (GOT1/2), glutamate dehydrogenase 1 (GLUD1), glutathione (GSH), arginase-1
(ARG1), nitric oxide synthase 2 (NOS2), nitric oxide (NO).
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Figure 5. Metabolic pathways in M1 and M2 macrophages
 
(A) M1 macrophages increase glycolysis, PPP to support the production of ROS, citrate efflux from 
the mitochondria, FAS, glutaminolysis and glutamine anaplerosis and arginine conversion to NO. 
On the other hand, M1 macrophages have a minimal requirement for FAO and do not divert 
arginine towards ornithine and polyamine synthesis. Moreover, M1 macrophages present two 
characteristic “brake points” of the TCA cycle, which are indicated with red crosses. These break 
points occur at the level of isocitrate dehydrogenase (IDH) and of succinate dehydrogenase 
(SDH), leading to the accumulation of citrate and succinate, respectively, and maintain 
intermediate levels of OXPHOS.
(B) M2 macrophages increase FAO, glutamine anaplerosis (GLS) and cataplerosis (GS), the TCA 
cycle, OXPHOS and arginine conversion to ornithine. Compared to M1, M2 macrophages 
maintain intermediate levels of glycolysis and FAS. Conversion of arginine to NO is reduced and 
the PPP is inhibited by CARKL.
Increased fluxes are indicated by a wider color band and/or thicker arrows, while reduced fluxes are 
indicated by a thinner color band and/or a dotted arrow. A transparent color band and a question mark 
next to the name of the pathway indicate that the contribution is still unclear. Abbreviations: pentose 
phosphate pathway (PPP), fatty acid oxidation (FAO), fatty acid synthesis (FAS), tricarboxylic acid 
cycle (TCA cycle), oxidative phosphorylation (OXPHOS), glucose transporter 1 (GLUT1), glucose-6-
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phosphate (G6P), phosphoenolpyruvate (PEP), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), lactate dehydrogenase A (LDHA), monocarboxylate transporter (MCT), nicotinamide 
adenine dinucleotide phosphate (NADPH), reactive oxygen species (ROS), coenzyme A (CoA), -
ketoglutarate ( -KG), oxaloacetate (OAA), flavin adenine dinucleotide (FADH2), nicotinamide 
adenine dinucleotide (NADH), electron transport chain (ETC), mitochondrial reactive oxygen species 
(mROS), acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY), adenine triphosphate (ATP), 
solute carrier family 1 member 5 (SLC1A5), glutaminase (GLS), glutamine synthetase (GS), 
glutamic-oxaloacetic transaminase 1/2 (GOT1/2), glutamate dehydrogenase 1 (GLUD1), glutathione 
(GSH), arginase-1 (ARG1), nitric oxide synthase 2 (NOS2), nitric oxide (NO), carbohydrate kinase-
like protein (CARKL).
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Figure 6. Metabolic pathways in neutrophils and myeloid-derived suppressive cells (MDSCs)
The metabolism of neutrophils is poorly characterized in the context of the tumor and the metabolism 
of neutrophil-specific subsets (i.e. N1 or N2) is completely underexplored. In the context of 
inflammation, neutrophils require an increased flux of glycolysis and PPP to sustain nucleotide 
synthesis, the respiratory burst and NET formation and have a minimal requirement for the TCA 
cycle, OXPHOS and FAS. In contrast, MDSCs display an enhanced FAO, exclusively express fatty 
acid transport protein 2 (FATP2) to import arachidonic acid required for the synthesis of PGE2, and
express high levels of ARG-1 and NOS, which altogether sustain their immunosuppressive function. 
Glutamine metabolism in neutrophils or MDSCs is unknown.
Increased fluxes are indicated by a wider color band and/or thicker arrows, while reduced fluxes are 
indicated by a thinner color band and/or a dotted arrow. A transparent color band and a question mark 
next to the name of the pathway indicate that the contribution is still unclear. Abbreviations: pentose 
phosphate pathway (PPP), fatty acid oxidation (FAO), fatty acid synthesis (FAS), tricarboxylic acid 
cycle (TCA cycle), oxidative phosphorylation (OXPHOS), glucose transporter 1 (GLUT1), glucose-6-
phosphate (G6P), phosphoenolpyruvate (PEP), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), lactate dehydrogenase A (LDHA), monocarboxylate transporter (MCT), nicotinamide 
adenine dinucleotide phosphate (NADPH), coenzyme A (CoA), -ketoglutarate ( -KG), oxaloacetate 
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(OAA), flavin adenine dinucleotide (FADH2), nicotinamide adenine dinucleotide (NADH), electron 
transport chain (ETC), mitochondrial reactive oxygen species (mROS), acetyl-CoA carboxylase 
(ACC), ATP citrate lyase (ACLY), prostaglandin E2 (PGE2), solute carrier family 1 member 5 
(SLC1A5), glutaminase (GLS), glutamine synthetase (GS), glutamic-oxaloacetic transaminase 1/2 
(GOT1/2), glutamate dehydrogenase 1 (GLUD1), glutathione (GSH), arginase-1 (ARG1), nitric oxide 
synthase 2 (NOS2), nitric oxide (NO), myeloid-derived suppressive cells (MDSCs).
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Figure 7. Metabolic pathways in conventional DCs (cDCs) and plasmacytoid DCs (pDCs)
Very little is known about DC metabolism, and in particular about tumor-associated DC metabolism. 
(A) Upon activation, conventional DCs (cDCs) increase glycolysis and PPP, but they decrease 
OXPHOS, while maintaining intermediate levels of the TCA cycle. This is thought to contribute 
to the efflux of citrate from the mitochondria to the cytosol. The channeling of citrate towards 
FAS supports organelle function, but lipid accumulation is associated with a tolerogenic 
phenotype. In NOS2-expressing DCs, NO production inhibits the ETC and further sustains the 
decrease of OXPHOS. The contribution of fatty acid and amino acid metabolism to cDC function 
is still subject to controversy.
(B) Plasmacytoid DCs (pDCs) increase FAO to support their maturation and decrease glycolysis and 
PPP. The contribution of FAS, OXPHOS and amino acid metabolism still remains unclear.
Increased fluxes are indicated by a wider color band and/or thicker arrows, while reduced fluxes are 
indicated by a thinner color band and/or a dotted arrow. A transparent color band and a question mark 
next to the name of the pathway indicate that the contribution is still unclear. Abbreviations: pentose 
phosphate pathway (PPP), fatty acid oxidation (FAO), fatty acid synthesis (FAS), tricarboxylic acid 
cycle (TCA cycle), oxidative phosphorylation (OXPHOS), glucose transporter 1 (GLUT1), glucose-6-
phosphate (G6P), phosphoenolpyruvate (PEP), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), lactate dehydrogenase A (LDHA), monocarboxylate transporter (MCT), nicotinamide 
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adenine dinucleotide phosphate (NADPH), coenzyme A (CoA), -ketoglutarate ( -KG), oxaloacetate 
(OAA), flavin adenine dinucleotide (FADH2), nicotinamide adenine dinucleotide (NADH), electron 
transport chain (ETC), mitochondrial reactive oxygen species (mROS), acetyl-CoA carboxylase 
(ACC), ATP citrate lyase (ACLY), solute carrier family 1 member 5 (SLC1A5), glutaminase (GLS), 
glutamine synthetase (GS), glutamic-oxaloacetic transaminase 1/2 (GOT1/2), glutamate 
dehydrogenase 1 (GLUD1), glutathione (GSH), arginase-1 (ARG1), nitric oxide synthase 2 (NOS2), 
nitric oxide (NO).
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Figure 8. Metabolic pathways in ILCs
Upon activation, NK cells increase glycolysis, which feeds the TCA cycle and OXPHOS and supports 
NK cell effector function. SREBP1c-induced export of mitochondrial citrate via the citrate malate 
shuttle is essential to support the metabolism of effector NK cells. Cytosolic acetyl-CoA could 
potentially be used for acetylation reactions rather than as fuel for FAS. ILC3 identity relies on the 
production of mROS, important to sustain . An increase of glutamine uptake in 
activated NK cells facilitates the uptake of long neutral amino acids, which are essential to sustain c-
Myc levels and thereby to fuel NK cell effector functions. Glutamine anaplerosis also takes place, but 
its contribution to NK cell function is unknown. The exact contribution of lipid metabolism has not 
been fully elucidated, but lipid accumulation in NK cells drives NK cell paralysis. In particular for the 
ILC2 subset, ARG-1 activity is increased and fuels polyamine synthesis. Further studies are required 
to study ILC subset-specific metabolism. 
Increased fluxes are indicated by a wider color band and/or thicker arrows, while reduced fluxes are 
indicated by a thinner color band and/or a dotted arrow. A transparent color band and a question 
mark next to the name of the pathway indicate that the contribution is still unclear. Abbreviations: 
pentose phosphate pathway (PPP), fatty acid oxidation (FAO), fatty acid synthesis (FAS), 
tricarboxylic acid cycle (TCA cycle), oxidative phosphorylation (OXPHOS), glucose transporter 1 
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(GLUT1), glucose-6-phosphate (G6P), phosphoenolpyruvate (PEP), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), lactate dehydrogenase A (LDHA), monocarboxylate transporter (MCT), 
nicotinamide adenine dinucleotide phosphate (NADPH), coenzyme A (CoA), -ketoglutarate ( -
KG), oxaloacetate (OAA), flavin adenine dinucleotide (FADH2), nicotinamide adenine dinucleotide 
(NADH), electron transport chain (ETC), mitochondrial reactive oxygen species (mROS), acetyl-
CoA carboxylase (ACC), ATP citrate lyase (ACLY), solute carrier family 1 member 5 (SLC1A5), 
glutaminase (GLS), glutamine synthetase (GS), glutamic-oxaloacetic transaminase 1/2 (GOT1/2), 
glutamate dehydrogenase 1 (GLUD1), glutathione (GSH), arginase-1 (ARG1), nitric oxide synthase 
2 (NOS2), nitric oxide (NO).
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Figure 9. Metabolic pathways in naïve, activated and memory T cells
T cell metabolism is strongly rewired upon activation and again in the acquisition of memory.
(A) Naïve T cells mostly rely on FAO, TCA cycle and OXPHOS and maintain intermediate levels of 
glutaminolysis and glutamine anaplerosis to support their metabolic needs. Accordingly, naïve T 
cells have a reduced flux of glycolysis, PPP and FAS. 
(B) Upon activation, T cells increase glucose and glutamine uptake, glycolysis, PPP, FAS, 
glutaminolysis, glutamine anaplerosis and arginine uptake and reduce FAO. Glutamate is also 
diverted towards polyamine synthesis and glutathione synthesis. Activated T cells maintain 
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intermediate levels of the TCA cycle and OXPHOS. TCA cycle and reductive carboxylation are 
also used as a source of metabolic intermediates. Moreover, uptake of leucine is required to 
sustain T cell activation.
(C) Memory T cells decrease glycolysis and increase both FAS and FAO and engage what has been 
termed “fatty acid futile cycle” to fuel the increased flux of the TCA cycle and OXPHOS. 
Moreover, the OAA produced in the first step of FAS is used for glycogen synthesis and 
subsequently undergoes glycogenolysis and fuels PPP and glutathione synthesis. Arginine is 
essential to promote mitochondrial fusion. 
Increased fluxes are indicated by a wider color band and/or thicker arrows, while reduced fluxes are 
indicated by a thinner color band and/or a dotted arrow. A transparent color band and a question mark 
next to the name of the pathway indicate that the contribution is still unclear. Abbreviations: pentose 
phosphate pathway (PPP), fatty acid oxidation (FAO), fatty acid synthesis (FAS), tricarboxylic acid 
cycle (TCA cycle), oxidative phosphorylation (OXPHOS), glucose transporter 1 (GLUT1), glucose-6-
phosphate (G6P), phosphoenolpyruvate (PEP), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), lactate dehydrogenase A (LDHA), monocarboxylate transporter (MCT), nicotinamide 
adenine dinucleotide phosphate (NADPH), coenzyme A (CoA), -ketoglutarate ( -KG), oxaloacetate 
(OAA), flavin adenine dinucleotide (FADH2), nicotinamide adenine dinucleotide (NADH), electron 
transport chain (ETC), mitochondrial reactive oxygen species (mROS), acetyl-CoA carboxylase 
(ACC), ATP citrate lyase (ACLY), solute carrier family 1 member 5 (SLC1A5), solute carrier family 
7 member 5 (SLC7A5), glutaminase (GLS), glutamine synthetase (GS), glutamic-oxaloacetic 
transaminase 1/2 (GOT1/2), glutamate dehydrogenase 1 (GLUD1), glutathione (GSH), arginase-1
(ARG1), nitric oxide synthase 2 (NOS2), nitric oxide (NO).
Downloaded from www.physiology.org/journal/physrev at Hauptbibliothek Univ Zurich (130.060.047.189) on September 17, 2019.
Riera-Domingo et al. (revised version) 122 
Figure 10. Metabolic pathways in CD4+ T cells
Metabolism strongly underlies and influences the differentiation of CD4+ T cells into T helper subsets 
and Tregs as well as their function and ability to adapt in certain metabolic environments.
(A) TH1 increase glycolysis, PPP, FAS, glutamine anaplerosis, glutathione synthesis, uptake of 
leucine and arginine and conversion of arginine into NO. TH1 cells maintain intermediate levels 
of the uptake of exogenous fatty acids and glutamine, glutaminolysis, TCA cycle and OXPHOS 
and suppress FAO. Engagement of GAPDH and LDHA in glycolysis promotes the expression of 
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IFN- through epigenetic mechanisms. Rheb/mTORC1 and HIF-1 signaling are key for TH1
metabolism and differentiation.
(B) TH2 increase glycolysis until the formation of pyruvate, which is imported to the mitochondria to 
feed the increased flux of the TCA cycle and OXPHOS, while the conversion of pyruvate to 
lactate is inhibited. Moreover, TH2 cells increase the uptake of arginine and the conversion of 
arginine into ornithine. TH2 cells maintain intermediate levels of FAS and suppress PPP, FAO, 
glutaminolysis, glutamine anaplerosis and the conversion of arginine into NO. Rheb-independent 
Raptor/mTORC1 and RhoA/Rictor/mTORC2 signaling are key for TH2 metabolism and 
differentiation.
(C) TH17 increase glycolysis, but the entry of pyruvate to the mitochondria is blocked by the 
expression of PHDK1. They also increase PPP, FAS, glutamine uptake, glutaminolysis (GLS 
activity) and leucine and arginine uptake. Glutamate is diverted into several pathways necessary
to maintain TH17 identity: it fuels glutathione synthesis thereby neutralizing ROS and allowing 
IL-17 synthesis and it is converted into -KG and subsequently to R-2-HG, which is required to 
epigenetically silence Foxp3. TH1 cells maintain intermediate levels of the uptake of exogenous 
fatty acids, TCA cycle and OXPHOS and suppress FAO and conversion of arginine into NO, 
although the fate of arginine is still unclear. Rheb/mTORC1 and HIF-1 signaling are key for 
TH17 metabolism and differentiation.
(D) Tregs increase FAO, the TCA cycle, OXPHOS and the uptake of isoleucine. Tregs maintain 
intermediate levels of PPP and glycolysis until the formation of pyruvate, which is imported to 
the mitochondria to feed the increased flux of the TCA cycle and OXPHOS, while the 
conversion of pyruvate to lactate is inhibited. Tregs suppress FAS and glutamine metabolism. The 
contribution of arginine metabolism is underexplored. AMPK signaling is key for Tregs
metabolism and differentiation.
Increased fluxes are indicated by a wider color band and/or thicker arrows, while reduced fluxes are 
indicated by a thinner color band and/or a dotted arrow. A transparent color band and a question mark 
next to the name of the pathway indicate that the contribution is still unclear. Abbreviations: pentose 
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phosphate pathway (PPP), fatty acid oxidation (FAO), fatty acid synthesis (FAS), tricarboxylic acid 
cycle (TCA cycle), oxidative phosphorylation (OXPHOS), glucose transporter 1 (GLUT1), glucose-6-
phosphate (G6P), phosphoenolpyruvate (PEP), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), lactate dehydrogenase A (LDHA), monocarboxylate transporter (MCT), pyruvate 
dehydrogenase kinase isozyme 1 (PDHK1), nicotinamide adenine dinucleotide phosphate (NADPH), 
coenzyme A (CoA), -ketoglutarate ( -KG), oxaloacetate (OAA), flavin adenine dinucleotide 
(FADH2), nicotinamide adenine dinucleotide (NADH), electron transport chain (ETC), mitochondrial 
reactive oxygen species (mROS), acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY), solute 
carrier family 1 member 5 (SLC1A5), solute carrier family 7 member 5 (SLC7A5), solute carrier 
family 3 member 2 (SLC3A2), glutaminase (GLS), glutamine synthetase (GS), glutamic-oxaloacetic 
transaminase 1/2 (GOT1/2), glutamate dehydrogenase 1 (GLUD1), glutathione (GSH), arginase-1
(ARG1), nitric oxide synthase 2 (NOS2), nitric oxide (NO), IL-17 (interleukin-17), interferon gamma 
(IFN- ), AMP-activated protein kinase (AMPK), mammalian target of rapamycin complex 1/2 
(mTORC1/2), hypoxia-inducible factor 1 alpha (HIF-1 ).
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Figure 11. Metabolic control of CD4+ T cell subset plasticity
Metabolic reprogramming is at the core of the balance between TH1, TH17 and Tregs. In the boxes, the 
top darker part indicates the main metabolic pathways, the middle intermediate part indicates the 
master signaling pathways and the bottom lighter indicates specific enzymes or proteins that sustain a 
particular subset. The metabolites, cytokines or target processes to tilt the balance in favor of one or 
another subset are indicated next to each arrow. 
Abbreviations: pentose phosphate pathway (PPP), fatty acid oxidation (FAO), fatty acid synthesis 
(FAS), oxidative phosphorylation (OXPHOS), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
lactate dehydrogenase A (LDHA), pyruvate dehydrogenase kinase isozyme 1 (PDHK1), -
ketoglutarate ( -KG), acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY), solute carrier 
family 1 member 5 (SLC1A5), solute carrier family 7 member 5 (SLC7A5), solute carrier family 3 
member 2 (SLC3A2), glutaminase (GLS), glutamic-oxaloacetic transaminase 1/2 (GOT1/2), 
glutathione (GSH), Von Hippel-Lindau (VHL), prolyl hydroxylases (PHDs), ROR-related orphan 
receptor gamma t (ROR t), adenosine A2A receptor (A2AR), P2X purinoceptor 7 (P2X7R), 
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interferon gamma (IFN- ), AMP-activated protein kinase (AMPK), mammalian target of rapamycin 
complex 1 (mTORC1), hypoxia-inducible factor 1 alpha (HIF-1 ).
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Figure 12. Metabolic pathways in effector CD8+ cytotoxic T cells (CTLs)
CTLs increase glycolysis, fatty acid uptake, FAS, glutamine uptake, glutaminolysis, glutamine 
anaplerosis, glutathione synthesis and uptake of leucine, serine and arginine. Engagement of GAPDH 
in glycolysis and the blockade of the pyruvate entry to the TCA cycle by PDHK1 promotes the 
expression of IFN- through epigenetic mechanisms. Glutamate is diverted into several pathways 
necessary for their effector function: it fuels glutathione synthesis and it is converted into -KG and 
subsequently to S-2-HG to mediate epigenetic regulation. Arginine is essential to promote 
mitochondrial fusion. mTORC1 and HIF-1 signaling are key for CTL metabolism and function.
Increased fluxes are indicated by a wider color band and/or thicker arrows, while reduced fluxes are 
indicated by a thinner color band and/or a dotted arrow. A transparent color band and a question mark 
next to the name of the pathway indicate that the contribution is still unclear. Abbreviations: pentose 
phosphate pathway (PPP), fatty acid oxidation (FAO), fatty acid synthesis (FAS), tricarboxylic acid 
cycle (TCA cycle), oxidative phosphorylation (OXPHOS), glucose transporter 1 (GLUT1), glucose-6-
phosphate (G6P), phosphoenolpyruvate (PEP), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), lactate dehydrogenase A (LDHA), monocarboxylate transporter (MCT), pyruvate 
dehydrogenase kinase isozyme 1 (PDHK1), nicotinamide adenine dinucleotide phosphate (NADPH), 
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coenzyme A (CoA), -ketoglutarate ( -KG), oxaloacetate (OAA), flavin adenine dinucleotide 
(FADH2), nicotinamide adenine dinucleotide (NADH), electron transport chain (ETC), mitochondrial 
reactive oxygen species (mROS), acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY), solute 
carrier family 1 member 5 (SLC1A5), solute carrier family 7 member 5 (SLC7A5), glutaminase 
(GLS), glutamine synthetase (GS), glutamic-oxaloacetic transaminase 1/2 (GOT1/2), glutamate 
dehydrogenase 1 (GLUD1), glutathione (GSH), arginase-1 (ARG1), nitric oxide synthase 2 (NOS2), 
nitric oxide (NO), interferon gamma (IFN- ), mammalian target of rapamycin complex 1 (mTORC1).
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Figure 13. General hypoxia and metabolism-based strategies to enhance immunotherapy
We propose four main metabolism/hypoxia-based therapeutic strategies that aim at reinvigorating the 
anti-tumor immune response via i) altering the recruitment (i.e., turning “cold” tumors into “hot” 
tumors) and the location of tumor-infiltrating immune cells within different tumor niches to promote 
anti-tumor immune phenotypes, ii) promoting cancer cell immune-recognition by inducing 
antigenicity or limiting immune evasion mechanisms, iii) rewiring immune cell fitness in order to 
improve their function in a restrictive TME, and iv) rewiring the TME into an immune permissive 
milieu that favors anti-tumor immune responses.
Abbreviations: tumor microenvironment (TME), tumor-associated macrophage (TAM), dendritic cell 
(DC), natural killer cell (NK cell).
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Avelumab 3 NCT02625623 No improvement in OS or PFS, but more manageable safety profile
compared with chemotherapy.
30052729
Melanoma Ipilimumab 1/2 NCT00261365 Objective response rate, response patterns, and safety consistent with 
previous trials of ipilimumab in melanoma. Positive association of 
baseline expression of immune-related tumor biomarkers and post-




Melanoma Ipilimumab 2 NCT00050102 Clinically meaningful responses. 20082117
Melanoma Ipilimumab 2 NCT00135408 Encouraging survival and manageable AEs. 25667295, 
19671877
Melanoma Ipilimumab 2 NCT00289627 Very limited clinical activity. Manageable toxicity. 25667295, 
19139884
Melanoma Ipilimumab 2 NCT00289640 Dose-dependent effect on efficacy and safety measures. 25667295,
20004617
Melanoma Ipilimumab 2 NCT00162123 Durable, long-term survival in a proportion of patients. 25210016
Melanoma Ipilimumab 2 NCT00623766 Activity in some patients. No unexpected toxic effects. Among long-term 





Melanoma Ipilimumab 2 NCT01216696 Clinically relevant activity. 29306769
Melanoma Ipilimumab 2 NCT01134614 Longer OS and lower toxicity with ipilimumab plus sargramostim vs 
ipilimumab alone, but no difference in PFS. 
25369488
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Ocular Melanoma Ipilimumab 2 NCT01355120 Very limited clinical activity. Manageable toxicity. 26541511,
25761109
Melanoma Ipilimumab 2 NCT01990859 Manageable AE profile in Japanese patients with clinical outcomes similar 
to that in Caucasian patients. 
26410424
Melanoma Ipilimumab 3 NCT00094653 Improved OS, with or without gp100 peptide vaccine, compared with 
gp100 alone. AEs mostly reversible with appropriate treatment. Durable 
objective responses and/or stable disease in patients who received 
retreatment upon disease progression. Toxicity profile similar to that seen 










Melanoma Ipilimumab 3 NCT00636168 Significantly higher rates of recurrence-free survival, OS, and distant 
metastasis-free survival, but more immune-related AEs compared with 




Melanoma Ipilimumab 3 NCT01515189 Significantly longer OS, but increased treatment-related AEs with 10 
mg/kg than with 3 mg/kg, 
28359784
Melanoma Tremelimumab 1 NCT00585000 No safety concerns when administered as 1-hour infusion. PK profiles of 
1- and 5-hour infusions similar.
23171508
Melanoma Tremelimumab 2 NCT00086489 Long-lived tumor responses in a subset of patients. T cell activation and 
memory markers as only readout of pharmacodynamic effects of 
tremelimumab in peripheral blood.
18452610
Melanoma Tremelimumab 2 NCT00471887 Increase in Th17 cells in peripheral blood. Frequent increases in 
intratumoral infiltration by T cells regardless of clinical responses. 
Modulation of signaling networks downstream of the TCR and cytokine 




Melanoma Tremelimumab 3 NCT00257205 No statistically significant survival advantage over standard-of-care 
chemotherapy.
23295794
Melanoma Nivolumab 3 NCT01721746 Greater proportion of patients achieving an objective response and fewer 
toxic effects compared with alternative available chemotherapy regimens.
25795410
Melanoma Nivolumab 3 NCT01721772 Significant improvements in OS and PFS compared with dacarbazine. 
Apparent clinical benefit without compromising safety for a substantial 
proportion of selected patients.
28662232, 
25891173
Melanoma Pembrolizumab 1 NCT02180061 Safety profile similar to that reported in previous clinical studies. 
Promising anti-tumor activity.
28283736
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Melanoma Pembrolizumab 1 NCT02821000 Well tolerated and clinically meaningful anti-tumor activity. 30981094
Melanoma Pembrolizumab 2 NCT01704287 PFS improved with 2 mg/kg and 10 mg/kg compared with chemotherapy. 
HRQoL better maintained than with chemotherapy. Numerically but not 





Melanoma Pembrolizumab 3 NCT02362594 Significantly longer recurrence-free survival compared with placebo, with 




3 NCT01866319 Prolonged PFS and OS, less high-grade toxicity and better maintenance of 





Melanoma Nivolumab or 
Ipilimumab
3 NCT02388906 Significantly longer recurrence-free survival and lower rate of grade 3 or 4 
AEs with nivolumab than with ipilimumab.
28891423
Melanoma Nivolumab plus 
Ipilimumab
1 NCT01024231 Manageable safety profile and clinical activity that appears to be distinct 
from that in published data on monotherapy, with rapid and deep tumor 
regression in a substantial proportion of patients. 
26771550, 
23724867
Melanoma Nivolumab plus 
Ipilimumab
2 NCT01783938 Clinically more benefits with nivolumab followed by ipilimumab 
compared with reverse sequence, albeit with higher frequency of AEs.
27269740




2 NCT01927419 Significantly greater ORR and PFS with nivolumab combined with 
ipilimumab than with ipilimumab monotherapy. Higher rate of grade 3 or 
4 AEs with combination, but still acceptable safety profile.
27622997, 
25891304
RCC; Melanoma Pembrolizumab 
plus Ipilimumab
1/2 NCT02089685 Manageable toxicity profile and robust anti-tumor activity with standard-
dose pembrolizumab in combination with four doses of reduced-dose 
ipilimumab followed by standard-dose pembrolizumab.
29358500, 
28729151
Melanoma Nivolumab plus 
Ipilimumab or 
either alone
3 NCT01844505 Significantly longer PFS and OS with nivolumab alone or combined with 
ipilimumab than ipilimumab alone. In patients with PD-L1-negative 
tumors, combination more effective than either agent alone. Maintenance 
of HRQoL and no clinically meaningful deterioration over time with 






NSCLC Nivolumab plus 
Ipilimumab
1 NCT01454102 Tolerable safety profile and encouraging clinical activity characterized by 




Nivolumab 2 NCT01721759 Clinically meaningful activity and manageable safety profile. 25704439
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Squamous 
NSCLC
Nivolumab 3 NCT01642004 OS, response rate and PFS significantly better compared with docetaxel, 
regardless of PD-L1 expression level. After 3 years' minimum follow-up, 
continued OS benefit versus docetaxel. OS benefit versus docetaxel in 






Nivolumab 3 NCT01673867 OS longer compared with docetaxel. After 3 years' minimum follow-up, 
continued OS benefit versus docetaxel. OS benefit versus docetaxel in 




NSCLC Nivolumab 3 NCT02041533 No significantly longer PFS compared with chemotherapy. OS similar 
between groups. Favorable safety profile, as compared with 
chemotherapy, with no new or unexpected safety signals.
28636851
NSCLC Pembrolizumab 2/3 NCT01905657 Superior OS with both doses (2 mg/kg and 10 mg/kg) compared with 
docetaxel, with similar outcomes for each pembrolizumab dose. Fewer 
high-grade toxic effects than with docetaxel.
26712084




NSCLC Pembrolizumab 3 NCT02220894 No sensitizing EGFR or ALK alterations and low PD-L1 tumor proportion 
score.
30955977
NSCLC Atezolizumab 2 NCT01903993 Significantly improved survival compared with docetaxel. Correlation 
between survival improvement and PD-L1 immunohistochemistry 
expression on tumor cells and tumor-infiltrating immune cells. Well 




Atezolizumab 3 NCT02008227 Clinically relevant improvement of OS compared with docetaxel, 





NSCLC Avelumab 3 NCT02395172 No improved overall survival compared with docetaxel, but favorable 
safety profile.
30262187
NSCLC Durvalumab 2 NCT02087423 Clinical activity and safety profile consistent with that of other anti-PD-1
and anti-PD-L1 agents. Responses observed in all cohorts. Higher 
proportion of patients with EGFR-/ALK- NSCLC (cohorts 2 and 3) 
achieving a response than proportion with EGFR+/ALK+ NSCLC (cohort 
1) achieving a response. Encouraging clinical activity in patients with 
-L1.
29545095
NSCLC Durvalumab 3 NCT02125461 PFS significantly longer compared with placebo. Secondary end points 
also better with durvalumab. Safety similar between groups.
30280658, 
28885881
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Prostate Ipilimumab 1/2 NCT00323882 Clinical anti-tumor activity with disease control and manageable AEs with 
10 mg/kg ± radiotherapy.
24695685, 
23535954 
Prostate Ipilimumab 3 NCT00861614 Primary analysis: no difference in OS between ipilimumab and placebo. 
Exploratory piecewise hazard model: hazard ratio for OS decreased over 
time, better survival compared with placebo at later time points.
24831977
Pancreatic Ipilimumab 2 NCT00112580 Overall ineffective, but significantly delayed response in one subject. 20842054
Hepatocellular 
Carcinoma




Tremelimumab 2 NCT01843374 No significantly prolonged OS compared with placebo. Safety profile 
consistent with the known safety profile of CTLA-4 inhibitors.
28729154
RCC Nivolumab 2 NCT01354431 Across the three doses studied (0.3, 2, or 10 mg/kg), anti-tumor activity 
with manageable safety profile. No dose-response relationship as 
measured by PFS. In subgroup analysis, sustained reductions in tumor 
burden or stabilization in the size of target lesions in a proportion of 
patients who continued treatment beyond RECIST-defined first 
progression, with acceptable safety profile. 
27243803, 
25452452
Clear-cell RCC Nivolumab 3 NCT01668784 Longer OS and fewer grade 3 or 4 AEs compared with everolimus. 





RCC Nivolumab + 
Ipilimumab
3 NCT02231749 Overall survival and objective response rates significantly higher with
nivolumab plus ipilimumab compared with sunitinib. Fewer symptoms 
and better HRQoL with nivolumab plus ipilimumab than sunitinib. 
30658932, 
29562145
SCCHN Nivolumab 3 NCT02105636 Longer OS compared with standard, single-agent therapy. Delayed time to 
deterioration of patient-reported quality-of-life outcomes compared with 
single-agent therapy of investigator's choice. In Asian patients with 
platinum-refractory recurrent or metastatic SCCHN, survival advantage 




SCCHN Pembrolizumab 2 NCT02255097 Clinically meaningful anti-tumor activity and acceptable safety profile. 28328302
SCCHN Pembrolizumab 3 NCT02252042 Clinically meaningful prolongation of OS and favorable safety profile. 30509740
SCCHN Durvalumab +/-
Tremelimumab
2 NCT02319044 Manageable toxicity profile with all 3 regimens. Clinical benefit with 
durvalumab and durvalumab + tremelimumab, with minimal observed 
difference between the two.
30383184
Hodgkin's Nivolumab 2 NCT02181738 Frequent responses with acceptable safety profile. 27451390
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Pembrolizumab 1 NCT01953692 Manageable safety profile and promising anti-tumor activity in heavily 






Pidilizumab 2 NCT00532259 First demonstration of clinical activity. 24127452
Urothelial Pembrolizumab 3 NCT02256436 Significantly longer OS and lower rate of treatment-related AE compared 





Urothelial Pembrolizumab 2 NCT02335424 Anti-tumor activity and acceptable tolerability. 28967485
Breast Pembrolizumab 2 NCT02447003 Preliminary evidence of clinical activity. 27138582
Merkel Cell 
Carcinoma
Pembrolizumab 2 NCT02267603 Objective response rate of 56%. Responses in patients with virus-positive 
and virus-negative tumors.
27093365
Bladder Atezolizumab 2 NCT02108652 Durable response rates, survival, and tolerability. Increased levels of PD-
L1 expression on immune cells associated with increased response. 
Prolonged clinical benefit in patients who continued atezolizumab beyond 





Bladder Atezolizumab 2 NCT02951767 Survival benefit compared with chemotherapy after 5-9 mo. 30929841
Bladder Atezolizumab 3 NCT02302807 No significantly longer OS, but more favorable safety profile compared 
with chemotherapy. Exploratory analysis of intention-to-treat population: 







Avelumab 2 NCT02859454 Safety and clinical activity. 31053174
Solid Tumors Pembrolizumab 1 NCT01848834 Preliminary evidence of clinical activity and potentially acceptable safety 
profile. 
Recurrent or metastatic PD-L1-positive gastric cancer: manageable 
toxicity and promising anti-tumor activity. 
Advanced SCCHN: well tolerated and clinically meaningful ORR with 
evidence of durable responses. In patients with locally advanced or 







Solid Tumors Pembrolizumab 1 NCT02054806 Favorable safety profile in advanced PD-L1-positive colorectal cancer 
(CRC). Anti-tumor activity in a single patient with microsatellite 
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cancer, anti-tumor activity and safety profile consistent with that seen in 
other tumor types. In patients with heavily pretreated, PD-L1-positive 
advanced esophageal carcinoma, manageable toxicity and durable anti-
tumor activity. In patients with pretreated, PD-L1-expressing small cell 
lung cancer, safety profile consistent with the known safety profile in 
other tumor types and promising anti-tumor activity. In patients with 
recurrent or metastatic nasopharyngeal carcinoma, anti-tumor activity and 
manageable safety profile. In patients with PD-L1-positive advanced 
squamous cell anal carcinoma, manageable safety profile and encouraging 
anti-tumor activity. In patients with PD-L1-positive malignant pleural 
mesothelioma, well tolerated and possibly anti-tumor activity. In certain 
patients with previously treated, advanced, PD- -






Solid Tumors Pembrolizumab 1 NCT01295827 In patients with advanced melanoma, high rate of sustained tumor 
regression, with mainly grade 1 or 2 toxic effects. Low incidence of 
relapse after median follow-up of approximately 2 years from 
discontinuation. Well tolerated and associated with durable anti-tumor 
activity in multiple solid tumors. In patients with non-small cell lung 
cancer, no significant exposure dependency on efficacy or safety across 
doses of 2-10 mg/kg. Acceptable side-effect profile and anti-tumor 
activity. In patients with advanced non-small cell lung cancer, longer 
progression-free survival and OS in patients with previous radiotherapy 


















Atezolizumab 1 NCT01375842 In patients with locally advanced or metastatic solid tumors or 
hematological malignancies, most effective in patients in which pre-
existing immunity is suppressed by PD-L1, and re-invigorated on antibody 
treatment. In patients with metastatic renal cell carcinoma, manageable 
safety profile and promising anti-tumor activity. In patients with heavily 









Solid Tumors Nivolumab 
alone or plus 
Ipilimumab
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Nivolumab 1 NCT00730639 In patients with non-small-cell lung cancer, melanoma, or renal-cell 
cancer, objective responses in approximately one in four to one in five 
patients. Acceptable AE profile. In patients with advanced treatment-
refractory melanoma, OS comparable to that in literature studies of similar 
patient populations. Durable responses and response persistence after drug 














1 NCT00729664 Durable tumor regression and prolonged stabilization of disease in 
patients with advanced cancers, including non-small-cell lung cancer, 
melanoma, and renal-cell cancer.
22658128
Criteria for selection of clinical trials were as follows: 1) registered at www.clinicaltrials.gov; 2) recruitment status: active, not recruiting, or completed; 3) 
with published results; 4) intervention/treatment: monoclonal antibodies against CTLA-4, PD-1 and/or PD-L1; if combined with other therapy: one arm with 
monoclonal antibody against CTLA-4, PD-1 or PD-L1 alone; 5) phase: 1, 2 or 3. Abbreviations: adverse events (AEs), health-related quality of life (HRQoL), 
non-small cell lung cancer (NSCLC), overall response rate (ORR), overall survival (OS), progression-free survival (PFS), renal cell carcinoma (RCC), 
squamous cell carcinoma of the anal canal (SCCA), squamous cell carcinoma of the head and neck (SCCHN), time to deterioration (TTD)
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Table 2. Outcomes of pre-clinical studies with immune checkpoint inhibitors in melanoma
Treatment Animal model Cells Outcome Ref. (PMID)







PP2A inhibitor (LB-100) +  anti-
PD-1 mAb
C57BL/6 mice B16F10 cells (s.c.) Inhibition of tumor growth.
Increase T cell cytotoxicity
Reduction of Tregs
29844427










C57BL/6 mice B16-OVA cells CTLA-4 mAb + melphalan 
Increase mice survival in melanoma 
Long-term anti-tumor immunity.
29339377
CDK4/6 inhibitor (palbociclib) +
anti-PD-1 mAb
C57BL/6 mice B16F10 cells (s.c.) Enhances tumor regression 
Increase overall survival rates in mouse 
29160310
Chemotherapy (Oxaliplatin) + 
locally expressed PD-L1 trap fusion 
protein 
C57BL/6 mice B16F10 cells (s.c.) Tumor inhibition 29884866
PeptiCRAd (oncolytic vaccine) + 
anti-PD-L1 mAb
C57BL/6 mice B16-OVA cells Tumor growth reduction
Increase the response rate to checkpoint inhibition
30221051
Thermogelling ROS-responsive 
hydrogel-based for release of anti-
PD-L1 mAb + dextro-1-methyl 
tryptophan (IDO inhibitor)
C57BL/6 mice B16F10 cells Enhancement of anti-tumor immune response 
Decreased tumor volume 
Increased mice survival
29786888
Anti–PD-1 + anti–CTLA-4 mAb C57BL/6J mice B16F10 cells Decrease of intracranial metastasis but only when 
extracranial tumor was present.
29386395
Poly(beta-amino ester) 
nanoparticles to deliver cyclic 
dinucleotides (CDNs) + anti-PD-1
mAb
C57BL/6 mice B16-F1 cells (s.c.) Reduction of tumor growth 29127039
Bifunctional antibody–ligand traps NSG mice A375 cells or Reduction tumor-infiltrating Tregs 29467463
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(Y-traps) targeting CTLA-4 or PD-
L1 
reconstituted with 
tumor- matched HLA 





Inhibition of tumor progression
Propranolol (b-adrenergic inhibitor) 
+ anti- PD-1 mAb
BALB/c and
C57BL/6 mice
B16-OVA cells (s.c.) Reduction of tumor growth in mice housed at 22º C. 28819022







Restore of anti-tumor immunity Reduction in tumor size 28912267
Autologous T cells (in the presence 
of IL-2) and anti-PD-1 mAb
NSG mice Melanoma PDX 
model
No benefit in adding anti-PD-1 mAb Not all tumors 
respond to ACT
28955032





B16F10 cells (s.c.) Inhibition of tumor growth 
Prolong mice survival
28931755
Engineered vesicular stomatitis 
virus (VSV) + ACT therapy
C57BL/6 mice B16 and B16-OVA
(s.c. or i.v.)
Increase of PD-1+ TIM-3+ CD8+ T cells 
No improvement in mice survival.
28237836
Intratumoral injection of IFN-
anti-PD-L1 mAb
C57BL/6 mice B16F10 cancer cells 
(s.c.)
Inhibition of tumor growth 
Increase survival
28624449
STING (Stimulator of interferon 
genes) KO + radiation + anti-
CTLA4 mAb
C57BL/6 mice B16F10 WT or 
STING KO cells 
(s.c.)
Prevent the regression of abscopal tumors in vivo 28759889
Selinexor (exportin-1 inhibitor) + 
anti-CTLA-4/PD-1/PD-L1 mAb
C57BL/6 mice B16F10 cells (s.c.) Reduction in tumor growth 28148715
c-Rel inhibition (PTXF, IT-603) + 
anti-PD-1/PD-L1 mAb
C57BL/6 mice B16F1 Reduction in tumor growth 28886380
Ipilimumab and Catumaxomab + 
trifunctional bispecific antibodies 
(trAbs)
C57BL/6 mice B78-D14 (i.p.) 
B16-EpCAM cells 
(i.v.)
Moderate reduction of tumor growth 27966460
CTLA-4 mAb
response tracked by PET/CT (using 
anti-CD8 89Zr-PEG20-VHH X118)
C57BL/6 mice B16 melanoma cells
Mesenchymal PB3 
cells 
Tumor homogeneous distribution of the anti-CD8 PET 
signal.
Reduction in tumor size.
28666979
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anti–PD-1/anti-CTLA4 mAbs + 
heparanase KO in NK cells
Hpse fl/fl NKp46-iCre 
C57BL/6 mice
B16F10 cells (i.v.) mAbs failed to inhibit tumor growth when NK cells 
lacked heparanase.
28581441







Decrease the number of metastasis. 28344878
A2BRi (adenosine 2B receptor 
inhibitor) + anti-PD-1 or anti-
CTLA-4 mAbs
C57BL/6 mice B16F10-CD73hi 
cells (i.v.)
Decrease the number of metastasis 27221704
Phosphatidylserine (PS) Ab + 





Inhibition of tumor growth 27045021
Inactivation of PD-1 gene (TALEN 
technology) in adoptively 
transferred tumor-reactive CD4þ 










Increase T cells recruitment tumor Enhance tumor 
growth control Complete rejection of established 
MCA205 fibrosarcoma.
27197251
Anti-PD-L1 and/or anti- CTLA-4
antibodies and/or IL18
C57BL/6J mice B16/F10 cell (i.v.) Decrease the number of metastasis 26755531
T cell–recruiting bsAbs (AC133 
CD3) + of PD-1 Ab 
C57BL/6 mice (s.c.) B16CD133 cells 
(s.c.)
Induce tumor regression 
Decrease tumor relapse
27302161
Infection with Murine 
Cytomegalovirus (expressing a 













C57BL/6 mice B16/ BL6 cells (s.c.) Loss of IFN- receptor induce resistance to anti-CTLA-4
mAb
27667683
Avasimibe + anti-PD-1 mAb C57BL/6 mice B16F10 cells (s.c.) Decrease tumor growth 
Increase mice survival 
26982734
Inhibition of CSF-1R + anti-CTLA-
4/PD-1 mAb
C57BL/6J B16F10 cells (i.d.) Decrease tumor growth 
Increase mice survival
27211548
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Inhibition of PD-L1, PD-1, CTLA-
4, Lag-3, TIM-3
C57BL/6 mice B16F10 cells Interferon signaling induces PDL1- resistance to ICIs 
and to radiation + anti-CTLA-4
27912061
Poly(lactide-co-glycolide) (PLG) 
cancer vaccine + anti–CTLA-4 or 
anti–PD-1 mAbs
C57BL/6 mice B16F10 cells (s.c.) Decrease tumor growth 
Increase mice survival
26669718
anti-tumor antibody (A), MSA-IL-2




B16F10 and  B16-
OVA cells




Anti-PD-1 or anti-CTLA-4 +mAb 
with PI3K-
cells
C57BL/6J mice B16F10 cells (i.d.) Decrease tumor growth 
Increase mice survival
27828943





B16F10 and LWT1 
cells 
Anti-CD96 + anti–PD-1 or anti-CTLA-4
Decrease the number of metastasis
Increase mice survival
Anti-CD96 + anti–PD-1
Inhibits the growth of the novo tumors.
26787820




B16 cells (s.c) Enhanced anti-tumor immunity 
Increase mice survival
26933175






Inhibition of tumor growth. 
Long-term immunity 
25658614
5-azacytidine (Aza) + anti-CTLA-4
mAb
C57BL/6J mice B16F10 cells (s.c.) Decrease tumor growth 26317466
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Radiation + anti-CTLA-4 and PD-
L1 mAb
C57BL/6 mice B16F10 wt and 
resistant cells (s.c.)
Increase mice survival
Decrease tumor growth 
25754329
Anti–CD4- Ab + anti–PD-1/PD-L1 
mAb
C57BL/6 mice B16F10 cells
(s.c.)
Inhibition of tumor growth 
Increase mice survival
25711759
Cancer vaccine TEGVAX + PD-1
mAb 




PD-1 mAb + TEGVAX: 
Decrease tumor growth 
PD-1 mAb + GM-vaccine:
modest anti-tumor response.
24812273
3M-052 (tissue-retained TLR 7/8 
agonist) + anti-CTLA-4/anti-PD-L1 
mAb
C57BL/6 mice B16.F10 cells (s.c.) Increase mice survival
Decrease tumor growth 
25252955
BRAF inhibitor + anti-PD-1/anti-
PD-L1 mAb 
C57BL/6 mice Established BP cells  





no effect on tumor growth or survival.
BRAF inhibitor + anti-PD-1/anti-PD-L1 mAb: 
Increase mice survival




Lag3 Pdcd1 mice B16  cells (i.d.) Increase mice survival
Decrease tumor growth 
22186141
Anti–PD-1 + anti–CTLA-4 mAb C57BL/6 mice B16/BL6 cells B16-
sFlt3L-Ig (Fvax) and 
B16-GM-CSF 
(Gvax)
In combination with Fvax vaccination: 
Rejection of B16 melanomas.
20160101
Downloaded from www.physiology.org/journal/physrev at Hauptbibliothek Univ Zurich (130.060.047.189) on September 17, 2019.
Riera-Domingo et al. (revised version) 
 
6 
GM-CSF-secreting cancer cell 
immuno-therapy + PD-1 mAb 
C57BL/6 mice B16 cells Increase mice survival
Decrease tumor growth 
19208793
PD-1 inhibition C57BL/6 (B6) wt or 
B6-PD-1-/- mice




No differences in tumor growth
Decrease of hematogenous dissemination into the liver
15611321







P815 and J558L tumor model: 
Decrease of tumor growth
B16 tumor model:
No differences in tumor growth
12218188
GM-CSF–producing cellular 




parental B16-F0 lines 
(s.c.)
Rejection of B16-BL6 tumors.
Decrease lung metastases and Increase mice survival
10430624
11514604
Anti–PD-1 mAb encapsulated in 
PLGA nanoparticles 
C57BL/6 mice B16F10 cells (s.c.) Decrease tumor growth 30333312
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Table 3. Outcomes of pre-clinical studies with immune checkpoint inhibitors in head and neck tumors
Treatment Animal model Cells Outcome Ref. 
(PMID)
Anti-PD-L1 and/or anti-




LY2 and MOC2 cells 
(orthotopic)
Anti-TIM-3 + anti-PD-L1 + RT:
Decrease tumor growth 
Increase mice survival 
Tumor relapse 
Anti-TIM-3 + anti-PD-L1 + RT + anti-CD25:
Tumor rejection
30042205
Dasatinib + CTLA-4 mAb Tgfbr1/Pten2 cKO 
mice 
- Decrease tumor growth 29955905
PI3K / inhibitor + PD-L1 
mAb
C57BL/6 mice (s.c.) MOC cells Decreased tumor growth 
Increased mice survival 
28364000





MEER (HPV+) or 
MOC1 cells
Decreased tumor growth 
Decrease cell dissemination
28931759
Anti-PD-1 mAb 4-NQO induced mouse 
model 
(22 p53+/- mice)
- Reduction of the number of developed oral lesions 
Inhibition of malignant progression.
29018057
Radiotherapy (RT) + anti-
PD-1 mAb
C57BL/6 mice (s.c.) MTEC (HPV+) cells Decreased tumor growth 28904066
Anti-B7-H1 mAb C3H/HeN mice SCCVII cells, B7-
H1+
B7-H1 mAb + activated T cells cured 60% of animals. 14559843
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Table 4. Outcomes of pre-clinical studies with immune checkpoint inhibitors in lung tumors
Treatment Animal model Cells Outcome Ref. 
(PMID)
PARP (olaparib) or 
CHK1 (prexasertib) 
inhibitors + PD-L1 
mAb
RPP (conditional 




SCLC cells derived 
from RPP 
mice(s.c.)
PARP + PD-L1 inhibition:
Decrease tumor growth
Increase mice survival




inhibitor + PD-1 mAb 
DBA/2 mice KLN205 cells Decrease tumor growth 30755715
Galectin-3 (GB1107) 
inhibitor + anti-PD-L1 
mAb
C57Bl/6 mice LLC1 cells (s.c.) Decrease tumor growth 30674531




H460 and PC9 cell 
line
PDX
Increase of tumor growth in both models 30206165








Decrease tumor growth 30352428
PD-L1- mAb humanized mice 
with PBMCs or 
HSPCs 
PDX mouse model 
+ PMBCs
H460 and A549 
cells
Atezolizumab and pembrolizumab in PBMCs mouse model:
Decreased tumor volume
Atezolizumab and pembrolizumab in HSPCs mouse model:
No decrease in tumor growth
Atezolizumab and MSB2311 in PDX + PMBCs mouse model 






mouse models of 
NSCLC
- Decrease tumor growth




C57Bl/6 mice LLC1 cells Decrease tumor growth 29487979
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No inhibition of tumor growth




+ anti-PD-1, TIM-3, 




TC-1 cells Decrease tumor growth
Increase mice survival
29464699
Anti-PD-1 mAb NSG mice (s.c.) M109 cells Increase tumor growth 29632720












Non-small cell lung 
cancer patient 
samples (ex vivo)




radiotherapy (RT) + 
anti-PD-L1 mAb
C57BL/6 mice LLC1 cells Anti–PD-L1 mAb: 




Anti-PD-L1 mAb + 
oncolytic adenoviral 
vector-mediated 




TP53) gene therapy 
BALB/c mice (s.c.) M109 cells Anti–PD-L1 mAb: 
No impact on tumor growth
Anti–PD-L1 mAb + Ad/E1-TRAIL/ Ad/CMV-TP53:
Inhibition of tumor growth
29296537











C57BL/6 mice CMT167 or LLC 
cells (orthotopic or 
Inhibited tumor growth 28819064
Downloaded from www.physiology.org/journal/physrev at Hauptbibliothek Univ Zurich (130.060.047.189) on September 17, 2019.








C57BL/6J mice LLC1 cells (s.c.) Decrease tumor growth 
Affected the brain and induced anxiety, cognitive impairment and
neuroinflammation in mice
27893434
Anti-tumor antibody + 
MSA-IL-2 + anti-PD-1
+ amphiphile-vaccine 




Strong tumor regression and durable cures 
Increase mice survival
27775706
Anti-CD96 Ab with 
anti-CTLA-4 or anti–
PD-1 mAb
C57BL/6 mice 3LL cells Anti-CD96 + anti–PD-1 or anti-CTLA-4








- Increase mice survival 26883990
ALK vaccine with 
anti-PD-1/PD-L1 mAb
ALK Transgenic 
Mice (EML4- ALK 
mice)
ALK-rearranged 
NSCLC cell lines: 
H3122, H2228 and 
DFCI032
Anti-PD-1 mAb: 
No effect on tumor growth




1/PD-L1 mAbs  
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Table 5. Outcomes of pre-clinical studies with immune checkpoint inhibitors in hematological tumors








C57BL/6J mice and 
Nox2-KO mice (s.c.)
EL-4 cells Decrease tumor growth 30315349
Vinorelbine, 
cyclophosphamide 
and 5-FU + anti-PD-
1/PD-L1 mAb
NSG mice A20 B cells (s.c.) Tumor growth reduction 29695766
Anti-PD-1 mAb + 
with BET inhibitors 
C57BL/6 mice -Myc lymphoma 
cells (i.v.)
Increase mice survival 28249162
anti–PD-1/anti-
CTLA4 mAbs + 
heparanase KO in 
NK cells





mAbs failed to inhibit tumor growth when 







d (SHrN) and 
BALB/c mice 




and A20 B-cell 
lymphoma cells 
(s.c.)







RMA-S cells Decrease the number of metastasis. 28344878
Ibrutinib + Anti–PD-
L1 mAb
C57BL/6 and A20 (B-cell 
lymphoma line), 
H11 pre–B-cell line 
Cure of the established A20 Tumors. 25730880






-/- T cells are resistant to PD-1-
mediated therapy
28916658
Downloaded from www.physiology.org/journal/physrev at Hauptbibliothek Univ Zurich (130.060.047.189) on September 17, 2019.
 







NOD.SCID mice Mononuclear cells 
collected from 
AML patients
Decrease tumor growth 27856600
Anti-CD47 antibody 
(ZF1)
BALB/c nude mice ALL CCRF cells or 
AML U937 cells
Increase mice survival 27863402
CD33/CD3 BiTE
ab (AMG 330) + 
anti-PD-1/PD-L1 
mAb
NSG mice Primary cells from 
patients with AML
PDX AML- 346
and AML-361 cells 
(ex vivo assays)
Increase of AML cells lysis 26239198





Prevention of leukemia development in mice. 25800048
Ibrutinib + Anti–PD-
L1 mAb


















Anti-PD-L1 mAb BALB/c, BALB/c nu 
nu, DBA 2, and 
C57BL/ 6 (B6)
PD-1-deficient mice 




SP2 0, P3U1, X63, 




Decrease P815 cells tumorigenesis and 
invasiveness in vivo
Inhibition of myeloma cells growth in vivo 
12218188
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Table 6. Outcomes of pre-clinical studies with immune checkpoint inhibitors in urologic tumors
Tumor type Treatment Animal model Cells Outcome Ref. 
(PMID)
                      
                      
Prostate
CP1 (patient-derived prostate-
specific microbe) + anti-PD-1
mAb
FVB/NJ mice Myc-CaP, LNCaP 
cells
(orthotopic)
Increase mice survival 





C57BL/6 mice TRAMP C2 cells CTLA-4 mAb + gemcitabine:
Increase mice survival in the prostate mice 
model.
29339377
Anti-CTLA-4 + anti-PD-1 mAb 








anti–PD-1/anti-CTLA4 mAbs + 




RM-1 cells (i.v.) mAbs failed to inhibit tumor growth when NK 
cells lacked heparanase.
28581441
Cytokine signaling checkpoint 




RM-1 cells Decrease the number of metastasis. 28344878
Anti-CD96 Ab with anti-CTLA-
4 or anti–PD-1 mAb
C57BL/6 mice RM-1 cells Anti-CD96 + anti–PD-1 or anti-CTLA-4:
Decrease the number of metastasis
Increase mice survival
26787820
CD73 + anti-CTLA-4 +anti-PD-
1 mAb
C57Bl/6 mice RM-1 cells
(s.c.)
Decrease tumor growth 23983257





Decreases tumor burden 23557194
Anti-CTLA-4 mAb + 
hcryoablation
C57BL/6 mice TRAMP C2 cells 
(s.c.)
Slower tumor growth Rejection of secondary 
induced tumors.
22108823







Significant reduction in tumor incidence and 
tumor grade.
10811122
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Renal Tumor-targeted Her2-AAV 
vectors
+ anti-PD-1 + chemotherapy
BALB/c mice Her2/neu+ RENCA 
cells (s.c.)
Her2-AAV+ PD-1:
Moderate reduction in tumor progression.
Her2-AAV+ PD-1 + chemotherapy: 
Decrease tumor growth.
30838171
Anti-CTLA-4 mAb + lycorine 
(growth inhibitor)
C57BL/6 mice RENCA cells
(orthotopic and i.v.)
Decreased tumor growth 
Decrease lung metastasis.
28416753
mTOR (everolimus) inhibitor + 
anti-PD-L1 mAb
BALB/c mice RENCA cells Decrease in the tumor burden 27712020
Oncolytic virotherapy  + CTLA-
4 mAb
BALB/c mice Renca cells 
(s.c.)
Decrease tumor growth 26187615
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PARP1/2 (Niraparib) inhibitor  
+ PD-1 mAb
C57BL/6 mice BL6078 tumor 
fragment
Decrease tumor growth 30755715
Urothelial Chemotherapy + anti-PD-1/ PD-
L1 mAb
C3H mice MB49 and  MBT-2
cells
Decrease tumor growth in MB49 model.
Inhibition of ICIs activity in the MBT-2
model.
30356816
Anti-CTLA-4 + anti-PD-1 mAb 
+ TLR agonists CpG 





No additive effect 
Anti-CTLA-4 or Anti-PD-1 + CpG: 
Increase mice survival
20445343
Anti-CTLA-4 + anti-PD-1 mAb C57BL/6 mice MB49 cells (s.c.) Anti-CTLA-4: 




Anti-PD-L1 mAb C57BL/6 mice MB49 cells (s.c. 
and orthotopic)
Decrease tumor growth
Durable and improved survival
26921031
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Table 7. Outcomes of pre-clinical studies with immune checkpoint inhibitors in breast tumors
Treatment Animal model Cells Outcome Ref.










Decrease tumor growth 30755715
Doxorubicin/ indoximod-
Liposomes + anti-PD-1 mAb
BALB/c mice 4T1 cells (orthotopic) Decrease tumor growth
Eradicate lung metastases.
30481959
Chemotherapy + anti-PD-1/ PD-
L1 mAb
BALB/c mice 4T1 cells No tumor response 30356816
PeptiCRAd (oncolytic vaccine) 
+ anti-PD-L1 mAb 
BALB/cOlaHsd mice 4T1 cells Tumor growth reduction
Increase the response rate to checkpoint inhibition
30221051
LSD1 inhibitor (HCI-2509) + 
anti-PD-1 mAb
BALB/c mice EMT6 cells (orthotopic) Tumor growth reduction
Decrease pulmonary metastasis
30111819
Anti-PD-1 mAb + zoledronic 
acid
BALB/c mice 4T1-fLuc cells Tumor growth reduction 29921237
Vinorelbine, cyclophosphamide 
and 5-FU + anti-PD-1/PD-L1 
mAb























Decrease tumor growth 29339738
Anti-CTLA-4 mAb + mRNA 
vaccine nanoparticles encoding 




4T1 cells Combination significantly enhanced anti-tumor immune 
response compared to vaccine or monoclonal antibody 
alone.
 29258739
TGF- -blocking + anti-PD-L1 
mAb
BALB/c mice EMT6 cells (orthotopic) Increase anti-tumor immunity 
Decrease tumor growth
29443960
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Chemotherapy ( Oxaliplatin) 
locally expressed PD-L1 trap 
fusion protein
BALB/c mice (s.c.) 4T1 breast cancer cells Tumor inhibition 29884866
Bifunctional antibody–ligand 
traps (Y-traps) targeting CTLA-
4 or PD-L1 
NSG mice 
reconstituted with 
tumor- matched HLA 
A2+ human CD34+ 
BM cells
MDA-MB231-Luc cells Inhibition of tumor progression 29467463
VEGF-A/Ang2- bispecific 
CovX-body (CVX-241) + anti-
PD-L1 mAb
BALB/c mice EMT-6/CDDP cells Increase mice survival 27651308





of luminal B-type 
(orthotopic)
Decrease tumor growth 
Increase mice survival
28273064
Anti-PD-1 + anti-CTLA4 mAb 
+ cisplatin






Decrease tumor growth 







B16-OVAcells (s.c.) Reduction of tumor growth in mice housed at 22º C. 28819022
CTLA-4 mAb
response tracked by PET/CT 
(using anti-CD8 89Zr-PEG20-
VHH X118)
C57BL/6 mice epithelial PB2 breast 
cancer cells 
Tumor homogeneous distribution of the anti-CD8 PET
signal.
Reduction in tumor size.
28666979
Anti–PD-1/anti-CTLA4 mAbs + 
heparanase KO in NK cells
Hpsefl/fl NKp46-iCre 
C57BL/6 mice 
E0771 breast cancer 
(orthotopic)
mAbs failed to inhibit tumor growth when NK cells 
lacked heparanase.
28581441
Small-molecule inhibitor of 
apoptosis antagonists (Smac 
mimetic compounds, SMCs), + 
anti-PD-1 or anti-CTLA-4 mAb
BALB/c mice EMT6 breast cancer and   
MPC-11 (mammary fat 
pad) multiple myeloma 
cells (i.v.)
Anti-tumor efficacy 28198370
Anti-PD-1 mAb + doxorubicin BALB/c mice 4T1 cells Decrease metastasis 26859684
-targeted 
photodynamic therapy (PDT) + 
anti-PD-1 mAb
BALB/c mice 4T1 cells (s.c.) Decrease tumor growth
Decrease lung metastasis 27022411
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MEK inhibitors + anti-PD-
1/PD-L1 mAb
C57BL/6 and FVB 
mice 
MMTV-neu, AT3ova 
and 4T1.2 cells 
(orthotopic)
Decrease tumor growth 26515496
Cellular vaccines (expressing 
B7-1 and glycolipid-anchored 
IL-12) + anti-PD-L1 mAb
BALB/c mice D2F2/E2 cells 
(transfected with the 
human HER- 2 gene)
(s.c.)
Decrease tumor growth 26308597
Phosphatidylserine-targeting 
antibody + anti-PD-1 mAb
C57BL/6 or BALB/c 
mice





A2BRi (adenosine 2B receptor 




4T1.2 cells (orthotopic ) Increase mice survival 27221704
Anti-PD-L1 and/or anti- CTLA-
4 antibodies and/or IL-18
BALB/c mice 4T1 cells (i.p.) Increase mice survival
Increase tumor rejection 
26755531
A (anti-tumor antibody), I 
(MSA-IL-2), P (anti-PD-1), and 
V (amphiphile-vaccine)
Balb/c mice DD-Her2/neu cells Strong tumor regression and durable cures 
Increase mice survival
27775706
Anti-PD-1 or anti-CTLA4 
antibodies with PI3K-
in myeloid cells
BALB/c mice 4T1 cells (s.c.) Decrease tumor growth 
Increase mice survival
27828943
Anti-CD96 Ab with anti-CTLA-
4 or anti–PD-1 mAb
C57BL/6 and BALB/c 
mice
4T1.2 and E0771 cells 
(orthotopic )
Anti-CD96 + anti–PD-1 or anti-CTLA-4




emtansine (T-DM1) + anti-
CTLA-4 and anti-PD-1 mAb
FVB mice) Pieces of Fo5 (MMTV–
human HER2) breast 
tumors
(orthotopic)
Anti-CTLA-4 + anti-PD-1 mAb:
Completely ineffective.
Anti-CTLA-4 + anti-PD-1+T-DM1: 
Strong anti-tumor efficacy.
26606967
Radiation + anti-CTLA-4 and 
PD-L1 mAb
BALB/c mice Res 237 and TSA cells 
(s.c.)
Increase mice survival
Decrease tumor growth 
25754329
Ibrutinib + Anti–PD-L1 mAb BALB/c mice 4T1-Luc cells Decrease tumor growth 25730880
Anti-PD-1 mAb + multipeptide 
vaccine
BALB/c mice TUBO cells (s.c.) Increase mice survival
Decrease tumor growth 
24728077
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Anti-PD-1 + anti-GITR mAb + 
chemotherapy
C57BL/6 mice 4 T1 breast cancer cells Decrease tumor growth 
Increase mice survival
24502656






Decrease tumor growth 
Increase mice survival
23523609
Adoptive transfer of anti-Her-2
T cells +  anti-PD-L1 mAb
C57BL/6 Her-2 tg 
mice and congenic 
Thy1.1þ Her-2 mice
24JK- Her-2 sarcoma 
(s.c)
e0771-Her-2 mice 
breast carcinoma cells 
(orthotopic)
Regression of established tumors. 23873688
CD73 + anti-CTLA-4 +anti-PD-
1 mAb
BALB/c mice 4T1.2 cells Decrease tumor growth 23983257
Anti–PD-1 + anti–HER2 mAbs BALB/c-MMTV-neu 
tg mice
H2N113 cells (s.c) Decrease tumor growth 21482773





4T1 cells (s.c) Decrease tumor growth
Increase mice survival 
Reduce lung metastasis formation
Involvement of iNKT cells in the response.
15701862 
19147765
B7-H1 and anti-PD-1 mAb BALB/c, 4T1 cells Decrease tumor growth 15705911





and N202.1E cells 
Extended disease-free survival
Decrease tumor growth  
12750275
Anti-CTLA-4 mAb + GM-CSF-
expressing vaccine
BALB/c mice SM1 cells (s.c.) Regression of the induced mammary carcinomas. 9707601
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Table 8. Outcomes of pre-clinical studies with immune checkpoint inhibitors in central nervous system tumors
Treatment Animal model Cells Outcome Ref.






Increase mice survival 29531161
GM-CSF + i.v. reovirus + 
anti-PD-1 mAb




C57BL/6 mice GL261 and CT-2A cells 
(orthotopic)
Increase mice survival 29016938
Anti-PD-1 + anti-CTLA-4
mAb + Flt3L 
C57BL/6 mice GL261 cells (orthotopic) Increase mice survival 28109087
Anti-PD-1 mAb C57BL/6 mice GL261 cells (orthotopic) Increase mice survival 28681455
Anti-PD-1 + anti-TIM-3 + 
stereotactic radiosurgery 
(SRS)
C57BL/6J mice GL261-Luc cells Anti-TIM-3 mAb + SRS or anti-TIM-3 + anti-PD-1
mAbs: 
Increase mice survival
Anti-TIM-3 + anti-PD-1 mAbs + SRS:
Increase mice overall survival (100%)
27358487
DC vaccination ± anti-PD-1
mAb + CSF-1R inhibitor
C57BL.6 mice GL261 cells (orthotopic) Increase mice survival 28115578
-mIL12, anti-CTLA-
4, anti-PD-1/PD-L1 mAb
C57BL/6 mice 005 glioblastoma stem-
like cells or CT-2A cells
G47D-mIL12 + anti-CTLA-4 or G47D-mIL12 + anti-PD-
1/PD-L1:
Increase mice survival




adenovirus) + anti-PD-L1 
mAb
C57BL/6 mice GL261 cells Inhibition of gliomas 






Glioma mice model GL261cells (orthotopic) Anti-PD-1 mAb shows anti-tumor effects 
IDO1 or CTLA-4 mAb fail or provided very marginal 
advantage.
28507806
Small-molecule inhibitor of C57BL/6 or CD-1 CT-2A, GL261 cells Cures mouse GBM 28198370
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(Smac mimetic compounds, 
SMCs), + anti-PD-1 or 
anti-CTLA-4 mAb






Spontaneous tumors 75% complete regression of small tumor 
Prevent the progressive growth of large tumors.
26957560
Anti-PD-1 + anti-CTLA-4
mAb + viroimmunotherapy 
C57BL/6 mice GL261 cells (orthotopic) Increase mice survival 26409567
Anti-CTLA-4 + anti-PD-
1/PD-L1/PD-L2 mAb 
C57BL/6 mice GL261 cells
(orthotopic)
Single-agent treatment:
Long-term tumor-free survival anti–PD-1 (50%), anti–
PD-L1 (20%), or anti–CTLA4 (15%) of treated animals
Anti-CTLA-4 + anti–PD-1 cured 75% of the animals.
26546453
Local chemotherapy + anti-
PD-1 mAb





C57BL/6J mice Ptch+/- cells (from 
Ptch+/- mutant mice) 
and NSC MB (from p53 
and c-myc mutant mice) 
(orthotopic)
Anti-CTLA-4 or Anti-PD-:
No treatment benefit in Ptch1 MB
Anti-CTLA-4:
No treatment benefit in NSC MB
Anti-PD-1 w/wo Anti-CTLA-4:
Increase mice survival in NSC MB
26405194
PD-1 inhibited NK cells 
(i.v.)
C57BL/6 mice GL261GSCs cells 
(orthotopic)
Inhibition of tumor growth 26266810
IDO inhibition + anti-
CTLA-4 and anti-PD-L1 
mAb
C57BL/6 mice GL261 cells (orthotopic) Mice treated with anti-CTLA-4 (40%), anti-PD-L1 (60%) 
and with anti-PD-L1+ anti-CTLA-4 (90%) were still alive 
at day 90th
Anti-PD-L1+ anti-CTLA-4 + IDOi
100% of mice treated with durable survival
24691018
4-1BB agonist ab + anti-
CTLA-4 mAb + focal 
radiotherapy
C57BL/6 mice GL261 cells (orthotopic Increase mice survival 25013914
Anti-PD-1 mAb +  
radiation
C57BL/6 mice GL261 cells (orthotopic) Increase mice survival 23462419
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Table 9. Outcomes of pre-clinical studies with immune checkpoint inhibitors in digestive tumors
Tumor type Treatment Animal model Cells Outcome Ref.
(PMID)
Colon Histamine dihydrochloride 






Decrease tumor growth 30315349




Increase mice survival 30087314
PARP1/2 (Niraparib) inhibitor  
+ PD-1 mAb
C57BL/6 mice MC38 cells Decrease tumor growth 30777870
Chemotherapy (Oxaliplatin) + 
locally expressed PD-L1 trap 







OxP + PD-L1 mAb
Decrease tumor size
OxP + PD-L1 trap fusion protein 
Decrease tumor size
29884866
PP2A inhibitor (LB-100) +  
anti-PD-1 mAb
BALB/c mice CT26.CL25 
cells (s.c.)
Inhibition of tumor growth.





mice (WNT, EGFR, 








(TG4010) + anti- PD-1/PD-L1 
mAb
BALB/c mice CT26.CL25 or
CT26-MUC1 cells 
(i.v.)
Increase mice survival 28925793
TGF- -blocking + anti-PD-L1 
mAb
C57BL/6 mice MC38 cells (s.c.) Increase anti-tumor immunity 
Decrease tumor growth
29443960






Decrease tumor growth 29124315
CDK4/6 inhibitor (palbociclib) 
+  anti-PD-1 mAb
C57BL/6 and
BALB/c mice 
MC38 and CT26 
cells (s.c.)
Enhances tumor regression 
Increase overall survival rates in mouse
29160310
Axitinib + anti-PD-1 and anti-
TIM-3 mAb
C57Bl/6 mice MC38 cells Decrease tumor growth 29487979
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Chemotherapy + anti-PD-1/ PD-
L1 mAb 
C57BL/6 mice MC38 cells Decrease tumor growth 30356816
Anti-KIT mAb + anti-CTLA-4
and anti-PD-1 mAbs
BALB/c mice CT-26 cells (s.c.) Increase of immune responses 28138031
Anti–PD-1 antibody and anti-











c-Rel inhibition (PTXF, IT-603) 
+ anti-PD-1/PD-L1 mAb
BALB/c mice CT-26 cells Reduction of tumor growth 28886380
Anti-CTLA-4 mAb + precision 
CT-guided peripheral 
radiotherapy 
BALB/c mice CT26 cells (s.c.) Decrease tumor growth 
Affected the brain and induced anxiety, 
cognitive impairment and neuroinflammation in 
mice
27893434
CDK4/6 (abemaciclib) inhibitor 
+ anti-PD-L1 mAb
BALB/c mice CT- cells (s.c.) Complete tumor regression 28813415
Anti-PD-1/ PD-L1+ anti-Lag-3
+ anti-CTLA-4 or anti-BTLA 
mAb
C57BL/6 mice MC38 cells Reduction of tumor growth 27050669
CD3 PET imaging agent 
targeting T cells + anti-CTLA-4
mAb 




based + anti-CTLA-4 mAb
BALB/c mice CT26-HER-2 cells 
(i.v.)
MVA-BN-HER2 + CTLA-4 mAb:
Increase overall survival
26961085
Anti-PD-L1 and/or anti- CTLA-
4 antibodies and/or IL18




Increase tumor rejection 
Decrease the number of metastasis
26755531
Inhibition of CSF-1R + anti-
CTLA-4/PD-1 mAb






BALB/c mice CT26 cells Decrease tumor growth 
Increase mice survival
27828943




CT26 cells (s.c) Enhanced anti-tumor immunity 
Increase mice survival
26933175
HT-SELEX TIM3 non-antigenic BALB/c mice CT26 cells (s.c.) Decrease tumor growth 26683225
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Anti-PD-1 and anti-CD137 mAb 
+  engrafted T lymphocytes
Rag2-/-IL2R null
mice 
HT29 cells Decrease tumor growth 26113085
Oncolytic virotherapy  + CTLA-
4 mAb 
C57/Bl6 mice MC38 cells (s.c.) Decrease tumor growth 26187615
Anti–CD4- Ab + anti–PD-1/PD-
L1 mAb
BALB/c mice CT-26 cells (s.c.), Inhibition of tumor growth 
Increase mice survival
25711759
Ibrutinib + Anti–PD-L1 mAb BALB/c mice CT26 cells Decrease tumor growth 25730880
CTLA-4 mAb + immature 
dendritic cells (iDCs)
BALB/c mice CT-26 cells Inhibition of tumor growth 
Increase mice survival
24316550
Radiation + anti–PD-1 mAb C57BL/6 mice MC38 cells Inhibition of tumor growth 24382348
Anti-CTLA- 4 mAb of different 
isotypes
C57BL/6 or BALB/c 
mice
CT26 or MC38 
cells (s.c)
Anti-CTLA-4 antibodies of IgG2a isotype have 
enhances anti-tumor activity
24777248
CD73 + anti-CTLA-4 +anti-PD-
1 mAb





Decrease induction of fibrosarcomas. 
23983257
Tumor Vaccine + anti-PD-1 + 
anti-CTLA-4 mAb






MC38 cells  and
Sa1N fibrosarcoma
anti-LAG-3 + anti-PD-1:      Decrease tumor 
growth. Lag3 Pdcd1 mice:  Increase mice 
survival
Decrease tumor growth 
22186141
Anti-Tim-3 + PD-1 mAb BALB/c mice CT26 cells (s.c.) Decrease tumor growth 20819927
GM-CSF-secreting cancer cell 
immuno-therapy + PD-1 mAb 
C57BL/6 mice CT26 cells Increase mice survival
Decrease tumor growth 
19208793
PD-1 inhibition BALB/c wt and PD-
1-/- mice
CT26 cells (i.v.) Decrease of hematogenous dissemination into 
the lungs.
15611321
Anti-CTLA-4 mAb BALB/c mice B7-51B Liml0 cells
Sal N fibrosarcoma 
cells
Tumor rejection, including the pre-established 
tumors.
8596936
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Gastric Met + Tetravalent bispecific 
anti- PD-1 ab
NOD-SCID mice MKN45 or 
MGC803 cells 
(s.c.)
Decrease tumor growth 30511201
Anti-PD-1 and anti-CD137 mAb 





Decrease tumor growth 26113085
PD-1 KO (CRISPR-Cas9) in T 
cells + radiotherapy
BALB/c nude mice Primary human T 
cells
and SNU-719 cells 
Decrease tumor growth 28197365
FAP (linagliptin) + anti-PD-1
mAb
C57BL/6 mice 424GC cells (s.c.) Decrease tumor growth 27983931
Esophageal Anti-PD-1 mAb Nude mice EC9706 cells Decrease tumor growth 28692048
GIST Imatinib + PD-1 or PD-L1 mAb Spontaneous 
tumors
Decrease tumor growth 27470968
Liver Synthetic double-stranded RNA 
polyinosinic-polycytidylic acid 
(polyIC) + PD-L1 mAb








did not show any therapeutic effect.




Lenvatinib + anti-PD-1 mAb C57BL/J mice Hepa1-6 cells (s.c.) Decrease tumor growth 30447042







RIL-175 cells (s.c./ 
orthotopic)
BNL cells (s.c.)
Decrease tumor growth 29959458
Anti-CTLA-4 or anti-PD-1 mAb NSG mice - PDX Patient-derived 
hepatocellular 
tumors
Decrease tumor growth 29602780
Anti-PD-L1 mAb + radiation C3H/HeN mice 
(i.m.)
HCA-1 cells Increase mice survival 28465485
Anti-PD-L1 mAb +anti-IL-6 BALB/c mice (s.c.) H22 cells Anti-IL-6 reversed anti-PD-L1 tumor resistance 28254435
Sunitinib + anti-PD-1 mAb C57BL/6 mice Induced tumors Activation of anti-tumor immunity 27520877
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Anti-PD-1 mAb + CXCR4 




Mst2F/– mice (i.v. 





Reduction the number of lung metastases
Regression of established tumors.
25529917
Oncolytic adenovirus + anti-PD-
1 mAb
C57BL/6 mice







Localized virus-mediated tumor infection 
overcomes systemic resistance to PD-1
immunotherapy in both models
26112079
HAT1 KD + anti-PD-1/PD-L1 
mAb
C57BL/6 mice Panc 02 cells (s.c.) Decrease tumor volume Increase mice survival 30709380
Epigenetic modulators + anti-
PD-L1 mAb
C57BL/6J mice Hepa1-6 cells (s.c.) Tumor regression 30626493





PANC-1 cells PD-1 KD: 
small tumor volume 
Anti-PD-1 mAb:
Tumor reduction 
Anti-PD-1 mAb + Anti-MEK1/2:
Strong tumor reduction
30377341
mAb-AR20.5 + PolyICLC + 
anti-PD-L1 mAb
MUC1.Tg mice Panc02.MUC1 
cancer cells
Rejection of human MUC1 expressing tumors 29204701
Anti-IL-6 and anti-PD-L1 
antibodies
PDAC model Panc02, MT5 or 





Inhibition of MLL1 (Verticillin 
A) +  anti-PD-1/PD-L1 mAb





Decrease tumor growth 28131992
Antibodies anti-B7-H1 or anti- C57BL/6 mice Panc02 (orthotopic) Regression of pre-established pancreatic tumors. 19724910
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Table 10. Outcomes of pre-clinical studies with immune checkpoint inhibitors in gynecological tumors
Tumor 
type
Treatment Animal model Cells Outcome Ref.
Ovarian PARP1/2 (Niraparib) 
inhibitor  + PD-1 mAb
FVB mice BRCA1-deficient 
cells (BRKras)
Decrease tumor growth 30755715






Increase mice survival 30518877
Anti-PD-L1 mAb MUC1KrasPten 
mice 
Cells isolated from 
spontaneous tumors 
(orthotopic)
Earlier anti-PD-L1 treatment increased survival. 25998800
Anti-CTLA-4 or anti-














C57BL/6 mice ID8 cells Tumor regression
Increases mice survival.
26573793
Anti-PD-1 + anti-GITR 
mAb + chemotherapy
C57BL/6 mice ID8 cells Decrease tumor growth 
Increase mice survival
24502656
Tumor Vaccine + anti-
PD-1 + anti-CTLA-4
C57BL/6 mice ID8-VEGF cells 
(s.c.)
Tumor rejection and in vivo tumor regression. 23633484




Lighter ability to inhibit autologous human ovarian 
carcinoma growth
12704383












Nude mice HeLa cells Decreased tumor size.
Evaluation of mice body weight indicated the safety of 
our nanohybrid.
29405579
DNA vaccine (HPV- 16
E7) + anti-PD-1mAb + 
Mouse cervical 
cancer model 
TC1 cells wild-type 
HPV16E6E7 cells 
Decrease of tumor volume 27699512
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HPV (HPV 16 genes E6 
and E7) + anti-PD-1
mAb
C57BL/6 mice TC-1 HPV-E6/E7 
expressing cancer 
cells (s.c.)
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